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Abstract 
Protein biomarkers are important diagnostic tools for detection of non-communicable 
diseases, such as cancer and cardiovascular conditions. In order to be used as diagnostic tools 
they need to be detected at very low concentrations in biological samples (e.g. whole blood, 
serum or urine). This has been currently performed in central laboratories using expensive, 
bulky equipment and time consuming assays. 
Microfluidic devices aim at translating commercial sensitive laboratory tests into Point-of-
Care (POC) tests, which need to match the ASSURED policy (affordable, sensitive, specific, 
user-friendly, rapid & robust, equipment-free and delivered). Nevertheless, the microfluidic 
technology has not yet achieved the expected performance for POC diagnostic tests 
commercialisation purposes. The two main reasons appointed are the lack of high sensitivity 
assays using power-free and portable detection systems, and the high manufacturing costs of 
the microfluidic devices. 
This PhD thesis presents the development and optimisation of a novel microfluidic platform, 
the Microcapillary Film (MCF), made from a melt extruded fluoropolymer (FEP), which is 
cost effective and easily mass produced. The MCF is a transparent flat film with embedded 
capillaries, which provides high surface area-to-volume ratio and excellent optical properties 
for sensitive low cost optical interrogation. Overall, the results achieved show that MCF 
platform allows rapid quantitation of protein biomarkers in biological samples, using PSA 
(prostate specific antigen) and IL-1β cytokine as proof-of-concept. The method uses low cost, 
portable and power-free equipment, such as flatbed scanner or smartphone camera for optical 
interrogation. In order to understand the higher sensitivity using low cost detection methods 
several studies were performed. From these studies, it was found that antibodies irreversibly 
adsorb to FEP-Teflon achieving a full monolayer at 400 ng/cm
2
, suggesting vertical antibody 
orientation. Also, microcapilary environment favours enzyme kinetics allowing higher end 
products concentration easily detected with a flatbed scanner or a smartphone. In addition, it 
was found that stop flow sample incubations favours assays sensitivity and speed. Ultimately, 
it was shown that negative effects of biological sample matrix can be overcome in MCF 
through antibody surface coverage and sample incubation time manipulation, eliminating the 
need for sample preparation.  
Key words: Immunoassay, diagnostics, point of care, microfluidics, microcapillary film, 
miniaturisation.  
ii 
 
Acknowledgments  
Firstly I would like to gratefully thank my supervisor Dr Nuno Reis for the support and 
guidance given through all the phases of the work presented, from experimental work 
planning and analysis to production of manuscripts and written thesis. He was always very 
present and supportive. I am also thankful for his enthusiasm that kept me going in the 
moments mine was running of.  
Secondly I am thankful to Capillary Film Technology Ltd and Lamina Dielectrics Ltd for 
providing the Microcapillary Film (MCF) platform and for giving me a great inside of 
industry perspective in point-of-care diagnostics.  
And then I am gratefull to Loughborough University, Chemical Engineering technical staff 
for always making sure I had all the equipament and training I needed to proceed with my 
work. Special thanks to David Smith, for his kindness and availability in the Bio Lab, and 
Paul Izzard for solving my IT related problems.  
After these, there is a list of people that made my PhD process easier to handle. I am 
therefore grateful to: my parents, Jose Barbosa and Emilia Barbosa, for always making me 
feel I belonged somewhere; Ana Castanheira for being an excellent lab colleague and 
supporting me in my down days; Tina Sutar for her insights in biological assays; Augusto 
Barreto, Poonam Gehlot and Kalpita Sidapra for their work and motivation in the lab; Dr 
Alexander Edwards for his insights in clinical diagnostics and feedback in manuscripts and 
thesis production; Filipa Pereira, Patrick Isherwood and Alex Eeles for their help proof 
reading this thesis; Biancamaria Maniscalco for being my friend; Celia Dias e Maria de 
Fatima Gomes for their unconditional support; Panagiota Moutsatsou and Eleni Nyktari for 
their support as friends and housemates; Alex Eeles for the everyday motivation and suport 
during the last phase of this project; And to my office colleagues Raffaella Casasola, Serena 
Morena Morelli, Ekanem Ekanem, Umarat Santisukkasaem, Elena Simone for their support 
and PhD problems sharing. 
  
iii 
 
Contribution of authors 
This thesis is presented as a collection of manuscripts written by the candidate with the 
collaboration of the co-authors. The manuscripts are based on experimental data generated 
from experiments designed and executed by the candidate, who was also responsible for data 
collection and analysis. The supervisor appears as co-author in all manuscripts reflecting his 
supervisory role during the execution of the work and his involvement in the manuscript 
preparation.  
On chapter 2 manuscript “Antibody (IgG) Adsorption onto FEP-Teflon microcapillary 
surfaces for quantitative point-of-care diagnostics” Augusto Barreto gave his contribution 
executing protein bioassays under the candidate supervision, during his undergraduate 
summer project exchange.  
On chapter 3 manuscript “Impact of HRP enzymatic optimization in sandwich ELISA 
microfluidic systems” Ana Castanheira appears as co-author due to her equal contribution in 
the experiments and manuscript planning and execution.  
On chapter 5 “A Lab-in-a-briefcase for rapid PSA screening from whole blood” Ana 
Castanheira and Alexander Edwards appear as co-authors due to their contribution in the 
manuscript preparation.  
On chapter 6 “Portable smartphone quantitation of prostate specific antigen (PSA) in a 
fluoropolymer microfluidic device” Poonam Gehlot and  Kalpita Sidapra appear as co-authors 
due to their contribution in the set up of MCF smartphone detection during their final 
undergraduate project. Alexander Edwards appears as a co-author due to his contribution in 
the manuscript revision.  
 
  
iv 
 
Table of Contents 
1. INTRODUCTION ................................................................................................................................... 1 
1.1. RESEARCH GAP AND THESIS AIM ............................................................................................................... 1 
1.2. FUNDAMENTALS .................................................................................................................................. 5 
1.2.1. Immunoassays: an extremely sensitive bioanalytical tool ......................................................... 5 
1.2.2. Antibody-antigen equilibrium .................................................................................................. 7 
1.2.3. Immunoassays configuration ................................................................................................... 8 
1.2.4. Sandwich ELISA ..................................................................................................................... 10 
1.2.5. ELISA performance ................................................................................................................ 11 
1.2.6. Considerations of solid-phase immunoassays ......................................................................... 12 
1.2.7. Enzymes: powerful tools for signal amplification in immunoassays ......................................... 14 
1.2.8. Immunoassay miniaturisation ................................................................................................ 16 
1.3. MICROFLUIDIC IMMUNOASSAYS FOR QUANTITATION OF PROTEIN BIOMARKERS: STATE-OF-THE-ART......................... 18 
1.3.1. Summary ............................................................................................................................... 18 
1.3.2. Introduction .......................................................................................................................... 18 
1.3.3. Antibody immobilisation ........................................................................................................ 24 
1.3.3.1. Passive adsorption to surfaces .........................................................................................................24 
1.3.3.2. Covalent binding ..............................................................................................................................27 
1.3.3.3. Combined immobilisation techniques ...............................................................................................30 
1.3.3.4. The relevance of surface area and surface-area-to-volume ratio .......................................................31 
1.3.4. Sample preparation ............................................................................................................... 33 
1.3.5. Fluid handling control ............................................................................................................ 34 
1.3.5.1. Pressure driven systems ...................................................................................................................35 
1.3.5.2. Centrifugal forces ............................................................................................................................35 
1.3.5.3. Magnetic forces ...............................................................................................................................36 
1.3.5.4. Passive flow systems ........................................................................................................................36 
1.3.6. Detection modes, signal amplification and readout systems ................................................... 38 
1.3.7. Manufacturing of microfluidic devices ................................................................................... 44 
1.3.8. Current challenges and perspectives ...................................................................................... 45 
1.4. STATE-OF-THE-ART OF PLASTIC MICROCAPILLARY FILMS (MCFS) ................................................................... 47 
1.4.1. The novel melt-extrusion process ........................................................................................... 49 
1.4.2. Geometrical and polymer related aspects of the Microcappilary Film (MCF) ........................... 50 
1.4.3. Preliminary data available for immunoassays in MCFs ........................................................... 54 
1.5. GENERAL METHODOLOGICAL CONSIDERATIONS, UNIQUE TO THE WORK REPORTED IN THIS THESIS ............................ 56 
2. ANTIBODY (IGG) ADSORPTION ONTO FEP-TEFLON MICROCAPILLARY SURFACES FOR QUANTITATIVE 
POINT-OF-CARE DIAGNOSTICS ....................................................................................................................... 60 
2.1. ABSTRACT ........................................................................................................................................ 60 
2.2. INTRODUCTION .................................................................................................................................. 61 
2.3. MATERIALS AN METHODS .................................................................................................................... 64 
2.3.1. Materials & Reagents ............................................................................................................ 64 
2.3.2. Determination of adsorbed mass antibody ............................................................................. 65 
2.3.3. Kinetics of adsorption to capillary surfaces ............................................................................. 67 
2.3.4. Quantitation of antibody adsorbed onto FEP-Teflon by ELISA technique ................................. 67 
2.3.5. MCF ELISA Digital Image Analysis .......................................................................................... 68 
2.3.6. IL-1β sandwich ELISA ............................................................................................................. 68 
2.4. RESULTS AND DISCUSSION .................................................................................................................... 69 
2.4.1. Surface capacity of FEP-Teflon MCF for antibody adsorption .................................................. 69 
v 
 
2.4.2. Kinetics of adsorption antibody (IgG) onto FEP-Teflon MCF .................................................... 74 
2.5. CONCLUSION ..................................................................................................................................... 79 
3. IMPACT OF HRP ENZYMATIC OPTIMIZATION IN SANDWICH ELISA MICROFLUIDIC SYSTEMS ............. 81 
3.1. ABSTRACT ........................................................................................................................................ 81 
3.2. INTRODUCTION .................................................................................................................................. 81 
3.3. MATERIALS AND METHODS................................................................................................................... 83 
3.3.1. Materials............................................................................................................................... 83 
3.3.2. Methodology ......................................................................................................................... 84 
3.4. RESULTS AND DISCUSSION..................................................................................................................... 86 
3.5. CONCLUSIONS ................................................................................................................................... 93 
4. THE FLOW EFFECT ON ASSAYS SPEED AND SENSITIVITY IN MICROCAPILLARY IMMUNOASSAYS ....... 94 
4.1. ABSTRACT ........................................................................................................................................ 94 
4.2. INTRODUCTION .................................................................................................................................. 95 
4.3. MATERIALS AN METHODS .................................................................................................................... 98 
4.3.1. Materials & Reagents ............................................................................................................ 98 
4.3.2. System overview and kinetic model ........................................................................................ 98 
4.3.3. Flow effect determination on antibody binding in FEP-Teflon microcapillaries ........................ 99 
4.3.4. Image analysis of MCF strips................................................................................................ 101 
4.4. RESULTS AND DISCUSSION .................................................................................................................. 102 
4.5. CONCLUSION ................................................................................................................................... 109 
5. A LAB-IN-A-BRIEFCASE FOR RAPID PSA SCREENING FROM WHOLE BLOOD ..................................... 110 
5.1. ABSTRACT ...................................................................................................................................... 110 
5.2. INTRODUCTION ................................................................................................................................ 110 
5.3. MATERIALS AND METHODS................................................................................................................. 113 
5.3.1. Reagents and Materials ....................................................................................................... 113 
5.3.2. “Lab-in-a-briefcase” components ......................................................................................... 114 
5.3.3. PSA Sandwich ELISA in the fluoropolymer MCF ..................................................................... 115 
5.3.4. PSA Sandwich ELISA optimization the fluoropolymer MCF .................................................... 117 
5.3.5. PSA IA Optimization in the MCF ........................................................................................... 118 
5.3.6. PSA IA in the Microtiter Plate (MTP) ..................................................................................... 118 
5.3.7. Measurement of Absorbance, Absorbance Ratio and Intra-assay variability in MCF strips..... 119 
5.3.8. Robustness studies for PSA sandwich ELISA in the MCF......................................................... 120 
5.4. RESULTS AND DISCUSSION................................................................................................................... 121 
5.4.1. Optimisation of manual and portable Lab-in-a-briefcase ELISA ............................................. 121 
5.4.2. Effect of MCF dimensions on assay signal............................................................................. 123 
5.4.3. Kinetics of ELISA in MCF capillaries....................................................................................... 125 
5.4.4. Assay performance with biological samples ......................................................................... 128 
5.4.5. Robustness of PSA sandwich ELISA in the MCF using MSA devices ........................................ 132 
5.5. CONCLUSIONS ................................................................................................................................. 134 
6. PORTABLE SMARTPHONE QUANTITATION OF PROSTATE SPECIFIC ANTIGEN (PSA) IN A 
FLUOROPOLYMER MICROFLUIDIC DEVICE ................................................................................................... 136 
6.1. ABSTRACT ...................................................................................................................................... 136 
6.2. INTRODUCTION ................................................................................................................................ 136 
6.3. MATERIALS AND METHODS................................................................................................................. 138 
6.3.1. Materials & Reagents .......................................................................................................... 138 
6.3.2. MCFphone – System overview.............................................................................................. 139 
vi 
 
6.3.3. PSA sandwich ELISA (Enzyme Linked ImmunoSorbent Assay) ................................................ 141 
6.3.3.1. Fabrication of MCF test strips ......................................................................................................... 141 
6.3.3.2. PSA sandwich assay ....................................................................................................................... 142 
6.3.4. Colorimetric and Fluorescence detection .............................................................................. 143 
6.3.5. Image Analysis .................................................................................................................... 144 
6.3.6. Recovery PSA experiments from whole blood samples .......................................................... 146 
6.4. RESULTS AND DISCUSSION .................................................................................................................. 146 
6.4.1. Sensitivity of MCFphone for detection of chromogenic and chemifluorescence substrates .... 146 
6.4.2. Effect of Enzyme on sensitivity of PSA sandwich ELISA in the MCFphone ............................... 149 
6.4.3. PSA measurement in whole blood samples........................................................................... 152 
6.5. CONCLUSIONS ................................................................................................................................. 154 
7. MANAGING BIOLOGICAL MATRIX INTERFERENCE IN MICROFLUIDIC MICROCAPILLARIES ............... 156 
7.1. ABSTRACT ...................................................................................................................................... 156 
7.2. MATERIALS AN METHODS .................................................................................................................. 160 
7.2.1. Materials & Reagents .......................................................................................................... 160 
7.2.2. Sample matrix viscosity effect on kinetics of antibody-antigen binding ................................. 161 
7.2.3. Viscosity measurements ...................................................................................................... 162 
7.2.4. Capillary diameter effect on kinetics of antibody-antigen binding in biological matrices ....... 162 
7.2.5. Mass determination of mouse IgG adsorbed by solution depletion technique in variable size 
MCF 163 
7.2.6. Overcoming biological sample matrix in MCF platform – three antibody-antigen systems .... 164 
7.2.7. Image analysis of MCF IA strips............................................................................................ 167 
7.2.8. Kinetic model antibody-antigen kinetic ................................................................................ 167 
7.3. RESULTS AND DISCUSSION .................................................................................................................. 168 
7.3.1. Sample matrix viscosity effect on kinetics of antibody-antigen binding ................................. 168 
7.3.2. Capillary diameter effect on kinetics of antibody-antigen binding in biological matrices ....... 171 
7.3.3. Overcoming biological sample matrix in MCF platform – three antibody-antigen systems .... 174 
7.3.4. General methodology for overcoming biological sample matrix in MCF platform .................. 181 
7.4. CONCLUSION ................................................................................................................................... 182 
8. PARTICLE LABEL DETECTION IN FEP-TEFLON MICROFLUIDIC CAPILLARIES ....................................... 184 
8.1. ABSTRACT ...................................................................................................................................... 184 
8.2. INTRODUCTION ................................................................................................................................ 184 
8.3. MATERIALS AND METHODS................................................................................................................. 187 
8.3.1. Materials & Reagents .......................................................................................................... 187 
8.3.2. Neutravidin coated carbon nanoparticles detection ............................................................. 188 
8.3.3. Gold nanoparticles detection with silver enhancement. ........................................................ 188 
8.3.4. MCF image analysis ............................................................................................................. 189 
8.4. RESULTS AND DISCUSSION .................................................................................................................. 189 
8.4.1. Carbon nanoparticles........................................................................................................... 189 
8.4.2. Gold nanoparticules label with silver enhancement .............................................................. 192 
8.5. CONCLUSION ................................................................................................................................... 193 
9. CONCLUSIONS AND FUTURE PERSPECTIVES .................................................................................... 194 
10. CUMULATIVE REFERENCE LISTING ................................................................................................... 198 
 
  
vii 
 
List of Figures 
Figure ‎1:1 – Immunoglobulin G (IgG) structure used in IA. ................................................................................ 6 
Figure ‎1:2 – Heterogeneous IA configurations................................................................................................... 9 
Figure ‎1:3 – General phases and steps of a sandwich ELISA heterogeneous immunoassay............................... 10 
Figure ‎1:4 – The immunoassay standard Microtiter Platform (MTP). ............................................................... 14 
Figure ‎1:5 – Velocity profile of a fluid in laminar flow regime. ......................................................................... 17 
Figure ‎1:6 – Examples of antibody covalent binding to surface chemistries and strategies for microfluidic 
devices used in biomarkers quantitation. ............................................................................................... 29 
Figure ‎1:7 – Strategies used for enhancing surface area in microfluidic devices for antibody immobilisation. .. 32 
Figure ‎1:8 – Examples of microfluidic approaches for whole blood sample treatment. .................................... 34 
Figure ‎1:9 – Fluid control approaches implemented in microfluidic devices for protein biomarker quantitation.
 .............................................................................................................................................................. 37 
Figure ‎1:10 – Detection modes and readout systems used in microfluidic devices for protein biomarker 
quantitation. .......................................................................................................................................... 41 
Figure ‎1:11 – The impact on CRP assay sensitivity and dynamic range of signal amplification on a microring 
resonator. .............................................................................................................................................. 43 
Figure ‎1:12 – The heated extrusion line used in the manufacturing of MCFs. L is the melt drawing length.117 .. 49 
Figure ‎1:13 - Diagram of the extrusion die used in the manufacturing of MCFs. Above die shown in the inset 
photograph at the right hand side.117 ..................................................................................................... 50 
Figure ‎1:14 – Comparison of optical properties of a fused silica capillary and FEP capillaries with different 
geometries.127 ........................................................................................................................................ 51 
Figure ‎1:15 – Colorimetric signal quantitation in MCF ELISA using a flatbed scanner. ...................................... 52 
Figure ‎1:16 - Geometrical characterisation of the MCF batch used for the experimental work presented in this 
thesis. .................................................................................................................................................... 54 
Figure ‎1:17 – Overview of the FEP-Teflon Microcapillary Film (MCF). .............................................................. 55 
Figure ‎1:18 - Strategies used for fluid handling in MCF assays: single syringe, MSA (Multiple syringe aspirator) 
and peristaltic pumps. ............................................................................................................................ 57 
Figure ‎1:19 – Multiple syringe aspirator (MSA) device used for PSA ELISA in the fluoropolymer MCF. .............. 58 
Figure ‎2:1 – MCF produced from fluorinated ethylene propylene copolymer (FEP-Teflon)............................... 64 
Figure ‎2:2 - IgG adsorption onto FEP-Teflon MCF 200 µm i.d. .......................................................................... 70 
Figure ‎2:3 - Effect of antibody density on detection zone in antigen-antibody binding on FEP-Teflon capillaries.
 .............................................................................................................................................................. 73 
Figure ‎2:4 - Antibody adsorption kinetics onto FEP-Teflon microcapillaries. .................................................... 75 
Figure ‎2:5 - IL-1β sandwich ELISA in FEP-Teflon capillaries............................................................................... 76 
Figure ‎2:6 - Langmuir and kinetics of IgG adsorption to different capillary surfaces. ........................................ 78 
Figure ‎3:1- Aspects of colorimetric detection in MCF and peroxidase inhibition. ............................................. 88 
Figure ‎3:2 - Kinetics of HRP conversion of OPD for varying concentration of chromogenic substrate. .............. 92 
Figure ‎3:3 - Comparison between two different OPD and H2O2 molar ratio in MCF sandwich assays. ............. 93 
Figure ‎4:1 – In flow MCF flow IA. .................................................................................................................. 101 
Figure ‎4:2 – Flow effect on antibody binding in the FEP-Teflon MCF at high antigen concentration regimes (1 
µg/ml nti-IgG). ..................................................................................................................................... 103 
Figure ‎4:3 - Flow effect on kinetics of antibody binding in the MCF at low antigen concentration (60 ng/ml). 106 
Figure ‎5:1 - Main components of “Lab-in-a-briefcase” for PSA screening. ...................................................... 114 
Figure ‎5:2 - Optimisation of PSA sandwich assay conditions in the fluoropolymer MCF platform using the MSA.
 ............................................................................................................................................................ 123 
Figure ‎5:3 - Correlation between capillary height (h) and absorbance (Abs) variability across a 10 bore 
fluoropolymer MCF material. ............................................................................................................... 125 
viii 
 
Figure ‎5:4 - Kinetic study of all assay steps illustrating minimum incubation times required for signal saturation 
with 3.75 ng/ml of PSA recombinant protein. ....................................................................................... 127 
Figure ‎5:5 - PSA sandwich ELISA in MCF platform using the MSA device. ....................................................... 130 
Figure ‎5:6 – Comparison of MCF vs MTP PSA colorimetric IA. ........................................................................ 131 
Figure ‎5:7 - Robustness of PSA sandwich assay in the MCF............................................................................ 133 
Figure ‎6.1 - MCFphone system overview. ..................................................................................................... 140 
Figure ‎6.2 - PSA sandwich assay with MCFphone signal quantitation. ............................................................ 143 
Figure ‎6.3 - Sensitivity of MCFphone for colorimetric and fluorescence detection. ........................................ 148 
Figure ‎6.4 - PSA full response curves in buffer, with MCFphone colorimetric and fluorescence systems. ....... 150 
Figure ‎6.5 - Smartphone fluorescence detection of PSA in the MCF in whole blood. ...................................... 154 
Figure ‎7:1 – Biological matrix effect in microcapillaries. ................................................................................ 160 
Figure ‎7:2 – Effect of sample matrix viscosity in antibody-antigen kinetics in an IL-1β sandwich assay, using 223 
µm diameter bore MCF. ....................................................................................................................... 169 
Figure ‎7:3 – Effect of human serum and whole blood matrices interference in IL-1β assay in the MCF platform 
in 223 ± 23 µm capillaries. .................................................................................................................... 170 
Figure ‎7:4 – Relationship between human serum matrix effect and capillary diameter in MCF assays. .......... 172 
Figure ‎7:5 - Surface coverage effect on human serum matrix interference on mouse IgG and Anti-IgG binding in 
223 µm capillary assays. ....................................................................................................................... 175 
Figure ‎7:6 - Surface coverage effect on human serum matrix interference of PSA sandwich assay in 223 µm 
capillary assays. ................................................................................................................................... 176 
Figure ‎7:7 - Surface coverage effect on human serum matrix interference of IL-1β sandwich assay in 200 µm 
capillary assays. ................................................................................................................................... 178 
Figure ‎7:8 – Methodology diagrams for minimizing biological matrix interference in MCF sandwich assays. .. 181 
Figure ‎8:1 – Microcapillary Film (MCF) IA platform........................................................................................ 187 
Figure ‎8:2 – Biotinylated antibody MCF adsorbed detection with carbon nanoparticles neutravidin coated (1:10 
dilution). .............................................................................................................................................. 190 
Figure ‎8:3– Carbon nanoparticles neutravidin coated detection of 40 µg/ml of biotin-antibody in the MCF. .. 191 
Figure ‎8:4 – Gold nanoparticles MCF IAs with silver enhancement. ............................................................... 192 
 
 
 
 
 
 
 
  
ix 
 
List of Tables 
 
Table 1:1 – Microfluidic heterogeneous IA for protein biomarkers quantitation reported between 2005 and 
2015. ..................................................................................................................................................... 21 
Table 1:2 - Available functional groups in proteins (including antibodies) and functional groups required on the 
surface for protein immobilisation.82 ...................................................................................................... 28 
Table 1:3 – Innovations in Microcapillary Films (MCFs) outside this PhD thesis. ............................................... 48 
Table 1:4 – Refractive index of thermoplastics resins used in the manufacturing of MCFs.136 .......................... 50 
Table 1:5 – Optimised assay conditions found by Chaín for PSA MCF sandwich assay.138 ................................. 56 
Table 2:1- FEP-Teflon IgG adsorption parameters variation with pH and temperature. .................................... 71 
Table 2:2 - FEP-Teflon IgG adsorption kinetic parameters variation. ................................................................ 76 
Table 2:3 - IgG Adsorption parameters to different capillary surfaces.............................................................. 78 
Table 2:4 - IgG Adsorption kinetic parameters to different capillary surfaces (IgG concentration = 40 µg/ml). . 79 
Table 3:1 - Kinetic parameters (non-competitive/mixed inhibition) for the two different molar ratios of 
OPD/H2O2 studied. ................................................................................................................................. 90 
Table 4:1- Anti-IgG volume passed in 4 cm MCF strip/minute. ...................................................................... 101 
Table 4:2 – Kinetic parameters of antigen antibody binding with flow in antigen excess systems................... 104 
Table 4:3 – Kinetic parameters of antigen antibody binding with flow in antigen limited systems. ................. 107 
Table 5:1 - Experimental conditions used for sandwich ELISA detection of PSA in a 96 well MTP. .................. 119 
Table 5:2 - Incubation times of ELISA reagents in the standard Microtiter Plate (MTP) and in the novel 
Microcapillary Film (MCF)..................................................................................................................... 127 
Table 5:3 - Parameters of fully-optimised response curves in the MCF using MSA device. ............................. 131 
Table 6:1 - Sensitivity comparison between MCFphone colorimetric and fluorescence PSA assay. ................. 153 
Table 7:1 - Kinetic constants of IL-1β binding for 1 ng/ml of IL-1β shown if Figure 7:2A. ................................ 169 
Table 7:2 - Kinetic constants of IL-1β binding for 0.1 ng/ml of IL-1β shown in Figure 7:2A. ............................ 170 
Table 7:3 - Kinetic constants of anti-IgG binding in buffer in different capillary diameter MCF. ...................... 173 
Table 7:4 - Kinetic constants of anti-IgG binding in human serum in different capillary diameter MCF. .......... 174 
Table 7:5 – PSA sandwich assay sensitivity considerations in buffer and in human serum with 15 minutes 
sample incubation. ............................................................................................................................... 177 
Table 7:6 – IL-1β sandwich assay sensitivity considerations in buffer and in human serum, Figure 7:7. .......... 180 
 
x 
 
Thesis Outlines 
 
Chapter 1 presents a theoretical introduction to the work described in the thesis and is divided 
in 5 sections: 
 Section1.1 introduces the motivations behind the development of microfluidic 
diagnostics platforms for sensitive quantitation of protein biomarkers at point-
of-care (POC) settings and refers the main objectives of this PhD thesis. 
 Section 1.2 provides the basic background knowledge about immunoassays and 
their miniaturisation, which is important for the reader to understand the work 
carried out in this PhD project. 
 Section 1.3  presents an overview of microfluidic immunoassays for protein 
quantitation field in the past 10 years and discusses the state-of-the-art of 
several aspects within this field, such as antibody immobilisation, biological 
matrix interferences, fluid control and detection modes. 
 Section 1.4 presents the state-of-the-art of plastic microcapillary films (MCFs) 
since their invention in 2005, describing previous applications, manufacture 
process, geometry and optical properties of FEP-Teflon MCF used in 
immunoassays. Also, a description of all previous work performed with MCF 
immunoassays can be found in this section. 
 Section 1.5 describes some general methodology aspects used for MCF 
immunoassays and described in more detail in the experimental chapters.  
Chapter 2 describes the physical adsorption of antibodies to FEP-Teflon microcapillaries and 
discusses surface coverage and kinetic aspects of this process as well as their implications in 
immunoassay performance. Comparison of antibody adsorption aspects onto Linear low-
density polyethylene (LLDPE), glass and FEP-Teflon microcapillaries have been made. 
Chapter 3 describes the optimisation of HRP enzyme and OPD enzymatic substrate system in 
solution, which can be applied to immobilised enzymes in miniaturised systems due to the 
smaller diffusion distance in these environments. The impact of this optimisation in 
microfluidic immunoassays sensitivity and speed with low cost detection modes is discussed 
in this chapter. 
Chapter 4 presents the effect of antigen continuous flow incubations in capillaries 
immunoassays and its impact on immunoassay performance. The flow effect is explored for 
high and low antigen systems.  
Chapter 5 presents quantitation of clinical range PSA (prostate specific antigen) in whole 
blood samples using the Lab in a Briefcase. The Lab in a Briefcase presents a group of small 
components, including the MCF platform, that allow portable, power free and sensitive PSA 
quantitation in whole blood in 15 minutes. These results and concept were published in Lab-
on-a-Chip (Barbosa et. al., 2014, 14, 2918). 
xi 
 
Chapter 6 focus on the development of power free and portable detection mode for MCF 
assays, using a smartphone camera. Sensitive PSA quantitation was achieved in whole blood 
samples using colorimetric and fluorescence detection with a smartphone camera. This work 
was published in Biosensors and Bioelectronics (Barbosa et.al, 2015, 50, 5-14). 
Chapter 7 describes the biological matrix interference in MCF immunoassays and discusses 
strategies for overcoming this interference by manipulating the immobilised antibodies 
density and sample incubation time.  Proof of concept for three antibody-antigen systems, 
mouse IgG and anti-IgG, PSA and IL-1β sandwich assays, is presented. 
Chapter 8 explores particle detection in FEP-Teflon microcapillaries. Carbon nanoparticles 
and gold nanoparticles were used as labels in the MCF platform for protein quantitation. PSA 
quantitation from 10 to 100 ng/ml with silver enhanced gold nanoparticles is presented in this 
chapter. 
Chapter 9, the conclusion and future perspectives, presents a summary of the work performed 
in this PhD thesis and discusses future developments that could be undertaken to further 
improve automation and  sensitive  quantitation of biomarkers in the MCF platform at Point-
of-Care settings. 
Chapter 10 provides a list of all references cited in this thesis. 
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BSA Bovine Serum Albumin 
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Fc Constant fragment (antibody) 
Fab Variable fragment (antibody) 
TNF-α Tumor necrosis factor alpha 
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MSA Multiple syringe aspirator 
PBS Phosphate buffer saline 
OPD o-Phenylenediamine dihydrochloride 
FDA Food and Drug Administration 
4PL 4 Parameter Logistic 
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1. Introduction 
1.1. Research gap and thesis aim 
Clinical diagnostics influences about 70% of health care decisions, which means they are the 
foundation of an effective health care system. Life expectancy has increased massively in 
recent years due to clinical diagnostics developments. They provide critical physiological or 
biochemical information that physicians or patients need to take for the best health care 
decisions, and therefore improve patients’ life quality and expectancy. Thus, it is generally 
believed that diagnostics should be ubiquous, accurate, simple and accessible, allowing every 
person on the planet to make appropriate decisions about their own health status. However, 
health care expenses in diagnostics represent only 3 to 5% of total health care budget.
1
 
Moreover, current diagnostic tests remain complex and rely on expensive equipment, which 
limits their performance to centralised laboratories and big hospital facilities. 
Decentralising diagnostics requires developing diagnostic technologies that are simple, low 
cost, portable or semi-portable and reliable tests for a wide set of health conditions. Several 
health conditions, such as cancer, cardiac diseases and infectious diseases (e.g. sepsis), rely 
on extremely sensitive quantitation of proteins in complex biological samples, such as whole 
blood. Such evaluation can only be reliably achieved in a controlled laboratory environment 
utilising sensitive and high precision equipment, which is usually bulky, expensive and 
demands specialised technical personnel to operate them. In order to achieve diagnostics 
decentralisation it is therefore necessary to translate laboratory techniques into Point-of-Care 
(POC) tests or create new technologies capable of detecting important diseases at POC 
settings. 
Diagnostics performance at POC requires the diagnostic test to meet the patient’s need and 
not the other way around. There are several levels of POC testing, from the ones performed 
by the patient at his home (often called over-the-counter tests) to the ones performed by 
physicians and nurses in local health care facilities. All levels contribute to diagnostic 
decentralisation and therefore to increased accessibility and patient informed decisions. 
POC testing is a need in both developed and developing countries. In developing countries, 
the health care facilities accessible to the majority of the population have very basic 
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laboratory equipment and workers with little training. Moreover, those facilities generally 
present intermittent electricity with power fluctuations, ambient temperature ranging from 10 
to more than 40ºC, dust, wind, pathogens and no acess to pipped water. Thus maintaining and 
calibrating even moderately complex instruments is challenging. Performing diagnostic tests 
requires, therefore, a different approach in developed and developing countries.
2
 
The role and impact of POC diagnostics differs with the setting. In developed countries POC 
tests contribute for what is called “personalised medicine”, reducing the frequency of hospital 
visits, travel expenses, loss of work time and above all making patients more responsible for 
managing their own health conditions. According to some studies,
3
 this improves patient 
adoption to diagnostic and treatment regimes, while reducing the levels of stress, since the 
patient has more control on his own well being.
2
 POC tests also contribute for the autonomy 
of patients towards the healthcare systems, which improves their overall efficiency, as the 
patient will only dislocate for a health centre if the diagnostic results are abnormal. Therefore, 
with less affluence, health care centres can provide a better service to their patients. In 
developing countries, POC tests dictates patient’s treatment but also survival rate, because in 
many cases they are the only mean of diagnostics available. The majority of the population 
has to travel large distances to access healthcare facilities. Travel is limited due to poor 
transport facilities and lack of economical income. Overall, the availability of POC diagnosis 
for a broad range of diseases will not just complement or improve the efficiency of the 
current healthcare system, but they are also the only way of increasing life expectancy for 
living in remote areas. 
The targeted diseases for POC tests also vary with regions. Infectious diseases, such as 
respiratory infections, AIDS and malaria are the main cause of death in developing countries, 
while in developed countries (e.g. US) the main cause of death is due to cancer and heart 
diseases.
1
 Non-communicable diseases, also known as chronic diseases, are non-contagious 
diseases responsible for 68% of deaths in 2012 worldwide, according to the fact sheet of the 
World Health Organization (WHO),
4
 and include cardiovascular diseases, cancer, chronic 
respiratory diseases and diabetes.
5
 
According to WHO, all POC diagnostics devices should follow the ASSURED policy: 
affordable, sensitive (avoid false negative results), specific (avoid false positive results), user-
friendly (easy to perform and use non invasive specimens), rapid & robust, equipment-free 
and delivered (accessible to end users).
6
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A number of POC tests have effectively made a difference on improving the health systems 
in both developed and developing countries, which are the case of glucose test for diabetes 
monitoring. In this case, the well-established leader of POC testing is based in a redox-
couple-mediated enzymatic oxidation of glucose and aims to detect a concentration of analyte 
on mM range, which is a much higher concentration than diagnostic markers.
2,7
 Another well 
established technology for POC testing is the Lateral Flow (LF) immunochromatographic 
assay, which is based in the specific reaction between antigen-antibody and signal detection 
of antigen-antibody complex. The most successful product based on LF is the pregnancy test 
which measures the level of hCG (human chorionic gonadotropin) levels, however other LF 
products that measure ovulation confirmation, HIV, influenza AB and group A of 
Streptococcus bacteria are also commercially available.
2
 This diagnostic test also targets 
antigens present at high concentrations. Some lab-on-a-chip technologies have been approved 
by FDA (Food and Drug Administration) or/and CE marked, such as iSTAT device for blood 
chemistries, coagulation and cardiac markers, and the Triage meter for cardiovascular 
diseases, drugs abuse and water parasites. Nevertheless, these devices have not yet achieved 
the mass production and commercialisation level of either glucose tests or LF tests.
7
 
POC tests remain a need for non-communicable diseases. These health conditions can be 
treated and the survival rate increases with early diagnostics. Since the 19
th
 century a 
correlation between organic compounds and certain health conditions has been established, 
and nowadays a number of measurable analytes and their concentration are used to diagnose 
certain diseases, but also to determine predisposition or the outcome of the disease 
(monitoring and prognosis).
8
 These analytes are intrinsically different, although they can be 
grouped into protein, cells, and nucleic acids biomarkers. The type of analyte will define the 
type of assay performed and therefore the type of POC diagnostic device. Non-communicable 
diseases are usually diagnosed through protein biomarkers, such as CK-MB, myoglobulin, 
troponin I and T for cardiovascular diseases (predicting a heart attack or monitoring after a 
myocardial infarction);
9,10
 D-dimer absence in blood can exclude a possible pulmonary 
embolism;
11
 PSA (prostate specific antigen) and CA-125 are used for evaluation and 
progression of prostate
12
 and ovarian
13
 cancer, respectively, as well as other type of cancer 
biomarkers that are currently being developed.
14,15
 Infectious diseases like sepsis can also be 
diagnosed through quantitation of cytokine levels.
16
 
Diagnosis through quantitation of protein biomarkers requires sensitivity in the range of 
concentration nM to fM that cannot be met with existing LF tests.
7,8
 For example, the clinical 
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threshold for Troponin I (TnI) in acute coronary syndrome, established in 2007, is 40 pg/ml 
of TnI;
17
 sepsis diagnosis demands detection levels of cytokines (e.g. IL-6, TNFα, IL-10) in 
the range of 17 to 70 pg/ml;
16
 PSA (prostate specific antigen) established clinical threshold is 
4 ng/ml, although cut-off values of 1 ng/ml have been proposed for screening purposes.
18
 
Consequently, biomarker quantitation is essential for diagnosing non-communicable diseases, 
which are responsible for the largest number of deaths worldwide. 
The main objective of this thesis is to develop protocols for quantitative protein sandwich 
immunoassays (IA) in a novel microfluidic platform allowing non-comunicable diseases to 
be detected for POC testing, which presupposes the creation of an ASSURED POC 
diagnostic platform. This was achieved through miniaturisation of IA in a fluoropolymer 
Microcapillary Film (MCF). The MCF consists of a parallel array of 10 microcapillaries 
embedded in a plastic film made of FEP-Teflon, produced by a patented melt-extrusion 
process, an affordable manufacturing process that uses low cost raw materials, therefore 
suitable for large scale cost effective fabrication of POC microfluidic devices. 
The main objectives of this thesis are: 
 To study and characterise passive antibody adsorption onto FEP-Teflon micro-
capillaries; 
 To study enzyme kinetics in miniaturised capillaries and its effect on assay sensitivity 
and speed; 
 To understand the effect of flow and biological matrix in antibody-antigen binding 
kinetics and on FEP-Teflon capillaries IA and their input on assay sensitivity; 
 To develop an optimised PSA (prostate specific antigen) immunoassay microfluidic 
test based on fluoropolymer MCF; 
To test different optical detection modes (e.g. colorimetric, fluorescent, carbon nanoparticles 
and gold nanoparticle) and low-cost optoelectronics read-out systems (e.g. Flatbed Scanner 
and Smartphone) for rapid and sensitive PSA quantitation. 
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1.2. Fundamentals 
1.2.1. Immunoassays: an extremely sensitive bioanalytical tool 
An immunoassay (IA) is a very powerful analytical chemical tool that uses antibodies 
properties to detect and accurately quantify a substance in a complex heterogeneous sample. 
IAs are one of the most common analytical techniques used in life sciences. Therefore, there 
is a large range of antibodies specific to a vast range of compounds commercially available. 
The high affinity between antibody and antigen enables such assays to achieve high 
sensitivity (in this thesis expressed as a direct correlation of Lower Detection Limit)
19,20
, and 
consequently the detection of very low concentration of antigen or antibody in a sample.
21
 
Antibodies (immunoglobulins) are glycoproteins with a unique characteristic, the ability to 
bind to a large range of molecules and cells, the antigens, with remarkable specificity and 
high binding strength between the molecule and the antibody. This binding strength is termed 
affinity.
22
 
Antibody properties are intimately related to their structure. Although immunoglobulins can 
be grouped in five different classes (IgG, IgA, IgM, IgD, IgE) that manifest structure 
diversity, they all share a monomeric subunit responsible for antigen binding. This 
monomeric subunit is constituted by two light chains (approximately 220 amino acids) and 
two heavy chains (450-575 amino acids) linked by disulphide bonds, responsible for 
stabilizing the molecular structure.
23
 The N-terminal domain of the polypeptide light and 
heavy chains is variable (varies in sequence and number of residues from antibody to 
antibody) and the C-terminal domain is constant in both chains (Figure 1:1A). The fragment 
containing the variable domains of light and heavy chains, plus the first constant domains is 
called the Fab. The constant fragments belonging to the two heavy chains, consisting of CH2 
and CH3 domains, are called Fc. Carbohydrates have been found in Fc fragment, although 
their biological functions are not yet known. The segment peptide that joins the Fab and Fc is 
called hinge (Figure 1:1).
23
 The hinge region contributes to antibody flexibility, important for 
the antigen binding capacity. 
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Figure 1:1 – Immunoglobulin G (IgG) structure used in IA.  
A Schematic representation of IgG molecule, showing the Fab fragments, with the variable 
regions (blue rectangles) and constant regions (orange and purple lines), the Fc fragment, 
composed by constant domains, and the disulphide bonds (-SS-), responsible for the heavy 
and light chains bonding and the chemical stability of the molecule. B Tree dimensional 
structure of IgG molecule, with approximate dimensions of 14.2 x 8 x 4 nm and relative 
molecular weight of 150000 Da.
24
 
 
The variable regions along the Fab fragment are involved in antigen binding. At the 
extremities of variable regions there are looped segments formed by hypervariable regions, 
which form a cleft in the three-dimensional structure. A specific part of the antigen (antigenic 
determinant or epitope) contacts with the antibody at this region, which is termed 
Complementary-Determining Region (CDR). Although the constant domains do not form 
bonds with the antigen, they are essential to produce the folding and maintaining the integrity 
of the binding site.
22
 Depending on the cleft dimensions more than one epitope, specific part 
of antigen that binds to the antibody, can bind to a CDR. Antibody-antigen binding happens 
due to multiple non-covalent intermolecular forces, such as hydrogen bonds, electrostatic, 
van der Waals and hydrophobic, which although individually weaker than covalent bonds 
make the antibody-antigen complex stable due to the binding nature multiplicity. The balance 
or energy summation (strength) between attractive and repulsive forces of an epitope with a 
CDR or the summation of energy dictates the complex affinity. 
The antigen binding specificity to an antibody is the key element for measuring analytes, the 
target molecule, in IAs. This specificity is given by the amino acids sequence and residues 
and by the folding of the polypeptide segments in the CDRs. A gene rearrangement process 
during B-cells differentiation makes possible the existence of a significant variety of 
antibodies creating specific CDRs to certain epitopes. 
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Antibodies are produced in mammals due to the presence of an immunogen, a molecule 
capable of inducing immune response when injected into an animal. An immunogen presents 
several epitopes, which allows the production of several antibodies specific to each epitope, 
generating a mixture of antibodies with different binding affinities and specificities. These 
antibodies are called polyclonal antibodies, since they are produced by more than one clone 
of B lymphocyte cells. Monoclonal antibodies, on the other hand, are the result of a selected 
clone of B lymphocyte, recognising only one epitope of the immunogen, therefore presenting 
similar affinity and specificity.
21,25
 
1.2.2. Antibody-antigen equilibrium 
IA are based in antibody-antigen interactions, whose understanding through the reaction 
kinetics is essential for assay development, since they will affect assay parameters, such as 
speed and sensitivity. 
The law of mass action represents the reaction between antibody-antigen, and is defined 
according to equations (1:1) and (1:2), in the following way: 
 [𝐴𝑔] + [𝐴𝑏]  [𝐴𝑔 − 𝐴𝑏] (1:1) 
   
 
𝐾𝑒𝑞 =  
𝐾𝑜𝑛
𝐾𝑜𝑓𝑓
=  
[𝐴𝑔 − 𝐴𝑏]
[𝐴𝑔]. [𝐴𝑏]
 
(1:2) 
where [Ag] is the concentration of antigen, [Ab] is the concentration of antibody, [Ag − Ab] 
is the concentration of antigen-antibody complex, Kon is the rate association constant, Koff is 
the rate dissociation constant, and Keq is the equilibrium or affinity constant, which represents 
the ratio of bond and unbound analyte and antibody, a key feature to understand antibodies 
performance in IA. 
Scatchard represented antibody-antigen equilibrium in equation (1:3), as follows: 
 𝐵
𝐹
= 𝐾𝑎(𝑁 − 𝐵) 
(1:3) 
where B is the concentration of bond antibody; F is the concentration of free antibody; Ka is 
the affinity constant, and (N-B) is the concentration of unoccupied sites. 
Kon 
Koff 
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Antibody affinity is the strength to which a CDR of an antibody binds to a specific epitope on 
an antigen. This means that high affinity antibodies will move the equilibrium towards the 
formation of antibody-antigen complex and the quantity of antigen bond at equilibrium will 
be higher compared with low affinity antibodies. However, antibody affinity is difficult to 
obtain experimentally as it demands an antigen with only one epitope and one monovalent 
antibody. Such conditions are hard to get in real world situations, since most of antibodies 
have at least two CDRs. In addition, polyclonal antibodies bind to all the epitopes of an 
antigen with different affinities, which means that measuring the affinity constant of a 
reaction between polyclonal antibodies with an antigen, only gives an average affinity. The 
practical manifestation of antibody-antigen affinity or the functional antibody-antigen affinity 
is termed “avidity”. Therefore, avidity is the overall strength of an antibody-antigen complex, 
which is dependent on the affinity of the antibody to the epitope, on the valency of antibody 
and antigen, and on the structural arrangement of the parts that interact. As the overall 
strength of antibody-antigen complex is influenced by conformational changes during 
immobilisation to solid surfaces or CDR distance, these aspects will also affect the avidity of 
an antibody-antigen complex. Avidity is a better measure of antibody binding in real world 
situations, because high avidity can compensate for low affinity.
21
 
1.2.3. Immunoassays configuration 
IAs have numerous applications, for example they can be used to detect pollutants in a water 
sample,
26
 undesirable substances or microorganisms in food,
27
 and metabolites, 
microorganisms and biomarkers in clinical diagnostics.
28
 IAs can be homogeneous, if the 
signal occurs during the immunoreaction, avoiding separation between the bound and 
unbound immunoreagents, or heterogeneous, if they require separation between 
immunocomplex and free immunoreagents.
29
 Due to the isolation of the antibody-antigen 
complex from unbound reagents, heterogeneous IA are the most sensitive and widely used for 
quantitative IA, presenting competitive and non competitive configurations (Figure 1:2). 
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Figure 1:2 – Heterogeneous IA configurations. 
A Immobilised antigen approach – immobilised antigen and free antigen compete for anti-
antigen label antibody. B Immobilised antibody approach – label antigen competes with 
antigen from the sample for anti-antigen antibody bonding. C Immobilised antigen approach 
– label anti-antigen antibodies bind to immobilised antigen. D Sandwich approach – antigen 
binds to an anti-antigen antibody immobilised and a second label antibody, also specific to 
the antigen, binds to the complex. 
 
In competitive IA the analyte is mixed with a limited quantity of tracer (label analyte or 
antigen). The mixed solution is incubated with a limited amount of antibody specific to the 
analyte. After incubation time, signal of bound or free tracer reagents is measured. In 
competitive IA the signal is inversely proportional to analyte/antigen concentration.
29
 
In non competitive IA the detection antibodies or antigens are in excess, so that after 
incubation time all analyte/antigen is in an immunocomplex form, being this quantified and 
related to the analyte. In this case, the signal is directly proportional to the analyte/antigen 
concentration.
29
 
Signal detection is extremely important in all IA configurations. The detection mode can be 
direct, when the signal-carrying or signal-generating molecule (e.g. radioisotope, enzyme, 
fluorescent or chemiluminescent label) is attached directly to one of the immunoreactants, or 
indirect, when the signal-carrying or signal-generating molecule is linked non covalently and 
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specifically bound to the immunocomplex after the immunoreaction is completed. An 
example of this happens whenever an enzyme label is conjugated with an avidin molecule 
and the enzymatic complex binds to the biotinylated detection antibody (DetAb) bound to the 
analyte/antigen.
29
 
1.2.4. Sandwich ELISA 
A sandwich ELISA (Enzyme Linked Immunosorbent Assay) immunoassay is a 
heterogeneous non competitive assay, which uses the sandwich approach and an enzyme as a 
detection label (Figure 1:3). 
 
Figure 1:3 – General phases and steps of a sandwich ELISA heterogeneous immunoassay. 
Immobilising an antibody on a surface is a feature of heterogeneous IA and is further 
discussed in this thesis, in chapter 2. The washing procedures are also essential to separate 
the bound from the unbound antigen and to ensure a better assay performance in terms of 
sensitivity. Therefore, one or more washing steps are generally performed after each step of 
an IA. In respect to sensitivity, the main washing steps are the ones related to the analyte, 
DetAb and enzyme removal, since these reagents are the ones responsible for non-specific 
binding which will decrease the signal to noise ratio. After immobilising the capture antibody 
(CapAb) on the surface, a solution containing a non-reactant protein is added in order to 
cover the remaining surface exposed and another washing step will remove unbound or 
loosely bound molecules from the surface. 
The second stage of a sandwich assay is related to two antibody-antigen reactions, the 
binding of the antigen to the immobilised antibody and the binding of the DetAb to the bound 
antigen. These two reactions will be influenced by the antibody-antigen affinity, by the 
overall avidity of the immobilised antibody layer, which will depend on the concentration of 
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active CDR’s on the antibodies, by diffusion distance from the bulk to the antibody 
immobilised layer, and by the biological matrix effect, which can frequently interfere in the 
antibody-antigen binding. 
The last stage of a sandwich assay, highlighted in Figure 1:3, is the amplification and 
detection mode. The detection mode has to be coupled with a read out system (e.g. microtiter 
plate, microscope, fluorimeter, scanner, etc.) for signal detection and following quantitation, 
and will depend on it and on the solid support used for the assay. The selected detection 
system depends whether the assay is label free or uses labels for signal amplification. In 
ELISA, the label is an enzyme that produces a colorimetric, fluorescent or 
chemioluminescent signal related to the enzyme concentration, and proportional to the 
analyte concentration. 
1.2.5. ELISA performance 
Assays performance must be evaluated from the early stages of development. Certain 
parameters such as precision (or reproducibility), sensitivity, accuracy and specificity must be 
assessed during that process. 
Precision is the measure of the variability of the signal in the same sample and is expressed in 
terms of coefficient of variation (CV), which is obtained by the ratio of the average and the 
standard deviation. Precision can be evaluated in the same assay run or in different runs, 
termed intra-assay and inter-assay variability, respectively. Intra-assay precision of IAs is 
generally ≤ 10%, while inter-assay precision can be up to 25% due to cumulative error effect 
during the different steps.
30
 
Sensitivity expresses the analyte concentration, which produces a signal that is certain to be 
different from zero. This parameter is assessed through repeated performance of assay blanks, 
being the limit of sensitivity or the lower limit of detection (LLoD) given by the blank signal 
plus 2 or 3 times the blank standard deviation. Sensitivity requirement depends on the 
application of the assay. 
The dynamic range of an assay is the analyte concentration interval within which is possible 
to quantify the analyte. It is limited by the lower limit of detection (LLoD) and the upper 
limit of detection (ULoD). The dynamic range requirement of an assay will also depend on 
the application of the assay. The limit of quantitation is provided by the lowest and highest 
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concentrations of analyte in a sample that can be determined with acceptable degree of 
accuracy and precision. Therefore, the lower limit of detection (LLoD) is usually determined 
by equation (1:4), while the lower limit of quantitation (LLoQ) is usually determined by 
equation (1:5):
31
 
 𝐿𝐿𝑜𝐷 = 𝐵𝑙𝑎𝑛𝑘 + (3 ∗ 𝜎) (1:4) 
   
 𝐿𝐿𝑜𝑄 = 𝐵𝑙𝑎𝑛𝑘 + (10 ∗ 𝜎) (1:5) 
where 𝜎 is the standard deviation of 10 measurements. 
Accuracy in analytical chemistry defines how close an average of measurements is to the true 
value. The most common procedure to measure accuracy is the recovery test, which assesses 
the calibration of an assay and the influence of differences between samples and calibration 
matrix. It can be performed by testing 3 different analyte spiking concentrations in a 
biological sample and in buffer, and then dividing the assay value obtained in the biological 
sample by the actual value obtained in buffer.
31
 
Another important aspect of IA analysis is the statistic model used for the assay calibration 
curve. In this thesis, all IA response curves were fit to the 4PL (4 parameter logistic) model, 
described in equation (1:6). 
 
Response = A +
(B − A)
1 + (
Conc.
C
)D
 
(1:6) 
The four parameters to be estimated are the constants A, B, C, and D, which represent: the 
top (A) and bottom (B) asymptotes of the model, the slope of the linear region (D), and the 
EC50 (C). This last constant refers to the concentration at which the response is halfway 
between the top and bottom asymptotes. The term “conc.” refers to the analyte 
concentration.
32
 
1.2.6. Considerations of solid-phase immunoassays 
Solid phase methods provide simple means of separating bound and free reactants, however 
antibody-antigen reactions are different in solution and at solid-liquid interfaces, mainly due 
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to the reactivity of adsorbed antibodies and the kinetic constrains of antibody-antigen 
reactions at solid-liquid interfaces.
33
  
Although many assays use antibody passive adsorption to a surface, the surface is not a 
passive component in the adsorption process. In fact, adsorbed antibodies usually undergo 
conformational changes that affect the number of active sites in the antibody monolayer and 
affect affinity of antibodies CDR’s to the antigen. Monoclonal antibodies are more affected 
by conformational changes during adsorption than polyclonal antibodies, due to their higher 
specificity. 
Antibody-antigen kinetics is also different in solid-phase IA compared to reactions in 
solution. At solid-liquid interfaces IA are generally diffusion limited and their association 
rate constants will depend on medium viscosity, reactor geometry and 3D structure of 
immobilised antibody. Therefore, Stenberg and Nygren (1988) proposed the introduction of 
the “sticking” coefficient into the equations, meaning that antibody-antigen can only bind 
when they position themselves in the correct alignment. This alignment is harder to happen 
when the antibody is immobilised, therefore the association rate constants are much lower in 
solid-phase IAs.
34
 
Another example of kinetic constrain in a solid-phase immunoassay is the presence of a 
boundary layer, where the antigen is rapidly depleted by the immobilised antibody monolayer 
and its replenishment is limited by diffusion, creating a quasi-stationary state between bulk 
solution and solid-phase bound antigen. Since the antibody concentration is very high at the 
boundary layer the reaction between antibody-antigen is almost irreversible with very low 
dissociation rates. 
Other aspect that makes antibody-antigen solid-phase kinetics different from solution kinetics 
is the possible presence of fractal clusters (agglomerates of highly organised antibody), which 
makes the association rate constant to become variable and the dissociation rate constant even 
lower.
33
  
Standard ELISA platform 
Microtiter plate (MTP) is the standard platform widely used in ELISA in laboratories around 
the world. It consists in a matrix of wells organized by columns and rows (Figure 1:4), where 
the reactions occur. The number and dimensions of wells are variable, but the most 
commonly found is the 96-wells plate. This consists of 96 wells, arranged in 8 rows by 12 
columns. Each well has a maximum capacity of approximately 300 µl of which up to 200 to 
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250 µl is effectively usable (Figure 1:4). The most commonly used material for MTP 
manufacture is polystyrene. 
IAs in MTP platform are very time consuming, need long incubation times, typically 4 to 10 
hours due to mass-transport limitations,
35
 and high reagents volumes. They also present a low 
multiplex potential and detection mode that, although accurate, relies in expensive and non 
portable equipment.
36
 
 
Figure 1:4 – The immunoassay standard Microtiter Platform (MTP). 
A Diagram with dimensions of a single well, from the 96-well plate, filled with 100 µl of 
solution. B The 24-well MTP. C Microplate reader. 
1.2.7. Enzymes: powerful tools for signal amplification in immunoassays 
Enzymes have replaced the radioisotopes labels in heterogeneous IA, since they do not 
exhibit radioactive activity and present higher activity stability.
37,38
 Enzymes are natural 
signal amplifiers, since a single enzyme molecule can convert up to 10
7
 molecules of 
substrate (colorimetric, fluorimetric or chemiluminescent) per minute.
39,40
 A drawback in the 
enzyme performance is related to its susceptibility to interferences (time, temperature, pH, 
inhibitory substances) during signal generation, while radioactive labels are more robust. 
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The two most common enzymes used as labels in IAs are horseradish peroxidase (HRP) and 
alkaline phosphatase (AP). HRP is a 44 KDa oxidoreductase that can be used with a variety 
of hydrogen donors to reduce hydrogen peroxide (H2O2) and this property has been utilised to 
generate coloured, fluorescent and luminescent products. AP is a 140 KDa enzyme that 
catalyses the hydrolysis of phosphate esters of primary alcohols, phenols and animes.
28
 
Enzymes are biocatalysts that accelerate a substrate conversation, without altering the 
reaction equilibrium and suffering no transformation. Enzymatic reactions usually display 
saturation kinetics, since for a given enzyme concentration the reaction rate increases linearly 
with the substrate concentration up to a certain high concentration of substrate, in which the 
reaction rate reaches the maximum. In this situation, all enzyme active sites are occupied and 
the reaction rate is determined by the intrinsic turnover rate of the enzyme, which is the 
maximum number of enzymatic reactions catalysed per second. This kinetics is described by 
Michaelis-Menten model, described by equations (1:7) and (1:8) for single substrate 
reactions: 
 
𝑣0 =
𝑣𝑚𝑎𝑥.[𝑆]
𝐾𝑀 + [𝑆]
 
(1:7) 
   
 𝑣𝑚𝑎𝑥 = 𝐾𝑐𝑎𝑡 . [𝐸]𝑡𝑜𝑡 (1:8) 
where 𝑣0 is the initial reaction rate, 𝑣𝑚𝑎𝑥 is the maximum reaction velocity, [𝑆] is the 
substrate concentration, 𝐾𝑀 is the substrate concentration responsible for ½ of 𝑣𝑚𝑎𝑥, 𝐾𝑐𝑎𝑡 is 
the enzyme turnover number, and [𝐸]𝑡𝑜𝑡 is the total enzyme concentration. 
Although this model is applied only to single substrate enzymatic reactions, in multi-substrate 
reactions, by keeping the concentration of one substrate fixed, the enzyme behaves just like a 
single substrate, therefore Michaelis-Menten kinetic model can also be applied to IAs. 
Enzymes are susceptible to inhibitors, substances that reduce or eliminate enzyme activity. 
Enzyme inhibition can be reversible, if the inhibitor substance is non covalently bound to the 
enzyme, to the enzyme-substrate complex or both, or irreversible, if the inhibitor changes the 
enzyme by covalent bound, for example. There are several types of reversible inhibition: 
competitive, uncompetitive, non-competitive, and mixed. These are fully reviewed 
elsewhere.
41,42
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In respect to IA it is important to understand how quickly an enzyme becomes saturated with 
a particular substrate, the maximum rate it can achieve and their optimal reaction conditions. 
This understanding will allow IA to be performed in less time, be more robust, and with 
higher sensitivity. 
1.2.8. Immunoassay miniaturisation 
Microscale IA differ from macroscale IA in several aspects, such as the importance of surface 
tension, the reduced volume on low concentration samples, and the antibody-antigen kinetics. 
Surface tension effects are significant at small scales, and consequently it can affect the 
distribution of samples or reagents in the reactive surface. In biological fluids, such as blood, 
serum, and urine, additional intermolecular attractive forces create higher surface tension and 
increase viscosity.  
Other significant difference in miniaturisation of IA relies on the sample volume. Although 
analyte concentration in the sample is the same, the number of analyte molecules is much 
lower in small volumes. For example, a sample with 1 nmol/L and a volume of 1 pL only 
contains 600 molecules, therefore quantitation becomes challenging. Other complication with 
low sample volumes is the fact that low concentration of analytes increases their dissociation 
rate from the immobilised antibody, which can affect quantitation. 
Beyond the challenges, microscale IA present several advantages, especially concerning the 
reduced diffusion distance of a molecule, which is responsible decreasing equilibrium time. 
These aspects are responsible for the fast development of miniaturised IA systems. 
Quantitative heterogeneous IA miniaturisation has been accomplished particularly in 
microfluidic systems in the last decade, as the manipulation of liquids in microscale 
environments allows sequence of reagents to be loaded into a device. The higher surface-
area-to-volume (SAV) of microfluidic systems increases the reactivity, making the IAs more 
sensitive and fast. This is further discussed in the following chapters. 
Due to the small scale, the flow in microfluidic devices is generally laminar, and therefore 
characterised by low Reynolds number, described in equation (1:9), meaning the viscous 
forces are prevalent compared to inertial forces: 
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𝑅𝑒 =  
𝜌. 𝑣. 𝐷ℎ
𝜇
 
(1:9) 
where 𝜌 (kg/m3) is the fluid density, 𝑣 (m/s) is the velocity of the fluid, 𝜇 (Ns/m2) is the fluid 
viscosity, and Dh (m) is the hydraulic diameter of the channel. The flow in a pipe is laminar 
for Re ≤ 2100 and turbulent when Re ≥ 4000. The higher the hydraulic diameter, which in a 
circular capillary is equal to its diameter, the lower is the Reynolds number at the same flow 
rate. 
The volumetric flow rate will also affect the flow regime in a pipe, as according to equation 
(1:10), affects superficial flow velocity: 
 𝑄 = 𝑣. 𝐴 (1:10) 
where 𝑄 (m3/s) is the volumetric flow rate, 𝑣 (m/s) is the flow velocity, and 𝐴 (m2) is the 
cross sectional area. Laminar flow presents a typical velocity profile in tubes, showing 
maximum velocity in the centre and zero velocities at the walls of the tube (Figure 1:5). 
 
Figure 1:5 – Velocity profile of a fluid in laminar flow regime. 
 
In laminar flow, molecules move parallel to each other and no mixing occurs. 
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1.3. Microfluidic immunoassays for quantitation of 
protein biomarkers: state-of-the-art 
1.3.1. Summary 
Non-communicable diseases, which include cardiovascular diseases, cancer, chronic 
respiratory diseases and diabetes, that are the mains causes of death worldwide. These 
chronic clinical conditions are diagnosed based on the quantitation of specific proteins 
released into the blood stream or other physiological fluids, including urine and saliva. The 
clinical thresholds for these diagnostics conditions are usual in the fM or pM range, which is 
challenging for current Point-of-Care (POC) tests. Microfluidic devices appeared around 15 
years ago offering unparalleled sensitivity and automation for immunoassays (IA). The 
microfluidic research community expected them to become widely widespread and 
commercialised within few years, however this did not happen until now. The present review 
accounts the development and adoption of microfluidic devices in the last 10 years (from 
2005 to 2015), which were able to quantify protein biomarkers in the fM or pM range. It also 
discusses the aspects of miniaturisation related to protein quantitation in parallel with their 
technological developments, in the perspective of potential POC diagnostic applications. 
1.3.2. Introduction  
Microfluidics is a technology characterised by the precise control and manipulation of fluids 
at the submillimetre scale. Therefore, it usually involves small sample volumes (µL, nL, pL, 
fL), small size (submilimeter channels or capillaries), reduced energy consumption and 
controlled microenvironment. 
The current application of microfluidic devices covers several areas, including screening 
conditions for protein crystallization,
43
 high throughput screening in drug development,
44
 
bioanalysis,
45
 single cell analysis,
46
 and chemical synthesis.
47,48
 
Bioanalytical microfluidic systems, including the ones related to quantitation of biomarkers 
in diagnostics, have rapidly developed in the past ten years, and shown the possibility to 
quantify low analyte concentrations in complex samples using small, miniaturised devices. 
Microfluidic devices appear to fulfil the gap between the simple-to-use POC tests and high 
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precision laboratory bioanalytical techniques. Improving diagnostic has the impact of 
improving life quality and average life expectancy, since protein biomarkers quantitation are 
responsible for diagnosing the non-communicable diseases, which are the main cause of 
death worldwide. Nevertheless, microfluidic diagnostics are not widespread into clinicians’ 
offices and patient’s homes, as anticipated by the research community, mainly because 
microfluidic device fabrication is still not mass produced in a cost-effective way and 
micorfluidic devices are not capable of reliably detecting lower analytes concentrations. The 
current ASSURED POC microfluidic devices struggle to quantify low analyte concentrations 
(<nM) in biological samples,
7
 mainly due to technological challenges related to sample 
preparation and the use of portable detection systems. Biological samples, such as blood or 
faeces, are complex and their matrix interferes with the bioanalytical procedure, therefore a 
better understanding is required. Another current bottleneck for the adoption of microfluidic 
diagnostics in POC is the signal detection, which is still commonly performed with a 
microscope located off the chip. The use of simpler and cheaper detection systems and 
readouts implies improving IAs signal amplification and using multiple steps assays, which 
complicates the IA procedure and makes difficult to implement in POC tests.
48
 Therefore, 
finding new, cost effective, and simple approaches for signal detection or understanding on 
how simple established readout systems can provide sensitive interrogation is essential for 
broad POC diagnostics commercialisation. An additional challenge often ignored in 
microfluidic bioanalytical systems is the fluid actuation and on-chip reagents storage.
48
 
Despite the limitations highlighted above, several microfluidic devices were developed with 
the capability of performing sensitive protein biomarker quantitation. Most of those devices 
developed to perform heterogeneous (solid phase) sandwich IA, whose fundamentals are 
discussed in section 1.2. Table 1:1 summarises some of the microfluidic devices reported in 
literature for biomarker quantitation, specifying some of their aspects related to performance 
and methodology. 
The most commonly targeted biomarkers in POC diagnostics are the cardiac biomarkers: 
troponin I (TnI), troponin T (TnT), creatine kinase (CK-MB), C-reactive protein (CRP), and 
myoglobin (Mb). All these markers are used to evaluate the heart function and early detection 
of myocardial infarction and other cardiac conditions, including acute infarction or severe 
pulmonary embolism.
49
 Other popular biomarkers include cancer biomarkers, like prostate 
specific antigen (PSA), carcinoma embryonic antigen (CEA), α-fetaprotein (AFP), and cancer 
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antigen 125. Cytokines (molecules involved in cell signalling) including TNF-α, IL-1, IL-4, 
IL-6, and IL-1 have been measured for sepsis and other inflammatory condition diagnosis. 
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Table 1:1 – Microfluidic heterogeneous IA for protein biomarkers quantitation reported between 2005 and 2015. 
Microfluidic system 
and publishing year 
Protein 
biomarker 
(analyte) 
Manufacturing 
Process 
Sample 
volume 
(µl) 
 LLoD
1
 
ng/ml (or pM) 
Sample type Immobilisation method/surface 
chemistry 
Total 
assay time 
(min) 
Fluid control Detection mode Readout 
system 
Ref. 
PDMS microfluidic 
immunoassay mosaic 
(2005) 
TNF-α2 Reactive ion 
etching 
0.6 ~0.02 (0.38 pM) 1% BSA in 
buffer 
Adsorption to PDMS ~12 Capillary pump; 
Continuous flow 30 
nL/min) 
Fluorescence; 
Fluorophore 
conjugation 
Fluorescence 
scanner 
50
 
Bio-barcode assay 
(2006) 
PSA
3
 Multilayer Soft 
lithography  
1  1.5 x10
-5
 
(5x10
-4
pM) 
Goat serum Covalent binding 
(gluteraldehyde-amine coupling 
on magnetic particle surface 
<60 Pump; 
Continuous flow 
(0.1 µl/min) 
Light Scattered; 
Silver enhanced gold 
nanoparticles 
amplification 
Verigene ID 
Scanning 
system 
51
 
Plasma panel 
capillary 
immunoassay (2007) 
Myoglobin; 
CK-MB; 
TnI
4
; 
FABP
5
 
Glass capillaries 
manufacture  
- 1.2 (71pM) 
0.6 (7.14pM) 
5.6 (233pM) 
4 (267 pM)  
Diluted plasma 
(12.5%) 
Covalent binding (glass pre-
treated with (APDMES)(3-
aminopropyltriethoxysilane and 
glutaraldehyde) 
<25 min - Chemiluminescence 
Enzymatic 
amplification 
Photodiode 
detector 
52
 
Dual network 
microfluidic chip 
(2008) 
TNF-α Photolitography 5-15 0.045 (0.9 pM) Human Serum Covalent binding (Tosylactivated 
paramagnetic microbeads)  
< 60 Pump; 
Stop flow 
Fluorescence; 
Enzymatic 
amplification 
Inverted 
fluorescence 
microscope 
53
 
Digital Microfluidic 
Platform (2008) 
Human 
Insulin; 
IL-6
6
 
Photolitography <5 - Buffer Adsorption to hydrophobised 
glass surfaces with Teflon AF 
7 Magnetic bead 
manipulation; 
Batch incubation 
Chemiluminescence; 
Enzymatic 
amplification 
Photomultiplier 
tube 
54
 
Optomagnetic 
Immunoassay 
Technology (2009) 
TnI Injection moulding 1 0.16 (3 pM) Non diluted 
plasma 
Adsorption to plastic surfaces 5 Magnetic particle 
control; 
Stop flow 
Label free; 
No amplification 
system; 
Total internal 
reflexion 
biosensor and a 
CCD camera 
55
 
PDMS microfluidic 
assay capillary 
driven (2009) 
CRP
7
 Photo-lithography 
and photoplotted 
polymer masks  
5 1 (9 pM) Human Serum Adsorption to Si wafers 14 Capillary Pump; 
Continuous flow 
(82 nL/min) 
Fluorescence; 
Fluorophore 
conjugation 
Fluorescence 
Microscope 
56
 
BioCD protein array 
(2009) 
PSA - - 4 (133 pM) Diluted human 
serum (1:4) 
Covalent binding 
(triethoxysilylbutyraldehyde 
(TESBA) cross-linking agent) 
<120 Pipetting; 
Stop flow 
Optical Interferometry 
(label free) 
BioCD 
scanning 
system 
57
 
Immuno-pillar 
microfluidic assay 
(2010) 
CRP 
AFP
8
 
PSA 
Injection moulding 0.25 0.1 
(0.9, 1.5, 3.3 
pM) 
Human Serum Adsorption to polystyrene beads 12 Pipetting 
Batch incubation 
Fluorescence 
Fluorophore 
conjugation 
Inverted 
Fluorescence 
Microscope 
58
 
Microbead assay in a 
plastic chip (2010) 
IL-8
9
 
Insulin 
Hot embossing 3.3 - - Adsorption to magnetic particles >65 Pump; 
Continuous flow 
(0.11 μL/min) 
Fluorescence 
detection; 
Fluorophore 
conjugation 
Epi-
fluorescence 
upright 
microscope 
59
 
Three dimensional 
helical glass tube 
with magnetic 
particles (2011) 
CEA
10
 
 
- 30 4x10
-3
 
(0.02 pM) 
Buffer Covalent binding (paramagnetic 
spheres coated with epoxy 
group) 
8 Pump; 
Stop flow 
Chemiluminescence; 
Gold nanoparticles 
functionalised with 
DNAzyme 
Spectofluoro-
meter 
60
 
Flow through 
detection cell with 
magnetic graphene 
nanosheets (2011) 
CEA 
AFP 
- 200 1x10
-3
 (0.005 
and 14.7 pM) 
Buffer Covalent binding (GOPS onto 
magnetic graphene nanosheets) 
<30 Pump; 
Stop flow  
Eletrochemical Electro-
chemical 
analyser 
61
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Table 1:1 – Microfluidic heterogeneous IA for protein biomarkers quantitation reported between 2005 and 2015 (continuation). 
Microfluidic system 
and publishing year 
Protein 
biomarker 
(analyte) 
Manufacturing 
Process 
Sample 
volume 
(µl) 
 LLoD
1
 
ng/ml (or pM) 
Sample type Immobilisation method/surface 
chemistry 
Total 
assay time 
(min) 
Fluid control Detection mode Readout 
system 
Ref. 
Spiral flow based 
separation 
microfluidic assay 
(2011) 
TnT
11
 Rapid prototyping 
techniques 
1.5 10-100 
(278-2780 pM) 
Whole blood 
(microfluidc 
device include 
flow based 
separation 
channel)  
Adsorption to cyclic olefin 
copolymer 
5  Syringe with a 
pressure gauge 
Stop flow 
Chemiluminsecence; 
Enzymatic 
amplification 
Photomultiplier 
tube and 
oscilloscope 
62
 
Silicon photonic 
microring resonator 
(2011) 
CEA Silicon-on-insulator - 25 (125 pM) 100% FBS 
(fetal bovine 
serum) 
Covalent (hydrazone-bond-
formation chemistry) 
30  Pump; 
Continuous flow 
(10 to 30 µL/min) 
Label free (measure 
shifts in microring 
resonance) 
Instrument that 
measures 
microring 
resonance 
62
 
Silicon photonic 
microring resonator 
(2011) 
CRP Silicon-on-insulator <10 0.02 
(200 fM)  
Diluted serum 
and plasma 
Covalent (hydrazone-bond-
formation chemistry) 
~60  Pump; 
Continuous flow 
(10-30 µL/min) 
Resonance 
amplification through 
streptavidin coated 
beads (~10µm 
diameter) 
Instrument that 
measures 
microring 
resonance 
63
 
Microfluidic 
Nanoelectrode array 
(2011) 
PSA UV lithography, 
electron-beam 
evaporation, and 
lift-off 
0.18 0.01 (0.33 pM) Buffer Covalent binding (self assembled 
thiols monolayer to Au surface 
bound to a linker complex of 
metalized peptide nucleic acid 
conjugated with antibody) 
~5 Pump; 
Stop flow 
Electrochemical; 
Enzymatic 
amplification: glucose 
oxidase PSA 
conjugated) 
Custom built 
potentiostat, 
remote source 
meter, shielded 
probe station 
64
 
Lab-on-paper (2011) AFP; 
Cancer 
antigen 125; 
CEA 
Paper 
manufacturing 
4 0.06 (0.9 pM) 
6.6x10
7
 
(3.3x10
8
 pM) 
0.05 (0.25 pM) 
Buffer Covalent binding (chitosan 
coating and glutaraldehyde 
cross-linking) 
~6 
 
Passive flow; 
Stop flow 
Chemiluminescence; 
Enzymatic 
amplification 
Luminescence 
analyser 
65
 
Microfluidic 
Microtiter Plate 
(2012) 
PSA 
IL-4
12
 
Injecting moulding  5 0.016 (0.5 pM) 
2x10
-4 
 
(0.02pM) 
Buffer Adsorption to polystyrene 120 Gravity; 
Stop flow 
Chemifluorescence; 
Enzymatic 
amplification 
Fluorescence 
plate reader 
66
 
Multiplexed 
magnetic bead assay 
(2012) 
IL-6 
TNF-α 
Soft lithography of 
PDMS 
5 0.01 (0.47 pM) 
to 1 (47.6 pM) 
Buffer Covalent binding (carboxyl 
terminated beads with Sulfo-
NHS and EDC chemistry) 
~12 Pump; 
Continuous flow 
rate (1 μL/min) 
Fluorescence; 
Fluorophore 
conjugation 
Flow cytometer 
67
 
Superparamagnetic 
beads (SPMBs) 
pattern-based 
immunoassay (2013) 
CEA 
AFP 
Soft lithography, 
electroplated nickel 
~50 3.5 (17.5 pM) 
3.9 (57.4 pM) 
Serum Covalent binding (iron oxide 
nanoparticles as the core with 
carboxyl groups on the surface) 
40 Magnetic field 
manipulation; 
Stop flow 
Fluorescence; 
Quantum dots 
ICCD camera 
68
 
Immunoassay glass 
capillaries with ZnO 
nanorodes (2013) 
PSA 
AFP 
CEA 
Glass capillaries 
manufacture 
- 1 (33.3 pM)  
5 (73.5 pM)  
5 (25 pM) 
Diluted human 
serum (10%) 
Covalent binding (adding GPTS 
to ZnO nanorodes) 
30 Pump; 
Continuous flow 
(50 µl/min) 
Fluorescence; 
Fluorophore 
conjugation 
Home made 
fluorescence 
read out 
69
 
Power-free chip 
enzyme 
immunoassay (2013) 
PSA Laser cutting 115 3.2 (107 pM) Non diluted 
human serum 
Covalent binding (APTMS 
functionalisation of magnetic 
particles) 
30 Magnetic field 
manipulation; 
Stop flow 
Colorimetric 
Enzymatic 
amplification; 
Cellphone 
camera 
70
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Table 1:1 – Microfluidic heterogeneous IA for protein biomarkers quantitation reported between 2005 and 2015 (continuation). 
Microfluidic system 
and publishing year 
Protein 
biomarker 
(analyte) 
Manufacturing 
Process 
Sample 
volume 
(µl) 
 LLoD
1
 
ng/ml (or pM) 
Sample type Immobilisation method/surface 
chemistry 
Total 
assay time 
(min) 
Fluid control Detection mode Readout 
system 
Ref. 
Silicon porous 
microarray (2013) 
PSA Double sided 
photolithography 
and chemical 
anisotropic wet-
etching using KOH 
- 1.7 (56.7 pM) Whole blood 
(integrated 
acousto-
phoresis-based 
separation of 
plasma) 
Adsorption to porous silicon 
chips 
15 Pump; 
Continuous flow 
(50 µl/min) 
Fluorescence; 
Fluorophore 
conjugation 
Confocal 
Microscope 
71
 
Gold/Graphene 
origami 
immunosensor 
(2013) 
CEA Paper 
manufacturing 
2 8x10
-4
 
(0.004 pM) 
Human serum Adsorption to gold/graphene ~60 Passive flow; 
Stop flow 
Electrochemical Photomultiplier 
tube 
72
 
Autonomus capillary 
system (2014) 
TnI Laser etching 15 0.024 (1 pM) Buffer Covalent binding (PMMA with 
APTES and cross linked 
glutaraldehyde) 
7 to 9 Capillary pump; 
Continuous flow 
assay (0.32 nL/min) 
Fluorescence labelling House built 
fluorescence 
reader 
73
 
Microfluidic 
multilayer array 
(2014) 
PSA 
TNF-α 
IL-1β 
IL-6 
Soft litography 5 nL 0.03 
0.052 
0.017 
0.021 (1pM) 
Serum Covalent to coated glass slides 
with epoxysilane 
14 Pipetting; 
Stop flow 
Fluorescence; 
Fluorophore 
conjugation 
Fluorescence 
Microarray 
scanner 
74
 
3-dimensional paper 
immunoassay (2014) 
hCG
13
 - 20 2.4 x10
5
 
(6.7x10
6
 pM)
14
 
Urine Adsorption (hydrophilic nylon 
membrane) 
10 Passive flow; 
Stop flow 
Colloidal Gold-
nanoparticles 
Flatbed 
Scanner 
75
 
Microfluidic 
microarray 
immunoassays 
(2014) 
IL-6 
IL-1β 
TNF-α 
PSA 
Multilayer-soft-
lithography 
5 0.084 (4 pM) 
0.07 (4 pM) 
1.6 (30 pM) 
0.45 (15 pM) 
4 pM 
Buffer Covalent (glass slides with epoxy 
silane) 
< 3 h Pipetting; 
Stop flow 
Fluorescence; 
Fluorophore 
conjugation 
Fluorescence 
Microarray 
Scanner 
76
 
Microtiter Graphene 
based immunoassay 
(2014) 
CRP Injection moulding - 0.07 (0.6 pM) Diluted whole 
blood and 
plasma 
Covalent binding (graphene 
nanoplatelets and APTES to 
polystyrene surface) 
< 30 Pipetting; 
Batch incubation 
Colorimetric; 
Enzymatic 
amplification 
Smartphone 
77
 
Lab-on-a-disc with 
TiO2 fibrous mat 
(2015) 
CRP 
TnI 
CNC 
Micromachining 
10 8x10
-4
 (~6 fM) 
0.037 (1.5pM) 
Whole blood 
(blood cell 
separation on 
the disc) 
Covalent binding (PDMS coated 
with silicon and nanofibers of 
TiO2 treated with GPDES 
30 Rotation actuation; 
Stop flow 
Chemiluminescence; 
Enzymatic 
amplification 
Home built 
detection 
system with 
cooled PMT 
module and 
CCD camera 
78
 
Surface plasmon 
resonance-based 
immunoassay (2015) 
CRP - 50 1.2 (11 pM) Diluted 
(1:1000) whole 
blood, serum 
and plasma 
Affinity binding (protein A/G 
covalently bound to the surface) 
3 Pump; 
Continuous flow 
(10 µL/min) 
Label free (Surface 
plasmon resonance) 
BIAcore 
surface 
plasmon 
resonance 
79
 
Notes: 
1
 LLoD – Lower limit of quantitation; 2 TNF-α – Tumor necrosis factor alpha; 3 PSA – Prostate Specific Antigen; 4 TnI – Troponin I; 5 FABP - Fatty-acid-binding proteins; 6 IL-6 – Interleukin 6; 7 CRP – C-reactive 
protein; 
8
 AFP - α-fetoprotein; 9 IL-8 - Interleukin-8; 10 CEA - Carcinoma embryonic antigen; 11 TnT – Troponin T; 12 IL-4 - Interleukin 4; 13 hCG - Human chorionic gonadotropin; 14 This value corresponds to 6.7 mIU/ml, 
based on 1U equilvalent to 1 µmol/min, and the mass and molar concentrations mentioned in the Table 3:1 corresponding to 1 minute activity. 
24 
 
This review focuses in four key areas essential to achieve ASSURED POC microfluidic 
devices capable of sensitive protein quantitation: 1) antibody immobilisation, 2) 
biological matrix interference, 3) fluid control, and 4) detection modes. A brief 
consideration about the manufacturing process of microfluidic devices and its relevance 
towards POC applications is also discussed. Additionally, it includes an analysis of 
microfluidic devices developed since 2005 for protein biomarker quantitation. 
1.3.3. Antibody immobilisation  
A universal important feature in heterogeneous IA is the presence of a solid phase 
which enables separation between bound and free reagents. Therefore, the first stage in 
a sandwich IA is surface preparation, including the capture antibody (CapAb) or antigen 
immobilisation and the blocking of the remaining binding sites. Immobilised antibodies 
must have the CDRs (complementary-determining region) available for the targeted 
analyte/antigen to bind, which means the immobilisation technique has to provide 
proper antibody orientation. The strength of the binding between antibody-antigen, also 
called the affinity, will differ depending on the antibody immobilisation process and the 
surface to which it was immobilised, since denaturation and conformational changes in 
antibodies can alter the structure of their CDRs.
80
 Therefore, in solid phase IAs it is 
important to consider antibody-antigen avidity,
81
 which is the sum of multiple antibody-
antigen non covalent interactions. 
There are several procedures for immobilising antibodies. The selected protocol usually 
depends on the microfluidic surface characteristics and on the long-term interactions 
between the antibodies and the surface. These ultimately impact also on the 
manufacturing of microfluidic tests and its successful commercialisation. 
1.3.3.1. Passive adsorption to surfaces  
Passive adsorption to surfaces is the simplest method for immobilising proteins, 
including antibodies. This requires placing the antibodies in direct contact with the 
surface, being a surface specific process, where the surface works as a “reactant”, also 
determining the amount of antibody adsorbed (surface capacity) and the orientation of 
antibody. The drawbacks of the adsorption mechanism are random orientation and weak 
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attachment to certain surfaces, since proteins may be removed by some buffers or 
detergents when performing the assays.
82
 
An ideal antibody adsorption surface would have high affinity to the antibody constant 
fragment (Fc), so that the variable region (Fab), where the antigen binds, remains 
available for binding. The bond between antibody and surface has to be strong enough, 
so that the immobilised antibodies and the antibody-antigen complex are not removed 
during subsequent washings, which would decrease the sensitivity of the assay. 
However, the binding cannot be strong enough to denature completely the antibody or 
changing Fab’s conformation and antibodies affinity to the antigen. Other important 
aspect about antibody surface adsorption is the specificity. It is important that the 
antibody affinity to the surface is higher than the antigen and other matrix proteins 
affinity to the surface to avoid competition for the binding sites on the surface. Also, 
higher antibody-antigen affinity compared to the surface-antibody or surface-antigen 
affinity is required in order to maximise the signal-to-noise ratio, which is directly 
linked to the sensitivity of the assay. 
Plastics are usually preferred as surfaces for passive antibody adsorption. The most 
common example is the immobilisation of antibodies onto polystyrene Microtiter Plates 
(MTP), the gold laboratory standard for quantitative IA. Other plastics, such as, 
polypropylene and polyvinyl chloride (PVC) are also common in the diagnostics 
industry.
21
 Plastics are hydrophobic surfaces, therefore the antibodies adsorb to plastic 
mainly by hydrophobic interactions, attaching their non-polar domains (CH3 and CH2) 
to the surface and establishing intermolecular bounds. 
Some microfluidic devices relying on antibody adsorption onto plastic surfaces were 
able to successfully quantify protein biomarkers in low concentrations, such as: IL-4 
and PSA, with antibody adsorbed onto polystyrene channels;
66
 CRP, AFP, and PSA, 
with polystyrene beads;
58
 human insulin and IL-6 with glass surfaces hydrophobised 
with Teflon AF;
54
 and troponin-T by adsorption onto cyclic olefin copolymer.
62
 
The use of thermoplastics in microfluidic devices fabrication is not as frequent as the 
use of silicon, glass and PDMS (polydimethylsiloxane) in academic environments. 
Thermoplastics are a class of synthetic polymers that exhibit softening behaviour above 
typical glass transition temperature, resulting from long-range motion of the polymer 
backbone, while returning to their original chemical state upon cooling. Compared to 
26 
 
more traditional microfluidic materials such as silicon and glass, thermoplastics offer 
considerable lower raw material and mass manufacturing costs and are, therefore, being 
used for manufacturing of microfluidic devices.
83
 
Although antibody adsorption is a reliable approach for antibody immobilisation, the 
amount and activity of antibody adsorbed is extremely dependent on the surface used. 
Therefore, microfluidic devices usually use covalent attachment of antibodies onto 
surfaces. In contrast, plastics seem to be the surface most common for passive antibody 
adsorption in microfluidic devices used in protein biomarker quantitation. 
Antibodies adsorption to glass appears to occur mainly due to electrostatic interactions. 
Nevertheless, these interactions do not appear to favour quantitative IA, as they are less 
strong and might allow multilayer formation, in which adsorbed antibodies become 
more polar binding to other antibodies, making it undesirable for IA quantitation. 
Consequently, microfluidic devices fabricated from glass usually use covalent 
immobilisation procedures. 
Silicon is another popular material used for antibody adsorption on microfluidic 
devices, however, antibodies adsorb less to silicon surfaces due to reversible bonding,
84
 
being covalent immobilisation also preferred. CRP protein has been quantified with 
LLoD of 1 ng/ml (9 pM) in an assay using antibody immobilisation onto silicon 
wafers,
56
 and PSA with LLoD of 1.7 ng/ml (56.7 pM), in an integrated acoustic immune 
affinity using antibody adsorption onto porous silicon chips.
71
 
PDMS is a hydrophobic material preferred by microfluidic researchers yet presenting 
problems related to non-specific adsorption, therefore undesirable for POC microfluidic 
tests.
85
 PDMS immunoassay antibody adsorption was used for sensitive quantitation of 
TNF-α with a LLoD of 0.02 ng/ml (0.38 pM).50Covalent attachment with previous 
surface modification appears to be the most common approach used for PDMS IAs 
surfaces. 
Detection of hCG (pregnancy hormone) was reported using a hydrophilic nylon 
membrane based on antibody adsorption with a detection limit of 6.7x10
6
 pM  
(6.7 mIU/ml). The detection limit of a pregnancy biomarker, even at early pregnancy 
detection is several orders of magnitude larger than the LLoD required for cancer and 
cardiac biomarkers.
75
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Antibodies were also passively adsorbed onto gold surfaces, although these are not very 
common in microfluidic devices for protein quantitation. Nevertheless, the combination 
of gold and graphene is becoming popular due to potentiometric detection, as it was 
reported on the gold and graphene origami immunosensor study quantifying CEA with 
LLoD of 8x10
-4
 ng/ml (0.004 pM).
86
 
Different surface chemistries promote different types of intermolecular bonds, which 
interfere with the signal-to-noise ratio. Surfaces properties and chemistries are therefore 
a paramount to high sensitivity required in biomarkers detection by IAs. 
1.3.3.2. Covalent binding  
Procedures for covalent immobilisation of antibodies onto surfaces will also depend on 
the type of surface, since it is necessary to find an intermediate linker to bind the 
antibody to the surface. Consequently, a wide variety of methods were developed and 
extensively reviewed by Kim et al. 
87
 Covalent immobilisation is usually regarded as 
more stable and offering higher surface coverage, important for assay sensitivity, being 
in theory preferable over passive adsorption. Nevertheless, covalent antibody 
immobilisation involves complex chemistries that do not guarantee proper antibody 
orientation and may reduce protein activity by linkage on antibodies active sites. This 
drawback has to be considered on the early stages of development of POC microfluidic 
devices. 
The majority of recently reported microfluidic devices used for sensitive biomarker 
quantitation use surface silanization for antibody immobilisation. Silanization is the 
covering of a surface through self-assembly with organo functional alkoxysilane 
molecules.
88
 Mineral components like mica, glass, and metal oxide surfaces can all be 
silanized, because they contain hydroxyl groups (-OH), which attack and displace the 
alkoxy groups on the silane. Typical organo functional alkoxysilanes are APTES ((3-
aminopropyl)-triethoxysilane), APDMES ((3-aminopropyl)-dimethyl-ethoxysilane), 
APTMS ((3-aminopropyl)-trimethoxysilane), GPMES ((3-glycidoxypropyl)-dimethyl-
ethoxysilane) and MPTMS ((3-mercaptopropyl)-trimethoxysilane).
88
 
Proteins usually have a number of potential immobilising sites. The functional groups of 
the proteins suitable for covalent binding include: (i) the α-amino groups of the chain 
and the ε-amino groups of lysine and arginine; (ii) the α-carboxyl groups of the chain 
end and the β- and γ-carboxyl groups of aspartic and glutamic acids; (iii) the phenol ring 
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of tyrosine; (iv) the thiol group of cysteine; (v) the hydroxyl groups of serine and 
threonine; (vi) the imidazole group of histidine; and (vii) the indole group of 
tryptophan. Details about all this groups are summarised in Table 1:2.
89
 
Table 1:2 - Available functional groups in proteins (including antibodies) and 
functional groups required on the surface for protein immobilisation.
82
 
Side groups Amino acids Surfaces 
-NH2 Lys, hydroxyl-Lys Carboxylic acid active ester (NHS), Epoxy, Aldehyde 
-SH Cys Maleimide, Pyridyil disulphide, Vinyl sulfone 
-COOH Asp, Glu Amine 
-OH Ser, Thr Epoxy 
 
Antibodies can be directly bound to a salinized surface, which has organo functional 
alkoxy silanes with amine groups and epoxy groups. This immobilisation technique has 
been utilised in many devices for protein biomarker quantitation. For example, TiO2 
nanofibers have been treated with GPDES (3-glycidoxypropyl) methyldiethoxysilane, 
reporting LLoD in serum of 8x10
-4
 ng/ml (0.007 pM) for CRP and 0.037 ng/ml(1.5 pM) 
for TnI (Figure 1:6A).
78
 An IA performed in glass capillaries was able to quantify PSA 
with LLoD of 1 ng/ml (33.3 pM), α-Fetoprotein (AFP) with LLoD of 5 ng/ml (74 pM), 
and carcinoembryonic antigen (CEA) with LLoD of 5 ng/ml (25 pM), based on 
antibody covalent binding promoted by adding (3-glycidoxypropyl) trimethoxy silane 
(GPTS) to ZnO nanorodes.
69
 A microfluidic device using magnetic graphene nanosheets 
was able to quantify CEA and AFP with a LLoD of 1x10
-3
 ng/ml (0.005 pM for CEA 
and 14.7 pM for AFP) using antibody covalent binding to 3-glycidyloxypropyl 
trimethoxysilane (GOPS) onto graphene nanosheets.
61
 A multilayer array using glass 
slides, silanized with epoxysilane surface coating to promote covalent binding of 
antibodies, achieved a LLoD of 1 pM for PSA (0.03 ng/ml), TNF-α (0.05 ng/ml), IL-1β 
(0.017 ng/ml), and IL-6 (0.021 ng/ml) biomarkers.
74
 Other microfluidic microarray with 
the same antibody immobilisation chemistry onto glass slides achieved LLoD of 0.45 
ng/ml (15 pM) for PSA, 1.6 ng/ml (30 pM) for TNF-α, 0.07 ng/ml (4 pM) for IL-1β and 
0.084 ng/ml (4 PM) for IL-6 biomarkers.
76
 PSA was quantified with a  
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Figure 1:6 – Examples of antibody covalent binding to surface chemistries and 
strategies for microfluidic devices used in biomarkers quantitation. 
A Schematic representation of antibody immobilisation and the immunoassay on the 
TiO2 NFs, starting with plasma activation of the surface and silanization process using 
GPDES ((3-glycidoxypropyl) methyldiethoxysilane).
78
 B Silanization on PMMA 
(Poly(methyl methacrylate)) using APTES ((3-aminopropyl)-triethoxysilane) followed 
by glutaraldehyde.
73
 C Aldehyde modification of SiO2 surface and antibody 
immobilisation, using Triethoxysilylbutyraldehyde (TESBA).
57
 D Silicon surface of 
microrings treated with APTES ((3-aminopropyl)-triethoxysilane) and S-HyNic 
(Succinimidyl 6-hydrazinonicotinamide acetone hydrazine) and antibodies modified 
with succinimidyl 4-formylbenzoate (S-4FB).
90
 
 
LLoD of 3.2 ng/ml (107 pM), using APTMS (3-aminopropyl)-trimethoxysilane coated 
magnetic nanoparticles. A microtiter platform using graphene nanoplatelets and 
functionalised with APTES (3-aminopropyl)-triethoxysilane measured CRP with a 
LLoD of 0.07 ng/ml (0.6 pM).
77
 
Silanisation and other surface modification chemistries also use aldehydes as cross 
linkers for protein immobilisation. Some studies showed that amine derivitization 
followed by glutaraldehyde (GA) linking yielded supports with greater amounts of 
immobilised enzyme and activity.
91
 Aldehyde is a reactive compound that forms the 
labile Schiff base with the amine and can be further reduced to form a stable secondary 
amine bond using NaCNBH3 or NaBH4. GA is a bis-aldehyde compound that has two 
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reactive ends, and therefore can cross link two amine functional groups, which can be 
two proteins or a protein and a surface polymer with amine groups, such as the organo 
functional alkoxy silanes.
87
 Consequently, GA has been used as cross linker for 
antibody immobilisation in microfluidic IA. GA antibody cross linking agent has been 
used with APTES ((3-Aminopropyl) triethoxysilane) for antibody covalent 
immobilisation to PMMA (Poly(methylmethacrylate)), yielding a LLoD of 0.024 ng/ml 
(1 pM) for TnI (Figure 1:6B).
73
 The same compounds were used for immobilisation 
onto glass surfaces obtaining 5.6 ng/ml (233 pM) of LLoD for TnI.
52
 The Bio-Barcode 
assay was able to quantify PSA, utilising glutaraldehyde amino coating to magnetic 
particles with LLoD =1.5x10
-5
 ng/ml (5x10
-4
 pM)
51
 and the bioCD protein array, 
quantified PSA with LLoD of 4ng/ml (133 pM), utilising aldehyde surface modification 
of silica (Figure 1:6C).
57
 GA cross linking was also used in chitosan surfaces on a lab-
on-a-paper device capable of quantifying AFP, cancer antigen 125, and CEA with 
LLoD of 0.06 ng/ml (0.9pM), 6.7x10
7
 ng/ml (0.33 U/ml), and  
|0.05 ng/ml (0.25 pM), respectively.  
1.3.3.3. Combined immobil isation techniques  
The combination of covalent binding with passive adsorption or affinity binding is also 
commonly used in antibody immobilisation. Theoretically this is an approach that 
allows the highest control of antibody orientation and activity, since a specific and 
known affinity binding is being promoted. The two most common techniques for 
antibody immobilisation by affinity binding are the avidin-streptavidin and protein A/G. 
The first uses the strongest non covalent bond in nature (Kd = 10
15
 M
-1
), allowing the 
use of harsh conditions during biochemical assays, while the protein A/G 
immobilisation, relies on the specific interaction with the Fc constant region of IgG 
molecules.
82
 Recently, conjugating antibodies with DNA,
92
 synthetic peptides,
93
 or 
oligonucleotides
94
 has also been applied to antibody immobilisation. All these 
techniques apparently lead to higher immobilised antibody affinity, due to proper 
orientation and good antibody density control. Nevertheless, only a few examples are 
found of microfluidic assays using this immobilisation approach. This might be due to 
complex immobilisation chemistry, since a combination of immobilising techniques 
must be considered. For example, achieving proper orientation and activity of 
immobilised protein A is challenging by itself and affects the antibody immobilisation 
step.
95
 A surface plasmon resonance immunoassay detected PSA with a LLoD of  
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1.2 ng/ml (40 pM) by covalently immobilising protein A/G to a glass surface, and then 
promoting affinity binding of antibodies. A microfluidic nanoelectrode array was able 
to quantify PSA with a LLoD of 0.01ng/ml (0.3 pM) using antibodies conjugated with a 
linker complex of metalized peptide nucleic acid that covalently attached to a self 
assembled thiols monolayer.
64
 
1.3.3.4. The relevance of surface area and surface -area-to-volume 
ratio 
Antibody-antigen equilibrium (discussed in section 1.2) shows that a higher 
concentration of immobilised CapAb in a reaction medium will push the equilibrium 
towards the formation of antibody-antigen complex. In order to create a high sensitivity 
system with the concentration of antigen available very low, around pM or fM, the total 
amount, the density and the activity of immobilised antibodies are, therefore, extremely 
important for analyte quantitation. Due to antibody immobilisation, the total amount of 
antibody is limited, since the antibodies have to be organised on a monolayer and steric 
hindrance must be avoided. However, surface chemistry is not the only variable to be 
considered. In addition, the total surface area with immobilised antibody has also to be 
accounted for. Since antibody immobilisation is a reaction between an empty surface 
and an antibody solution, the surface-area-to-volume ratio of the microchannel or 
microcapillary is also important. This depends on the antibody affinity to the surface, 
which in turn depends on the antibody immobilisation technique. There are several 
examples of microfluidic platforms that achieved high sensitivity by enhancing the 
surface area available. For example, a lab-on-a-disc device used antibody immobilised 
on coated polystyrene beads to yield a LLoD of 0.27 ng/ml (11.3 pM) for TnI, 0.27 
ng/ml (1.45 pM) for CRP, and 0.32 ng/ml (37.7 pM) for NTproBNP in whole blood 
samples.
96
 Using a similar device but with electrospun TiO2 nanofibers printed onto the 
surface of the chambers, the LLoD achieved for TnI was 0.037 ng/ml (1.5 pM) and for 
CRP was 8x10
-4
 ng/ml (0.007 pM), in whole blood and serum, respectively (Figure 
1:7A).
78
 This represented a 7-fold increment in LLoD for TnI and about a 300-fold 
increment on LLoD for CRP, by increasing the overall immobilisation area for CapAb. 
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Figure 1:7 – Strategies used for enhancing surface area in microfluidic devices for 
antibody immobilisation. 
A TiO2 nanofibers used in a Lab-on-a-Disc for CRP and TnI detection. SEM images of 
the TiO2 nanofibers (NFs): (i) top and (iii) side views of low-density TiO2 NFs 
remaining on the donor Si substrate and (ii) top and (iv) side views of a high-density 
TiO2 NF mat transferred to the target Si substrate; insets 1 and 2 are the photographs of 
the TiO2 NFs (2 cm × 2 cm).
78
 B SEM images of ZnO nanorods grown on the inner 
surface of a glass capillary. (i) to (iii) Top-view; (iv) cross-sectional view; the inset of 
(i) shows the optical images of a capillary after (left) and before (right) the nanorod 
growth. C SEM images of the porous silicon network. (i) Cross sections and (ii) top 
views of the rigid sponge like porous silicon network structure.
97
 D Electron micrograph 
of a hot embossed microwell containing a microbead. The scale bar of the image is 4 
μm, and the magnification is 30 000×.59 
 
A glass capillary microfluidic device was able to quantify PSA, AFP, and CEA in 
serum with a LLoD between 1-5 ng/ml (33.3 pM for PSA, 74 pM for AFP, and 25 pM 
for CEA) based on ZnO nanorods deposited within the glass capillaries (Figure 1:7B).
69
 
A porous silicon array was able to increase PSA LLoD from 1.7 ng/ml (56.6 pM)
71
 to 
800 fg/ml (0.027 pM) just by increasing the CapAb concentration for passive 
adsorption.
98
 This increment of more than 2000 times in PSA sensitivity was only 
possible due to large surface area of the porous substrate produced by electrochemical 
dissolution of monocrystalline silicon (Figure 1:7C).
97
 A popular approach used for 
enhancing surface area is to immobilise the antibodies onto small beads (Figure 1:7D). 
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The antigen/analyte is immobilised onto the beads and detected with a second label 
antibody that binds to the complex antibody-antigen on the beads,
51,53,58–60,67,70,99
 or the 
secondary antibody immobilised onto the inner surface of channels, which captures the 
complex bead-antibody-antigen.
55
 The beads can be magnetic which facilitates the fluid 
actuation, the mixing, and the separation of bond from unbound antigen (washing). The 
use of magnetic beads in microfluidics has been fully reviewed by Tekin et al..
100
 Other 
authors have generally reviewed the use of beads in microfluidic IAs.
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1.3.4. Sample preparation 
Most of the protein biomarkers produced in the human body are released into the blood 
stream. Sensitive quantitation of these molecules involves therefore sample preparation 
of a complex biological matrix, such as human whole blood, since the matrix 
components of biological samples usually interfere with the assay performance.  
The use of biological samples is fundamental for validation of assays performance, 
however most of developed microfluidic IAs still use buffers spiked with protein 
biomarker.
50,54,60,61,65–67,73,76
 Some studies used other types of biological matrices as 
analyte diluents, as an attempt to mimic human biological matrices, such as non diluted 
goat serum,
51
 or fetal bovine serum,
62
 while other studies relied on diluted human whole 
blood,
79
 plasma
52,79
 or serum.
57,63,69,79
 There are a few microfluidic devices that were 
able to quantify protein biomarkers in non diluted human plasma
55
 or human 
serum.
53,56,58,70,72,74,99
 However, so far there is no reported use of non diluted whole 
blood samples systematically in biomarkers quantitation in heterogeneous sandwich 
assays. Microfluidic devices capable of quantifying biomarkers from whole blood 
samples involved a level of sample preparation embedded in the chip structure. For 
example, a Lab-on-a-disc was capable of quantifying CRP and TnI from whole blood 
samples, by separating the red blood cells through centrifugation.
78
 A silicon porous 
microarray integrated an acoustophoresis system for plasma separation from whole 
blood samples (Figure 1:8A).
71
 Other microfluidic devices incorporated a flow based 
blood separation channel for whole blood protein quantitation (Figure 1:8B).
62
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Figure 1:8 – Examples of microfluidic approaches for whole blood sample treatment. 
A Integrated blood analysis chip design fabricated in COC (cyclic olefin copolymer): (i) 
a blood sample is injected into a long spiral flow-based separation channel; (ii) 
haematocrit is evaluated based on the number of serpentine switchbacks that are filled 
with packed erythrocytes; (iii) the blood sample is then flowed into a high surface area 
to volume ratio ELISA protein quantitation segment where a biomarker of interest is 
evaluated.
62
 B Sequence showing the starting phase of plasma production (i) with 
inactive ultrasound, (ii) starting acoustophoresis, and (iii) continuous phase of plasma 
production, with the final fractions of red blood cells removed via the central outlet.
71
 
1.3.5. Fluid handling control 
The usual procedure of sandwich heterogeneous IAs includes multiple sequential 
reagents addition, with multiple washing steps between reagent incubations. This 
procedure allows a higher amount of antigen to be bond to the immobilised antibodies 
due to the extended sample incubation time. This way the equilibrium towards the 
formation of antibody-antigen complex is favoured, whilst reducing interference of 
substances like the detection antibodies. When the DetAb binds to the analyte before it 
binds to the immobilised CapAb the sensitivity of the assay is usually reduced, as the 
detection-antigen complex takes longer and steric hindrance difficult binding to the 
immobilised layer. 
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The washing procedures are important to reduce the non-specific signal from the 
antigen, DetAb, or enzyme molecules that bond non-specifically to the solid surface. 
Consequently, sandwich assay requires a multistep procedure to achieve high 
sensitivity,
7
 although attempts were made in a microfluidic device for one step sensitive 
protein biomarker quantitation. For example, Gervais et al. was able to quantify CRP 
protein with a LLoD of 10 ng/ml (90 pM) in 3 minutes, and < 1 ng/ml  
(9 pM) in 14 minutes, in PDMS chip involving integrated reagents with flow controlled 
by a capillary pump.
56
 This was possible due to the reduced low flow rates (30 nL/min) 
promoted by the capillary pump. Consequently, fluid handling and actuation are 
paramount factors for achieving sensitive protein quantitation in microfluidic IAs. 
1.3.5.1. Pressure driven systems  
Pressure driven flow systems presuppose the use of an external fluid control actuation. 
The most common external fluid control in microfluidic systems are flow pumps, such 
as syringe pumps. 
Pumps can deliver a wide range of flow rates from pL/min to ml/min, as well as 
allowing alternating between stop and continuous flow procedures, which are important 
for reagents loading and incubation in sandwich assays. They are easily connected to 
microfluidic channels or capillaries, generating laminar flow systems due to the small 
dimensions of the system. However, pumps are usually expensive, requiring power 
supply and compromising the portability of the system. Most of the developed 
microfluidic devices rely on external pumps for fluid control in order to achieve 
sensitive protein biomarkers quantitation in sandwich IAs. Few microfluidic devices use 
procedures with continuous flow of reagents for variable flow rates (Table 
1:1),
51,59,62,67,69,79
 while others opt to stop the flow for reagents incubation.
53,60,61,64,71
 The 
geometries of these microfluidic devices are variable, however they all comprise 
microchannels or microcapillaries as reaction chambers. 
1.3.5.2. Centrifugal forces  
Another type of microfluidic devices uses centrifugal forces for fluid movement in IAs. 
For example, a Lab-on-a-disc capable of measuring CRP and TnI with a LLoD of 0.27 
ng/ml (11.3 pM) and BNP with 0.32 ng/ml (37.6 pM), moves reagents from one 
chamber to the other, based on a rotation disc and a specific valve actuation.
78,96
 Honda 
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et al. also described a disc based microfluidic platform capable of quantifying AFP, IL-
6, and CEA with detection limits of 0.01, 0.026, and 0.26 ng/ml (0.14, 1.24, 1.3 pM), 
respectively, using centrifugal forces. Other IA have used centrifugal force for reagents 
actuation and are described in detail by Gorkin et al. in their critical review.
101
 
1.3.5.3. Magnetic forces  
The use of magnetic field is another form of fluid actuation implemented in microfluidic 
devices, which also allows performing heterogeneous IAs with multiple steps, and has 
been used in quantitation of protein biomarkers.
102
 In these systems the CapAb is 
usually immobilised onto the magnetic beads surface and then moved through a 
sequence of chambers containing a series of reagents (Figure 1:9D).
54,99,103
 It can also 
have the magnetic beads containing the antigen already captured binding to another 
coated onto the inner surface of the channel for further detection.
55
 
1.3.5.4. Passive flow systems  
In passive flow systems the fluid actuation is not promoted by an external mechanical or 
magnetic force, but by intrinsic device characteristic, such as surface properties. For 
example, LF technology relies on hydrophilic strip properties and geometry of 
nitrocellulose. Fluids move through the nitrocellulose membrane due to capillary forces. 
Some microfluidic systems also rely on passive flow, with flow rates determined by the 
design of the device. Typical driving forces for propelling liquids in passive 
microfluidics are, for example, chemical gradients on surfaces, osmotic pressure, 
degassed PDMS,
104
 permeation in PDMS,
105
 gravity, and capillary forces.
106
 However, 
generally the flow rates, sample volumes, and incubation times are more difficult to 
control using these systems. Compared to pressure driven systems, the possibility of 
using wax patterning hydrophobic barriers onto hydrophilic paper allowed patterning 
microchannels and reaction chambers onto paper creating paper microfluidic devices 
where fluids move through capillarity. Therefore, a lab-on-a-paper device was able to 
quantify α-AFP, cancer antigen 125, and CEA with LLoD of 0.06 ng/ml (0.9 pM), 
6.6x10
7
 ng/ml (0.33 U/ml), and 0.05 ng/ml (0.25 pM), respectively.
65
 Also, an origami 
gold/graphene paper immunosensor was able to quantify CEA with LLoD of  
8x10
-4
 ng/ml (0.004 pM).
72
 The pregnancy hormone, hCG was also quantitated, with an 
LLoD of 6.7x10
6
 pM (6.7 mIU/mL) in a paper microfluidic device (Figure 1:9C).
75
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Paper microfluidic devices achieved good sensitivities for protein quantitation by using 
printing channels and architecting 3D paper structures to control antibody 
immobilisation and reagents incubation times. These features are not found in LF 
devices though, which probably explains their lack on sensitive quantitation. Paper 
microfluidic diagnostics have been fully reviewed by Yetisen et al..
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Figure 1:9 – Fluid control approaches implemented in microfluidic devices for protein 
biomarker quantitation. 
A Fluidic control in a microchannel using capillary pumps with average flow rate of 82 
nL/min: (i) sample collector ending with hierarchical delay valves; (ii) flow resistors 
and central deposition zone for detection antibodies; (iii) reaction chamber; and (iv) 
capillary pump.
56
 B Microfluidic microtiter plate (optimiser microplate) with gravity 
controlling the fluid flow.
66
 C Fluid handling through a 3D microfluidic paper device 
with hydrophobic patterned barriers (black areas).
75
 D Magnetic automated bead 
transfer device: (i) the magnet pulls the beads from the carrier stream to the reagent 
stream and the current stream is diverted to waste; (ii) assembled three layers PDMS 
microdevice.
67
 
 
In addition to capillary forces, gravity can allow a fluid to move along a microfluidic 
surface. A novel microfluidic microtiter plate was able to quantity PSA and IL-4 with 
LLoD 0.016 ng/ml (0.53 pM) and 2x10
-4
 ng/ml (13.3pM), respectively, using gravity as 
a force for fluid actuation (Figure 1:9B).
66
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A more complex and challenging approach, in terms of microfabrication was proposed 
by Zimmernann et al. and involves a series of autonomous capillary systems with 
liquids displaced by capillarity with accurate volumes of liquids and precise flow rates. 
The capillary pumps comprise microstructures of various shapes with dimensions in the 
range of 15–250 mm, positioned in the capillary pumps to encode a desired capillary 
pressure and provide a flow rate between 12 and 222 nL/min.
106
 Capillary pumps 
integrated in microfluidic devices have been used to quantify TnI with LLoD of 0.024 
ng/ml (1 pM),
73
 TNF-α with LLoD of 0.02 ng/ml(0.38 pM),50and CRP with an LLoD of 
1 ng/ml (9 pM).
56
 The last was performed in one step using reagents integrated in the 
device and the assay triggered only by addition of sample (Figure 1:9A). 
1.3.6. Detection modes, signal amplification and readout systems 
An essential feature in IAs quantitation is the detection of the antibody-antigen 
complex. Miniaturised systems, due to the small volumes (pL to µL) used, are able to 
detect a few molecules up to a thousand molecules. Most heterogeneous IAs use optical 
detection based on labels, which are molecules that can produce a detectable signal. 
Depending on the nature of the signal, IAs can be characterised as colorimetric, 
fluorescent and chemiluminescent. Other IA detection modes are based on 
electrochemical signal changes or refractive index changes, whose techniques are called 
label free techniques, since they do not rely on labels. 
Colorimetric assays measure antibody-antigen complex through colour intensity of a 
solution or particles. Colorimetric detection is inherently less sensitive than 
fluorescence and chemiluminescence, since in order to measure low concentrations of a 
chromogen, small differences in intensity must be measured at high light intensity, 
which limits the LLoD. Also, relationship between optical absorbance and intensity of 
transmitted light is logarithmic. Therefore, at high chromogen concentrations relatively 
large differences in optical absorbance correspond to small differences in the intensity 
of transmitted light, which usually corresponds to narrow dynamic range for IAs.
108
 
Nevertheless, chromogenic substrates offer speed, simplicity, well-established assay 
chemistry, high quality reagents, and widespread cost-effective readers. For this reason 
many researchers have been working on finding new ways to increase the performance 
of colorimetric detection; for example, through enzymatic amplification systems
109,110
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with a detectable chromogen in solution, or through the use other amplification systems, 
such as gold nanoparticles silver enhancement,
111–113
 with the colour intensity given by 
small particles. 
Enzyme amplification depends on biocatalytic capability of these molecules, as a single 
enzyme molecule can produce up to 10
7
 molecules of substrate per minute, increasing 
the strength of the signal and therefore the sensitivity by a million fold, when compared 
to a label that produces just a signal event.
39
Colorimetric enzymatic amplification is 
discussed in more detail in chapter 3. 
Silver enhancement is an amplification technique that makes use of larger gold 
nanoparticles, becoming easier to detect at low concentrations. This technique depends 
on silver ions adhering to gold nanoparticles surface. The gold has the capacity to 
catalyse the silver ions reducing to silver atoms promoted by electrons released from the 
reducing molecules in solution around the gold nanoparticles. Silver atoms have the 
same catalytic capability of gold nanoparticles, therefore successive layers of silver 
atoms are deposited increasing the particle size.
112
 
To the best of our knowledge, there are no reports of colorimetric microfluidic IA 
applied to sensitive protein biomarkers quantitation without amplification. A 
microfluidic paper device was able to quantify hCG, the pregnancy hormone, using only 
colloidal gold nanoparticles and a flatbed scanner as a readout system, however 
pregnancy tests LLoD are much higher than cancer and cardiovascular diseases LLoD 
tests.
75
 For example, PSA was quantified in a microfluidic platform using colorimetric 
enzymatic amplification and a cell phone with LLoD of 3.2 ng/ml (107 pM).
70
 CRP was 
quantified with a LLoD of 0.07 ng/ml (0.6 pM) also based on colorimetric enzymatic 
amplification and a smartphone camera.
77
 The bio-Barcode was able to quantify PSA 
using silver enhanced gold nanoparticles with a LLoD of  
1.5x10
-5
 ng/ml (5x10
-4
 pM).
51
 
Fluorescence is mostly applied in microfluidic IA for sensitive protein quantitation. 
This is probably due to the fact that fluorescence detection systems are characteristically 
more sensitive, as they are measured relatively to the absence of light.
108
 Fluorescence 
occurs due to certain molecules, fluorophores that emit light at a certain wavelength. 
For the emission to occur fluorophores need to absorb light at a different wavelength 
that will excite electrons forcing them to move to a higher energetic level. The 
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excitation and emission wavelength depends on the fluorescent molecule. Several 
microfluidic devices were able to detect protein biomarkers without the need of 
amplification systems, using fluorophores as assay labels. However, these IAs used 
expensive and bulky readout equipment. For example, an immuno-pillar platform was 
able to quantify CRP, α-AFP, and PSA with a LLoD of 0.1 ng/ml (0.9, 1.5, and 3.3 pM, 
respectively), using fluorophores (FITC, Alexa Fluor 555, and Dylight 649) directly 
conjugated to the DetAb and an inverted fluorescence microscope.
58
 Some other 
fluorescent IAs used a combination of different readout systems and fluorophores, all 
directly conjugated to the DetAb, as described in the following examples. The CRP 
detection with LLoD of 1 ng/ml (9 pM) was performed by a microfluidic assay using 
Alexa Fluor 647 and detected with a fluorescence microscope.
56
 Interleukin-8 and 
insulin were quantified in a microfluidic immunoassay using Alexa fluor 488 and an 
epifluorescence upright microscope.
59
 IL-6 and TNF-α were quantitated with a LLoD 
between 0.01 ng/ml (0.48 pM) and 1 ng/ml (19.2 pM) using phycoerythrin and a Bio-
Plex 200 flow cytometer as a readout system.
67
 PSA was quantified with 1.7 ng/ml 
(56.7 pM) LLoD, in a porous silicon substrate, using FITC and a confocal microscope 
as a readout system.
71
 
Fluorescente scanners were also successfully used in protein biomarker quantitation 
with fluorescent signal detection without signal amplification. For example, TNF-α was 
detected with a LLoD of 0.02 ng/ml (0.38 pM) in a mosaic microfluidic platform using 
detection antibodies directly conjugated to fluorophores Cy5 and Alexafluor 647
50
. 
PSA, TNF-α, IL-1β, and IL-6 were quantitated with LLoD of 1 pM (0.03, 0.05, 0.017, 
0.021 pM, respectively) using neutravidin conjugated fluorophores Dylight 488, 550, 
and 650.
74
 Also, IL-6, IL-1β, TNF-α, and PSA were quantified with LLoD between 4 
and 30 pM with fluorophores Alexa fluor 647, phycoerythrin, and Alexa fluor 546, 
directly conjugated to DetAb.
76
 
Several attempts to create a portable, low-cost and sensitive fluorescent readout system, 
capable of reading non-amplified fluorescent signals, have been reported. For example, 
TnI was quantified with a LLoD of 0.024 ng/ml (1pM) using detection antibodies 
conjugated with FITC (Fluorescein isothiocyanate) with a house built readout system, 
with dimensions of 10x7x7 cm
3
, an LED (Nichia ultra bright blue LED) for 
fluorescence excitation, an excitation and emission filter, 10x objectives and a detector 
(H9858 photosensor module) (Figure 1:10A).
73
 PSA, α-AFP, and CEA were quantified 
41 
 
using antibodies directly label with fluorophore Cy3, presenting a LLoD of 1 to  
5 ng/ml (14.7 to 25 pM), respectively, with a home made fluorescence readout, 
consisting of white light emitting diode (LED) light, source, optical filters, an aperture, 
optical lens, and a photodetector (Figure 1:10B).
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Figure 1:10 – Detection modes and readout systems used in microfluidic devices for 
protein biomarker quantitation. 
A Configuration of fluoroimmunosensing device for autonomous capillary microfluidic 
signal detection system.
73
 B Fluorescence detection system in glass microcapillaries: (ii) 
photograph of the homemade handheld analyzer (ii) and schematic layout of the 
fluorescence readout module.
69
C Changes in reflectance obtained during antibody 
binding in an immunoassay using system that obtains 2D reflectance map with 20 m 
transverse resolution on oxide silicon wafers.
57
 D The set-up for the measurement of 
chemiluminescence using a photodiodetector and the special stand for the vertical 
positioning of the capillaries.
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Signal amplification in fluorescence systems can be achieved through enzymatic 
amplification. However this is far less common than the use of directly conjugated 
fluorophores, probably because the sensitivity is achieved without the need for extra 
steps in an immunoassay. TNF-α was quantified with LLoD of 0.045 ng/ml (0.86 pM) 
using streptavidin AP-conjugated and biotinylated antibodies, and an inverted 
fluorescent microscope.
53
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Fluorescence can be also detected by quantum dots nanocrystals, with quantum 
mechanical properties and excitation confined to the nanocrystal. For example, CEA 
and α-AFP were quantified with a LLoD of 3.5 (17.5 pM) and 3.9 (57.3 pM) ng/ml, 
using streptavidin conjugated to quantum dots and an ICCD camera.
99
 
Chemiluminescence is caused by a molecular reaction of two (or more) ground state 
molecules producing a final molecule in an excited state. The energy in the reactants is 
transferred to the products and, while being formed they are also excited. In 
chemiluminescence the signal is usually amplified using enzyme labels (more 
commonly, HRP) and chemiluminescent substrate (most common is luminol). Many 
microfluidic devices use chemiluminescence for sensitive protein quantitation. Some 
examples of chemiluminescence assays are following described, most of them using the 
DetAb directly conjugated to HRP. For example, CRP and TnI were quantified using 
HRP with LLoD of 8x10
-4
 and 0.037 ng/ml (7 and 1.5 pM), respectively, measuring 
chemiluminescent signal with a home built system, constituted by cooled PMT module 
and CCD camera.
78
 IL-4 and PSA (LLoD of 2x10
-4
 ng/ml, 0.5 pM, and 0.016 ng/ml, 
0.02 pM, respectively) were also quantitated based on chemiluminescence, HRP and a 
microplate fluorescent reader.
66
 Insulin and IL-6 have also been quantified by 
chemiluminescence, using biotinylated AP bond to streptavidin magnetic beads and a 
photomultiplier tube.
54
 CEA has been quantified with a LLoD of 0.041 ng/ml (0.02 pM) 
with gold nanoparticles functionalised with DNAzyme.
60
 Troponin T was quantified 
with LLoD in the range of 10 to 100 ng/ml (278 to 2780 pM) with HRP, using a 
photomultiplier and an oscilloscope.
62
 Myoglobin, CKmb, TnI and FABP were 
quantified with LLoD of 1.2, 0.6, 5.6, and 4 ng/ml (71, 7.14, 233, and  
267 pM), respectively, based on chemiluminescence, with HRP and a photodiode 
detector (Figure 1:10D).
52
 AFP, Cancer antigen 125, and CEA were quantified with  
0.06 ng/ml (0.9 pM), 6.6x10
7
ng/ml (0.33 U/ml), and 0.05 ng/ml (0.25 pM) of LLoD, 
respectively, by chemiluminescence with HRP and a luminescence analyser.
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Other detection modes used for microfluidic protein quantitation involved non optical 
detection modes, such as electrochemical detection, important for opaque substrates and 
dense optical matrices.
114
 These have reported PSA quantitation with 0.01 ng/ml  
(0.33 pM) using glucose oxidase PSA conjugated in a competitive assay and a custom 
built potentiostat as readout system.
64
 CEA and AFP were quantitated with 1x10
-3
 ng/ml 
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(0.005 and 0.014 pM) of LLoD using electrochemical detection and an electrochemical 
analyser.
61
 
Label free techniques, based on refractive index changes of magnetic beads attachment 
to a surface were able to quantify TnI with a LLoD of 0.024 ng/ml (1pM), using a total 
internal reflexion biosensor and a CCD camera.
55
 CRP was quantified with a LLoD of 
1.2 ng/ml (11 pM), using BIAcore surface plasmon resonance.
79
 Label free techniques 
can be performed with less steps, being usually faster, however not always as sensitive 
as the label techniques, and most of the times using expensive equipment. For example, 
a label free technique based on measuring shifts in microring resonance was able to 
increase sensitivity from µg/ml to pg/ml by amplifying the signal with streptavidin 
coated microbeads (Figure 1:11).
63
 
 
Figure 1:11 – The impact on CRP assay sensitivity and dynamic range of signal 
amplification on a microring resonator. 
A Schematic and real-time data plot showing sequential addition of CRP, biotinylated 
secondary antibody, and streptavidin-functionalized beads on the microrings resonators. 
The red trace is 1 µg/ml of CRP and the blue trace is 0.01 µg/ml of CRP. B A log–log 
calibration plot showing the response of the microring resonators to varying 
concentrations of CRP using the three-step assay. Black squares indicate the initial 
slope of the primary binding (right axis), red circles indicate secondary antibody shift, 
and blue triangles indicate bead shift (left axis).
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Readout systems are important for sensitive protein quantitation in microfluidic devices, 
they are mainly responsible for the cost, but also for the higher sensitivity of the assays. 
Therefore, more than 90% of microfluidic IA use complex, non-portable and expensive 
readout systems to quantify protein biomarkers. Only a few microfluidic devices have 
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reported the use of readout systems with low cost optoelectronics compatible with the 
ASSURED policy, such as a flatbed scanner
75
 or a smartphone.
70,77
 
1.3.7. Manufacturing of microfluidic devices 
Sensitive biomarker quantitation in microfluidic systems is achieved through a complex 
interaction of effects related to miniaturised sandwich IA and technological 
instrumentation currently available, which is mainly related to manufacturing processes 
and detection readout systems. In order to develop ASSURED POC microfluidic 
devices capable of sensitive protein quantitation all the effects related to IA 
miniaturisation must be combined in such a way that a low cost detection readout 
system can be used. The optimisation of an immunoassay in a microfluidic POC 
platform is very linked to the manufactoring tecnologies available, which set the 
geometry and materials used, and ultimately the economic cost that ditactes the 
adoption of the microfluidic POC test. According to Becker
115
 the reduced level of 
microfluidic devices commercialised is related to underestimation of microfluidics 
manufacturing processes, which are usually overlooked by the designers and the people 
working the application area. Becker claims that there are no technical barriers to build 
microfluidic devices, however to be able to compete with convential solutions a 
thoughtful study of design and manufacturing planning must be performed. For 
example, the number of produced units will influence the cost of the microfluidic 
device, therefore for low to medium volumes of manufacturing processes lower initial 
investments are prefered, such as elastomer casting of soft polymers, including PDMS, 
and hot embossing. These are the most popular manufacturing techniques in academic 
environment. If a large volume of products is desired, for example in the field of POC 
diagnostics, injection molding is more suited, although requiring a high initial 
investment, it compensates at high product volumes with the low cost of raw 
materials.
115
 Manufacturing techniques and materials used for fabrication of 
microfluidic devices was criticaly reviewed by Waldbaur et al.
116
 
An analysis of the manufacturing processes used in microfluidics shows that most 
protein quantitation devices are fabricated for small scale production. Therefore, soft 
litography and fast prototyping techniques are most popular manufacturing 
processes.
50,51,54,56,62,64,67–71,73,74,76,78
 This is certainly one of the reasons why 
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microfluidics are still not widely commercialised, as those tecnhiques lack scalability, 
and alternative technologies become expensive with a complex manufacturing process 
involving many steps. Nevertheless, some microfluidic devices already use scalable 
manufacturing process adequated to mass production of POC diagnostic devices, such 
as injection molding.
55,58,66,77
 Several researchers have developed sensitive quantitation 
of protein biomarkers in paper due to the low cost of paper manufacturing.
65,72,77
 
1.3.8. Current challenges and perspectives 
Microfluidic protein quantitation is a promising area for POC diagnostics. The most 
sensitive analytical tool used for protein quantitation is sandwich IA, which are a type 
of heterogeneous solid phase IA, relying on antibody-antigen binding. According to 
fundamental kinetics of antibody-antigen binding, four main areas are responsible for 
formation of antibody-antigen complex: antibody immobilisation, biological matrix 
interference, fluid control, and signal detection modes. These are key aspects of 
microfluidic IA that should be deeply explored to achieve sensitive quantitation. 
Microfluidic devices have used several methods for antibody immobilisation, including 
passive adsorption, common in plastic surfaces, covalent binding, where silanization 
seems to be the base of most of covalent binding techniques and a combination of the 
two techniques involving with antibody orientated techniques, which is still not widely 
used. Antibody covalent binding is the most used method for antibody binding to 
surfaces, resulting in better stability and antibody density. Most microfluidic devices 
developed for sensitive protein quantitation use buffers or non biological matrices to 
mimic biological samples in IA, however some present integrated structures for plasma 
separation for whole blood samples. Fluid control is still mostly done by pumps, which 
are external instruments to the chip, therefore the reagents are loaded through pressure 
driven systems capable of stop flow incubation times and multiple steps assays. The 
most common detection mode is optical fluorescence that uses complex and expensive 
readout systems such as microscopes, flow cytometers or fluorescent scanners. Signal 
amplification is often used for microfluidic protein biomarker quantitation and usually 
related to detection mode and readout system. All of these aspects should be combined 
integrated in a microfluidic device aiming POC diagnostic applications. 
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At first sight, it appears that sensitive protein biomarker quantitation is easy and 
possible in microfluidic systems; however, microfluidic diagnostics are still not much 
widespread or commercialised. This might be due to the fact that microfluidic 
researchers are still at the stage of showing that is possible to quantify proteins on chip 
in academic environments and not concerned about industrial implications. This has 
been demonstrated by the large amount of microfluidic devices that rely on expensive 
and bulky external pumps and expensive and non-portable readout systems for IA 
biomarkers quantitation. In addition, most microfluidic devices are manufactured by 
prototyping techniques, instead of easily scalable manufacturing processes.  
The future of microfluidic protein biomarker quantitation should involve simplifying 
the manufacture techniques by using low cost raw materials, so that they become 
scalable and simplifying the immunoassay procedure without compromising the 
sensitivity, eliminating external powered instruments, such as pumps and microscopes. 
This might be achieved through the immunoassay procedure and without the need of 
expensive powered instruments. For example, adding a signal amplification step to the 
immunoassay might eliminate the need to use an expensive readout system. The same 
way, using high surface area for antibody immobilisation might eliminate the need for 
signal amplification. Eliminating the need for sample preparation with better 
understanding of matrix effect in miniaturised IA performance will equally contribute to 
reducing the cost of microfluidic devices manufacturing. 
Overall, a better understanding of miniaturised IA is essential for designing and 
planning the future manufacturing of microfluidic devices for affordable POC 
applications. 
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1.4. State-of-the-art of Plastic Microcapillary Films 
(MCFs)  
In section 1.3 several microfluidic devices and IA used for protein biomarker 
quantitation were reviewed. One of the main conclusions is reflected on the urgent need 
for affordable microfluidic devices capable of sensitive protein quantitation, which can 
be achieved by mass production manufacturing processes and low cost raw materials. 
In this section, the development of novel low cost microfluidic platform called the 
Microcapillary Film (MCF) is reviewed. MCF consist of a parallel capillary array film 
continuously manufactured from thermoplastics using a novel melt-extrusion process.
117
 
The number of capillaries in the film and internal diameter can vary according to the 
application. Invented at the University of Cambridge, in 2005, the MCF has been 
developed and demonstrated on a variety of applications (Table 1:3), including heat 
transfer,
118,119
 organic synthesis,
120
 measurement and characterisation of residence time 
distributions,
121
 capture of superparamagnetic nanoparticles in a magnetic field,
122,123
 
and its use in therapeutics,
124
 continuous flow transfer hydrogenation,
125
 solar heat 
collector,
126
 IA,
127
 two-phase flow separation,
128
 fast cation-exchange separation of 
proteins,
129
 generation of singlet oxygen in continuous flows,
129
 and high-throughput 
process analytics and photochemical synthesis.
130
 Fluoropolymer MCFs are now 
produced by Lamina Dielectrics Ltd (Billingshurst, West Sussex, UK). 
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Table 1:3 – Innovations in Microcapillary Films (MCFs) outside this PhD thesis. 
Innovations Characteristics of the MCF Reference 
Extrusion of processable materials with a plurality of capillary channels 
(2005, 2008) 
Variable number (1, 10 and 17 capillary array), variable diameter (from 200 to 
750 µm), linear low-density polyethylene (LLDPE), polyvinyl alcohol (PVA) 
and Polyolefin elastomer 
117,131,132
 
Fluid flow and heat transfer performance (2006) 
17 bore MCF with mean diameter 200 µm produced from linear low-density 
polyethylene (LLDPE) 
118
 
Measurement and characterisation of residence time distributions (2008) 19 capillary array, mean diameter 230 µm, (LLDPE) 121 
Fast transient micro-heat exchange (2008) 19 capillary array, hydraulic diameter 200 µm, (LLDPE) 119 
Development of voidage and capillary size (2008) 
19 capillary array, mean hydraulic diameter 
200 µm, (LLDPE) 
133
 
Observation and modelling of capillary flow occlusion resulting from the 
capture of superparamagnetic nanoparticles in a magnetic field (2008) 
19 capillary array, mean hydraulic diameter 
200 µm, linear low-density polyethylene (LLDPE) 
122
 
The in-flow capture of superparamagnetic nanoparticles for targeting 
therapeutics (2008) 
19 capillary array, mean hydraulic diameter 
410 µm, LLDPE 
124
 
Solar heat colector (2009) 2 strips with 19 capillary array, 200 and 350 µm diameter, (LLDPE) 126 
Microdroplet formation within a plastic microcapillary array (2009) Single capillary used 740 µm internal diameter, LLDPE 
134
 
Fabrication of voided polyethylene microstructures by heat melding of plastic 
microcapillary films (MCFs) to form microcapillary monoliths (MCMs) (2009) 
19 capillary array, mean diameter 230 µm, linear low-density polyethylene 
(LLDPE) 
135
 
Magnetic capture of superparamagnetic nanoparticles (2009) 19 capillaries mean hydraulic diameter of 210 μm, polyolefin plastomer resin 
123
 
Continuous flow transfer hydrogenation (2010) 19 capillary array, 146 μm mean internal diameter EVOH 
125
 
Organic synthesis (2010) 10 capillary array, mean hydraulic diameters between 150 and 400 μm, LLDPE 
120
 
MCF immunoassays (2010, 2011) 10 capillary array, 200 µm diameter, FEP-Teflon 127,136 
Separating aqueous phase slugs from the surrounding organic matrix phase in 
segmented two phase flow (2011) 
1 capillary, 630 µm internal diameter polyolefin eleastomer 128 
Fast cation-exchange separation of proteins (2011) 19 capillary array, diameter of 142 μm, EVOH 
129
 
Through-wall mass transport as a modality for safe generation of singlet oxygen 
in continuous flows (2013) 
10 capillaries array, mean internal diameter 
104.2 μm ± 10.6 μm, FEP-Teflon 
137
 
Rapid photochemical transformations, high-throughput process analytics and 
photochemical synthesis (2015) 
10 capillaries, 103 to 494 µm, FEP-Teflon 130 
49 
 
1.4.1. The novel melt-extrusion process 
Melt-extrusion is a manufacturing process where a raw thermoplastic in the form of 
nurdles or small beads are melted and shaped continuously. 
The concept of extruding MCF was invented in 2004 and first published by Hallmark et 
al. Figure 1:12 shows a heated extrusion line, composed by a single-screw extruder and 
a gear pump, used in the production of MCFs. 
Upon exiting the extrusion die, with a convergent mid-section, the extrudate is taken 
through a quench bath. Since the extrudate is quenched, it is transported outside the 
extrusion line. A sensor assembly is placed over the extrudate for monitoring process 
regime.
117
 
 
Figure 1:12 – The heated extrusion line used in the manufacturing of MCFs. L is the 
melt drawing length.
117
 
The MCF presents multiple parallel capillaries, therefore multiple injectors have to be 
assembled within the single die, as shown in Figure 1:12. Assemblies were designed in 
such a way that the tips of each injector would be flushed with the exit of the die.
117
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Figure 1:13 - Diagram of the extrusion die used in the manufacturing of MCFs. Above 
die shown in the inset photograph at the right hand side.
117
 
1.4.2. Geometrical and polymer related aspects of the Microcappilary Film (MCF) 
Several MCFs materials containing different bore number and diameters were 
manufactured from a range of thermoplastic materials, including: fluorinated ethylene 
propylene copolymer (FEP), ethylene vinyl acetate (EVA), ethylene vinyl alcohol 
(EVOH), linear low-density polyethylene (LLDPE), and cyclic olefin copolymer 
(COC). Those polymers differ on the refractive index, as shown in Table 1:4. 
Table 1:4 – Refractive index of thermoplastics resins used in the manufacturing of 
MCFs.
136
 
Thermoplastic polymer Polymer Refractive Index 
Fluorinated ethylene propylene (FEP) 1.338 
Ethylene vinyl acetate (EVA) 1.48 
Ethylene vinyl alcohol (EVOH) 1.51-1.52 
Linear low-density polyethylene (LLDPE) 1.51 
Cyclic olefin copolymer (COC) 1.53 
 
Edwards et al. discovered the flat film geometry of MCF contributed to low refractive 
index of fluoropolymers which favour optical interrogation, with MCFs showing 
superior transparency compared to individual cylindrical capillaries (Figure 1:14).
127
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Figure 1:14 – Comparison of optical properties of a fused silica capillary and FEP 
capillaries with different geometries.
127
 
 
The curvature of individual capillaries results in poor signal-to-noise ratios, with the 
light being focused at the centre of the capillary with the wall working as a lens. This is 
fairly independent of the refractive index of the wall material. 
Fluoroploymer MCFs are fully transparent to light, and such transparency is paramount 
to achieve high assay sensitivity with optical detection, since all the light transmitted 
through the capillaries can be detected with minimal background from the polymer 
(Figure 1:15A). 
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Figure 1:15 – Colorimetric signal quantitation in MCF ELISA using a flatbed scanner. 
A Relevance of geometry and refractive index matching on signal-to-noise ratio. B 
Colorimetric signal quantitation in the fluoropolymer MCF using an off-the-shelf 
flatbed scanner in transmittance mode. C Example of RGB channels separation obtained 
from ImageJ software, using chromogenic ELISA substrate. D Examples of blue 
channel image from scanned fluoropolymer MCF test strips following completion of a 
PSA sandwich assay using (i) 0 ng/ml, (ii) 15 ng/ml, and (iii) 60 ng/ml of recombinant 
protein (data collected in this PhD project and further explained in chapter 5). E 
Absorbance calculated from the grey scale based on Lambert-Beer law,  
Abs = -Log10(I/I0). 
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The unique MCF transparency allows an immunoassay signal to be detected with a 
simple flatbed scanner (Figure 1:15B). The light emitted by the flatbed scanner lamp 
(I0) crosses the MFC and is captured by the detector embedded by the flatbed scanner. 
When the capillaries are filled with a coloured solution, part of the light is absorbed 
reducing the transmitted light. The RGB (red, green and blue) image can be split into 
separate channels using simple image software, such as ImageJ (Figure 1:15C) to fit the 
absorption peak of the substance. Using the same software it is possible to plot the grey 
scale across the strip (Figure 1:15D). The grey scale varies from 0 (black) to 255 
(white), meaning that every valley shape represents the absorbance in a single capillary. 
Higher concentrations of coloured solutions result in higher absorbance, therefore 
deeper valleys. The baseline depends on exposure settings of the detection but ideally 
kept to grey scale of 255. The ratio between incident light, I0, and transmitted light, I, 
yields absorbance values as according to equation (1:11). Based on Lambert-Beer law, 
the absorbance is proportional to the concentration of the coloured product, as described 
by equation (1:12): 
 𝐴𝑏𝑠 =  −𝑙𝑜𝑔 𝐼/𝐼0  (1:11) 
   
 𝐴𝑏𝑠 =  𝜀. 𝑐. 𝑙 (1:12) 
 
where 𝐼0 is the incident light intensity, 𝐼 is the transmitted light intensity, 𝜀 is the 
extinction coefficient of the substance, 𝑐 is the concentration of the coloured solution 
and 𝑙 is the light path distance, which corresponds to the height of a capillary at the 
centre of the peak signal. 
In addition to the unique optical properties, the raw material used for the production of 
MCFs (thermoplastic resin) is cheap, typically £20/Kg, with a meter of MCF typically 
weighting 5-10 g. It is possible therefore to manufacture a meter of MCF for a cost 
around £0.10-0.20 which is sufficient to manufacture hundreds of microfluidic devices. 
The capillaries in the film present very similar geometrical shape, creating the 
possibility for parallel independent micro reactors. However, due to the intrinsic 
characteristics of the melt-extrusion process, the geometry of the 10 capillaries can 
present slight differences since the polymer in the middle moves faster than the polymer 
at the edges of the film, making internal capillaries more elliptical than capillaries on 
the edges Figure 1:16.  
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Figure 1:16 - Geometrical characterisation of the MCF batch used for the experimental 
work presented in this thesis. 
A Cross sectional view of the 10 micro capillaries. B Capillary height according to 
MCF capillary number. C Capillary width according to MCF capillary number. D 
Capillary area according to MCF capillary number. E Capillary perimeter according to 
MCF capillary number. F Capillary hydraulic diameter (HD) according to MCF 
capillary number. 
1.4.3. Preliminary data available for immunoassays in MCFs 
The possibility of performing an immunoassay in the MCF was first reported by 
Edwards et al..
127
 The authors used a 10 capillary MCF with inner diameter 211 ± 10 
µm, 4.5 ± 0.1 mm wide, and 0.6 ± 0.05 mm thickness (Figure 1:17), which is the same 
used on this thesis. 
55 
 
 
Figure 1:17 – Overview of the FEP-Teflon Microcapillary Film (MCF). 
A 3 meters MCF reel. B MCF cross section showing the 10 capillaries. C Single 
capillary image. 
 
The authors reported a multiplex device capable of quantifying biomolecules through a 
colorimetric ELISA, using the quantitation of Hepatitis B antibody, from 1 to 40 ng/ml 
in a non-competitive immunoassay, as a proof of concept. In this assay the antigen was 
immobilised by adsorption on the inner wall of the fluoropolymer MCF and a HRP 
label antibody used for detection. Simultaneous detection of Hepatitis B and FLAG 
peptide was also performed as a proof of concept for multiplex detection, using a 
fluorescence substrate and a confocal microscope. That preliminary work showed that 
proteins effectively adsorb to FEP-Teflon standing the washing steps. The Hepatitis B 
detection used a flatbed scanner for protein quantitation.  
Chahín performed the first sandwich ELISA assay in the MCF platform for quantitation 
of PSA.
138
 Using a chromogenic substrate, a flatbed scanner, and a syringe attached to a 
silicone tubing, the PSA ELISA was successfully translated from MTP to the 
fluoropolymer MCF. A set of variables were individually optimised which involved 
testing the effect of PSA CapAb concentration in the range from 1 to 20 µg/ml, 
concluding that the optimal concentration of CapAb was 10 µg/ml. Also, the optimal 
concentration of DetAb reported was 2 µg/ml, although its influence did not appear to 
significantly affect the overall assay performance. Chaín also optimised sandwich 
ELISA steps incubation times, concluding that 2 hours of incubation time was sufficient 
for the CapAb, followed by 10 minutes for the DetAb, and 30 minutes for the enzymatic 
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substrate. Enzymatic substrate (OPD) concentration was also optimised, being 1 mg/ml 
the optimal found.
138
 
Table 1:5 – Optimised assay conditions found by Chaín for PSA MCF sandwich 
assay.
138
 
Assay Step Concentration 
(µg/ml) 
Incubation time 
(min) 
CapAb 10  120 
Blocking Reagent diluent 120 
PSA 0.0025-0.08 10 
DetAb 2  10  
Enzyme 2  10 
Substrate 1  30 
 
These experiments used only one-concentration reagents per incubation time and these 
two variables (concentration and incubation time) are extremely related and have a high 
impact in signal-to-noise of the assay and on assay time. Further in this thesis is 
demonstrated the importance of DetAb concentration and incubation times for 
increment of assay signal-to-noise ratio, which is extremely important for sensitivity. 
Also, for IA optimisation in a platform is important to understand the limits of that 
platform. For example, it would be important to understand how much antibody active 
can be adsorbed in the MCF and then work from those ranges. Understanding the 
enzyme kinetics in miniaturised systems will be extremely important for reducing assay 
time and increase its sensitivity, as it can be seen further on this thesis. 
1.5. General methodological considerations, 
unique to the work reported in this thesis 
The fluid handling in Chaìn’s study consisted of a pressured driven system driven by an 
individual and disposable syringe.
138
 This thesis expanded the work conducted by 
Chaìn, by using different pressure driven fluid handling systems, such as the multiple 
syringe aspirator (MSA) device and peristaltic pumps (Figure 1:18). More details about 
the use of these fluid handling mechanisms are given in chapters 2 to 9. 
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Figure 1:18 - Strategies used for fluid handling in MCF assays: single syringe, MSA 
(Multiple syringe aspirator) and peristaltic pumps. 
The Multiple Syringe Aspirator (MSA) consists of 8 parallel syringes attached to a 3 cm 
length MCF strip at one end, via a rubber seal. The other end of the syringes is 
connected to a centrally controlled single knob, which pulls all syringe plungers 
simultaneously allowing aspirating a precise small volume (<100 µl) of reagents from 
the wells. The whole device fits into a SLA printed polyurethane microwell plate 
(Figure 1:19A). The MSA was tested by NG with the aim of reducing assay variability, 
which involved extended incubation times of 30 minutes for enzymatic substrate 
conversion, using OPD as chromogenic enzymatic substrate with flatbed scanner 
detection, and introducing the absorbance normalisation value by capillary height as 
data processing.
139
 
The MSA device operates 8 MCF strips simultaneously, which simplifies the ELISA 
procedures previously discussed in section 1.2. A schematic of an optimised PSA 
sandwich ELISA using the MSA is presented in Figure 1:19B. Every turn of the knob 
pulls 13 µl.139 In the PSA assay 78 µl were used in each ELISA steps, which 
corresponds to 6 full rotations of the central knob in the MSA. The PSA 
standard/sample is first aspirated, and the MSA left to incubate on the well allowing the 
PSA to bind the CapAb immobilised in the pre-coated strips (Figure 1:19B(ii)(1)). The 
MSA is then moved to next row of wells containing pre-loaded DetAb (Figure 
1:19B(ii)(2)), and the procedure repeated for enzyme conjugate, washing step and 
enzymatic substrate (Figure 1:19B(ii)(3)-(5)). After the full optimisation of PSA assay 
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presented in this thesis, no additional intermediate washing steps were required to 
achieve the desirable assay performance. 
 
Figure 1:19 – Multiple syringe aspirator (MSA) device used for PSA ELISA in the 
fluoropolymer MCF.  
A MSA components: (1) close photograph of a meltextruded MCF reel with 10*211 µm 
i.d. embedded microcapillaries; (2) cartridge incorporating an array of eight parallel 1 
ml syringes used for fluid aspiration; (3) close up at the rubber push-fit seal; (4) push-fit 
of 30 mm long pre-coated MCF strips in the rubber seal; (5) fully assembled device, 
with a plastic frame used to hold syringes, a syringe plugholder with a central knob 
allowing fluid aspiration by rotation, a rubber seal with MCF test strips incorporated 
which interfaces with a sample tray with preloaded reagents; (6) close up at the 
polyurethane microwell plate with 72 wells, organized in 8-wells arrows allowing all 
sandwich assays reagents to be pre-loaded; (7) MCF filled with PBS buffer, revealing 
excellent transparency; and (8) MCF filled with air, revealing opaque film. B 
Sequential, semi-automatic fluid aspiration in the MSA: (i) with every full rotation of 
the central knob the syringes aspirate simultaneously 13 µl of reagents/samples from the 
wells through the MCF strip; and (ii) solution are sequentially aspirated, with no need 
for intermediate washing steps. 
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The work presented in this thesis was focused on the technological developments of 
MCF IA technology in light of preliminary work discussed in section 1.4.3, of section 
1.4. The work aimed at establishing principles for immunoassay miniaturisation. 
Therefore, the novel aspects of this work can be summarised as follows: 
 Studying antibody adsorption onto FEP-Teflon micro capillary surfaces; 
 Optimising kinetics of HRP substrate conversion in miniaturised systems, with 
particular focus on sandwich assays in the MCF; 
 Studying the effect of flow in antibody binding in FEP-Teflon micro capillaries; 
 Fully optimisation of sandwich PSA immunoassay for operation with whole 
blood samples, without sample preparation; 
 Developing new protocols for colorimetric, fluorescence and particle detection 
of PSA in MCF strip; 
 Studying biological matrix components interference in antibody-antigen binding 
equilibrium and kinetics. 
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2. Antibody (IgG) Adsorption onto FEP-Teflon 
microcapillary surfaces for quantitative point-of-care 
diagnostics 
2.1. Abstract  
The adsorption characteristics of antibodies onto FEP-Teflon surfaces were studied in a 
Microcapillary Film (MCF) produced from FEP-Teflon, being relevant to the 
development of a new generation of microfluidic sandwich immunoassay (IA) devices. 
Antibodies were adsorbed onto FEP-Teflon as a monolayer with maximum coverage of 
400 ng/cm
2
, which coincides with the theoretical monolayer coverage of vertically 
oriented antibodies. When different antibody surface coverages were applied to IL-1β 
cytokine detection, the antibody binding capacity increased up to 220 ng/cm
2
 and 
decreased for surface coverages above 275 ng/cm
2
.The maximum binding capacity of 
an adsorbed antibody layer on FEP-Teflon therefore happens slightly above half 
monolayer coverage, which agrees with previous studies performed on other surfaces.  
The microcapillary film (MCF) geometry, 10 bore with 200 µm diameter embedded in a 
FEP-Teflon flat film, allows the necessary surface area to obtain a monolayer dense 
enough to perform sensitive IA. The geometry is combined with a surface chemistry 
(FEP-Teflon) that favours irreversible antibody binding of a monolayer to the surface, 
maintaining their antigen binding capacity.  
The integration of FEP-Teflon antibody adsorption capacity with its excellent 
transparency allows femtomolar detection of cytokines (IL-1β, IL-6, IL-12 and TNF-α) 
and rapid and sensitive detection of prostate cancer antigen (PSA) using colorimetric 
signal detection with a flatbed scanner as a readout system. This transforms the 
microcapillary film (MCF) into a quantitative platform for point-of-care diagnostics.   
Keywords: Biosensor, point-of-care, microfluidic, capillary geometry, antibody 
adsorption, ELISA, FEP-Teflon.   
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2.2. Introduction 
Immunoassays (IA) are powerful laboratory assays that use antibodies specificity for 
bioanalytical purposes, with applications in the environment,
140
 food,
141
 disease 
diagnostic and other pharmaceutical industries.
142
 Point-of-care diagnostics devices are 
proficient at detecting a wide range of health conditions from cancer to infectious 
diseases, and are necessary for personalized medicine in developed countries
2
 and early 
diagnostics in remote areas of developing countries.
6
 Consequently, adapting IA for 
miniaturized devices capable of portable, power-free, disposable and low cost disease 
detection with minimal sample preparation is an urgent demand for global health. 
143
  
Immunoglobulin G is the main type of antibody used in IAs. These biomolecules with 
150 KDa present an Y shape, with two variable regions (Fab fragments), capable of 
binding specifically to other molecules, and one constant region (Fc fragment).
144
 The 
most sensitive format of immunoassays, the heterogeneous sandwich IAs, presupposes 
an antibody immobilisation onto a solid surface (capture antibody), followed by several 
reaction steps which rely on the maintenance and stability of the immobilised antibody 
layer. The density, uniformity, stability and orientation of the antibody immobilised 
layer is fundamental for development of sensitive and robust assays. 
21
 
Sandwich immunoassays rely on a solid support and detection modes, which have to be 
capable of detecting a signal that correlates with the immobilised antibody-antigen 
complex. 
33
 
In laboratories the gold standard for IAs support is the microtiter plate (MTP) and the 
microplate reader, however this technology is not suitable for point-of-care detection. In 
recent years, several microfluidic technologies have emerged with new materials for IAs 
solid support. Miniaturized microfluidic systems are portable, disposable and 
automated, thus suitable for analytical procedures outside the laboratory, including 
point-of-care disease diagnostics.
7
 However, a miniaturized support creates a 
miniaturized signal, which needs to be precisely detected and quantified. This is a major 
challenge for point-of-care microfluidic devices to overcome as they often need a 
sophisticated equipment for signal measurement such as microscopes, which contradicts 
the ideal of simple, portable, power-free and cost effective microfluidic IAs for point-
of-care testing. 
56,58
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Subsequently, microfluidics solid supports must compensate the detection mode with 
their high analytical eficiency, which is intrinsically related to their size. The Scatchard 
model
145
 shows that higher concentrations of antibody favor the formation of antibody-
antigen complex in an antibody-antigen binding reaction. Accordingly higher numbers 
of immobilised antibodies will capture more analytes (antigens) in the microfluidic 
system.
145
 
Individual capillaries have been widely used as a solid support phase for bionalytical 
purposes, as small diameter capillaries allow reduced reagent consumption, fast reaction 
times and easy incorporation of flow systems.
146
 
In order to attach a higher number of immobilised antibodies onto a surface it is 
necessary to have a large surface available in the immobilisation zone (the solid phase 
area where analytes bind and signal detection can be performed). In microfluidics IAs, 
where antibodies are immobilised in the inner walls of a channel, the immobilisation 
area is mainly reserved to a particular part of the channel, known as the reaction 
chamber. Microfluidic channels are usually very small (typically in the order of 100-500 
µm), therefore yielding large surface-area-to-volume ratios. Consequently the 
immobilisation zone surface area is typically very small, which limits the number of 
immobilised antibodies. Hence, complex antibody immobilisation methods are needed 
in order to obtain a dense antibody monolayer and expensive laboratory signal detection 
systems are required for performance of sensitive and robust IAs. 
50,56,147
 Although 
surface area-to-volume ratio is important for point of care (POC) diagnostics, the total 
antibody immobilisation surface area is relevant for sensitive POC assay cost and 
portability. Kai et al (2012) understood this balance between total surface area and 
surface-area-to-volume ratio, reporting a novel microfluidic microplate with 
microchannels providing similar surface area to conventional microplates, but with a 50 
times increment in surface-area-to-volume ratio. A fluorescent plate reader was still 
needed for signal detection however.
66
 
Geometry limits the number of antibodies in the surface and the rate they adsorb to the 
surface. Nevertheless surface chemistry and antibody immobilisation methods 
determine the density, uniformity and effectiveness of bond antibodies and their 
orientation.  
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Passive adsorption on bare substrates is the most simple and one of the most common 
antibody immobilisation methods.
87
Antibody adsorption happens mainly due to 
electrostactic, van der Waals, hydrogen bonding and hydrophobic interactions. It 
therefore depends on the surface chemistry, pH, temperature and ionic strength of the 
buffer during antibody adsorption. Hydrophobic substrates, such as plastics and 
PDMS
87,148,149
 are usually chosen for antibody adsorption, since hydrophobic 
interactions are strong enough to effectively bind an antibody to a surface.
87,150,151
 
Beyond allowing simple antibody immobilisation, thermoplastic resins are cheap and 
enable mass fabrication.
21,87
 These are important features for manufacturing point-of-
care diagnostic devices. 
The microcapillary film (MCF) is a melt extruded thermoplastic film that contains 
embedded hollow capillaries.
117
 Several plastic polymers were used to produce the 
MCF by melt-extrusion, such as fluorinated ethylene propylene copolymer (FEP), 
ethylene vinyl alcohol (EVOH) and linear lower density polyethylene (LLDPE). The  
cost for pelleted FEP material is in the range of £20/kg, which means a 10-plex, 50mm 
long MCF FEP test strip can be produced for less than £0.10 using the melt extrusion 
procedure.
127
 
Previous studies reported the use of 10*200 µm fluorinated ethylene propylene 
copolymer (FEP-Teflon)
1
 for immunoassays. This polymer was chosen for its excellent 
transparency, allowing sensitive signal detection with low cost readout systems.
127,152
 
According to Barbosa et al. (2014) PSAcould be quantified on this platform with a 
lower limit of detection (LLoD) of 0.9 ng/ml of PSA in 13 minutes total assay time, 
using a flatbed scanner as a readout system and passive adsorption as the antibody 
immobilisation technique.
152
 The LLoD was improved to 0.08 ng/ml using fluorescence 
detection with a smartphone.
153
 Also, Castanheira et al. (2015) reported (IL-1β, IL-6, 
IL-12 and TNF-α) using the same method.154 
Fluoropolymers have excellent chemical and thermal resistance and form non-reactive 
surfaces with a variety of chemicals and solvents which make them ideal for many 
applications, including medical diagnostics.  
                                                             
1
 Fluorinated ethylene propylene (FEP) is a plastic copolymer of hexafluoropropylene and 
tetrafluoroethylene, invented by DuPont under the brandname Teflon FEP. 
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In this study we aim to characterize antibody adsorption onto FEP-Teflon 
microcapillary films (MCFs) (Figure 2:1), demonstrating that antibody adsorption is 
reliable for MCF sandwich assays in point-of-care diagnostics.  
 
Figure 2:1 – MCF produced from fluorinated ethylene propylene copolymer (FEP-
Teflon). 
A Photograph of a 10 bore 200 µm bore FEP-Teflon microcapillary film. B 
Transparency of FEP-Teflon MCF (i) capillaries filled with air (ii) capillaries filled with 
PBS buffer. C Chemical composition and structure of FEP-Teflon polymer. D 
Geometry comparison between the gold IA standard, the microtiter plate, and the MCF. 
Note that a typical MCF test strip has 10 capillaries and 3 cm in length. 
2.3. Materials an Methods 
2.3.1. Materials & Reagents 
Mouse IgG (whole antibody) was purchased from Life Technologies (Paisley 
UK), rabbit Anti-IgG (whole molecule) conjugated with peroxidase and 
SIGMAFAST
TM
 OPD (o-Phenylenediamine dihydrochloride) tablets were supplied by 
Sigma-Aldrich (Dorset, UK). The BCA Protein Assay Reagent (bicinchoninic acid) was 
sourced from Thermo Scientific (Lutterworth, UK). The IL-1β recombinant protein, 
Anti-Human IL-1β biotin and Anti-Human IL-1β purified were supplied from 
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eBiosciences (Hatfield, UK). High sensitivity streptavidin-HRP was supplied by 
Thermo Scientific (Lutterworth, UK).  
Phosphate buffered solution (PBS) and Bovine Serum Albumin (BSA) were sourced 
from Sigma Aldrich, Dorset, UK. PBS pH 7.4, 10mM was used as the main 
experimental buffer. Anhydrous Sodium Carbonate was supplied from Fisher Scientific 
and HEPES from Sigma-Aldrich, Dorset, UK. The blocking solution consisted of 3% 
w/v protease-free BSA diluted in PBS buffer, except for IL-1β assays, which used a 
superblocking solution supplied by ThermoScientific (Lutterworth, UK). For washings, 
PBS with 0.05% v/v of Tween-20 (Sigma-Aldrich, Dorset, UK) was used.  
The MCF was fabricated from FEP-Teflon using a melt-extrusion process by Lamina 
Dielectrics Ltd. (Billinghurst, West Sussex, UK). The MCF presented 10 bore parallel 
capillaries with the mean 0.2 mm internal diameter. An MCF produced from LLDPE 
was also produced at Cambridge University
117
 and presented 19 parallel capillaries with 
0.2 mm internal diameter. Glass capillaries, 152 mm in length and 0.58 mm internal 
diameter, were purchased from World Precision Instruments, Inc. (Hitchin, 
Hertfordshire, UK). 
2.3.2. Determination of adsorbed mass antibody  
The MCF was trimmed into 20 cm strips, and each strip filled with a solution with 
concentrations of 0, 6.25, 12.5, 25, 50, 100, 200 and 400 µg/ml of mouse IgG, prepared 
from a serial dilution of 400 µg/ml Mouse IgG in PBS and incubated for 2 hours at 
room temperature (20 ºC). The solution inside MCF strips was collected using a syringe 
attached to a silicone tube and transferred into microplate wells. BCA protein assay was 
used for quantifying the antibody concentration in the aliquots based on solution 
depletion technique. 
In order to understand the effect of temperature on antibody adsorption, the temperature 
was kept constant during IgG incubations at 37 ºC and at 4ºC.  
The pH effect on IgG adsorption to FEP-Teflon was studied by preparing IgG serial 
dilution solutions in Sodium Carbonate buffer 10 mM at pH 10.7, in Phosphate buffer 
(PBS) 10 mM at pH 7.4 and HEPES 10 mM at pH 4.8. The IgG solutions were 
incubated inside the FEP-Teflon capillaries for 2 hours at room temperature.  
66 
 
The effect of surface chemistry on IgG adsorption was studied by comparing antibody 
adsorption in FEP-Teflon with LLDPE (CH3 plastic polymer, with 102º water contact 
angle) and glass capillaries (silica with 15º water contact angle), pH 7.4, for 2 hours at 
room temperature.  
For IgG quantification in aliquots 25 µl of solution was placed in a microwell and 200 
µl of BCA working reagent (1 reagent B: 50 reagent A) was added to each well and 
mixed for 5 seconds with a multiple channel micropipette. The microwell plate was 
covered with parafilm to avoid liquid evaporation and incubated at 37 ºC for 3 hours. 
Every sample was tested in triplicate. A set of IgG standard solutions was placed in the 
same microwell plate to obtain a calibration curve. For this purpose 25 µl of IgG 
solution from each concentration previously prepared were mixed with 200 µl of BCA 
working reagent (1:50).  
Following incubation of IgG standards and samples with the BCA working reagent, the 
microtriter plate was left to cool down for a few minutes at room temperature. The end 
point absorbance was measured at 562 nm using a microplate reader (Epoch, BIOTEK).  
The absorbance values of IgG standard solutions were used to build a calibration curve. 
The equation obtained from this calibration curve was used to estimate the initial 
concentration of IgG in solution and the remaining IgG concentration in the 
microcapillaries. The concentration of IgG adsorbed (µg/ml) was obtained from a mass 
balance to the IgG in the microcapillaries (2:1) and converted to adsorbed density 
(ng/cm
2
) through equation (2:2). 
1.  [Ads IgG] = [Initial IgG solution] − [Remaining IgG solution] (2:1) 
 
2.    
3.  SA
V
=
4
D
 
(2:2) 
 
where SA is the surface area, V the volume and D the mean hydraulic diameter of the 
capillary. 
The percentage surface coverage was calculated by considering a theoretical antibody 
monolayer with the antibody orientation being vertical. The percentage surface 
coverage was normalised by the total surface area for comparison of different capillary 
materials.  
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2.3.3. Kinetics of adsorption to capillary surfaces 
A solution containing 20 µg/ml of mouse IgG in PBS was prepared and aspirated into 8 
FEP-Teflon MCF strips each of 20 cm in length. The IgG incubation time on each strip 
varied from 0 to 120 minutes. After IgG incubation the solution inside the capillaries 
was placed in a microwell and 25 µl of this solution were used for protein quantitation 
with BCA assay. The procedure was repeated with 40 and 200 µg/ml IgG solutions in 
FEP-Teflon MCF and with 20,40 and 200 µg/ml IgG in MCF fabricated with LLDPE 
and glass capillaries.  
2.3.4. Quantitation of antibody adsorbed onto FEP-Teflon by ELISA technique  
To study the effect of immobilised antibody density in overall antibody binding in an IA 
(i.e. capacity of a coated solid phase to specifically capture molecules) 8 FEP-Teflon 
MCF strips were incubated for 2 hours at room temperature with 0, 6.25, 12.5, 25, 50, 
100, 200 and 400 µg/ml of mouse IgG in PBS. The strips were then washed with 1 ml 
of PBS-Tween and then incubated for 10 minutes at room temperature with 0.06 µg/ml 
of anti-IgG conjugated to peroxidase. The strips were washed with 1 ml PBS-Tween 
after which 1mg/ml of OPD enzymatic substrate was aspirated. The MCF strips were 
scannned in transmittance mode using a Flatbed Scanner (HP ScanJet G4050 Scanner) 
after 5 minutes of OPD incubation and a digital image with a resolution of 2400 dpi was 
processed using Image J (NIH, Maryland, USA) sofware for absorbance calculation. 
The experiments were repeated with 0.6 and 6 µg/ml of Anti-IgG, peroxidase 
conjugated.  
The effect of immobilised IgG incubation time in antibody binding was studied by 
incubating 40 µg/ml of IgG in PBS in FEP-Teflon MCF strips from 0 to 120 minutes, 
before washing the strips with 1 ml PBS-Tween. A solution of 0.6 µg/ml of Anti-IgG, 
peroxidase conjugated was then added and incubated for 10 minutes. After another 
washing step, OPD enzymatic substrate was added at the concentration of 1 mg/ml. The 
MCF strips were then imaged after 5 minutes incubation of OPD in transmittance mode.  
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2.3.5. MCF ELISA Digital Image Analysis 
RGB digital images were split into 3 separated channels in Image J. The blue channel 
images were used to calculate absorbance values, based on the grey scale peak height of 
each individual capillary of FEP-Teflon MCF as described elsewhere.
127,152 
Absorbance 
(Abs) was calculated for each individual capillary based on equation (2:3): 
 
Abs =  −log10(
I
I0
) 
(2:3) 
Where I is the transmitted light and corresponds to I0 minus peak height and I0 is the 
maximum grey scale value. The absorbance values were averaged across 10 capillaries 
for the MCF strip.  
2.3.6. IL-1β sandwich ELISA 
6 cm long FEP-Teflon MCF strips were filled with IL-1β monoclonal antibody 
solutions of 20, 40, 100 and 140 µg/ml and incubated for 2 hours. The remaining 
binding sites were blocked with super blocking solution by incubating the MCF for 2 
hours. The strips were then washed with 1ml of PBS-Tween. Each coated MCF strip 
was trimmed into two 3 cm long strips, which were used as a positive and a negative IL- 
1β test. These strips were inserted into the multiple syringe aspirator device, which 
allows simultaneous fluid aspiration in all eight MCF strips, through manual rotation of 
a knob. A dilution with 0.5 ng/ml of recombinant IL-1β was incubated for 2 minutes in 
four of the MCF strips and the remaining strips incubated with PBS solution. After a 
washing step a solution of 10 µg/ml of IL-1β biotinyated detection antibody was 
aspirated and incubate for 10 minutes. A 4 µg/ml solution of High Sensitivity 
Streptavidin-HRP was aspirated following another washing step with PBS-Tween and 
incubated for 10 minutes, followed by a washing step. A solution with 4 mg/ml os OPD 
enzymatic substrate was then aspirated into the capillaries and incubated for 5 minutes, 
and the strips imaged with the Flatbed Scanner at 2400 dpi.  
For the IL-1β response curves, two 30 cm long FEP-Teflon MCF strips were filled with 
40 µg/ml of IL-1β capture antibody (CapAb). One of the strips was incubated for 30 
minutes and the other for 2 hours. The strips were then blocked with superblocking 
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solution by incubating for 2 hours, followed by a washing step. The MCF strips were 
then trimmed into smaller 3 cm long pieces and inserted into the multiple syringe 
aspirator device (MSA). Eight solutions of IL-1β from 0 to 1 ng/ml were aspirated into 
the MCF strips and incubated for 5 minutes, followed by a washing step. Then a 10 
µg/ml solution of IL-1β biotinylated antibody was aspirated into the MCF strips and 
incubated for 10 minutes, followed by a washing step and 4 µg/ml high sensitivity 
streptavidin-HRP incubation for 10 minutes. A solution of 4 mg/ml of OPD was 
aspirated into the eight MCF strips following a washing step, and the strips were imaged 
after 5 minutes incubation.  
2.4. Results and Discussion 
2.4.1. Surface capacity of FEP-Teflon MCF for antibody adsorption 
A key challenge to commercialisation of microfluidic POC diagnostic devices is the 
possibility of mass production methods for microfluidic platforms, which are currently 
lacking, as most lab-on-a-chip devices are made through micromachining methods. For 
mass produced diagnostic devices the antibody or protein needs to be immobilised in 
bulk quantities, therefore the immobilisation method has to be simple, easy, 
reproducible and cost effective, which is often achieved with antibody adsorption to 
polymeric materials.
87
 
Adsorption is the most common method for antibody immobilisation, however it is very 
specific to surface chemistry, total surface area available for binding, surface geometry, 
pH, temperature and buffer ionic strength.
151
 The antibody adsorption onto FEP-Teflon 
MCF is shown in Figure 2:2.  
70 
 
 
Figure 2:2 - IgG adsorption onto FEP-Teflon MCF 200 µm i.d. 
A FEP-Teflon MCF used. B IgG Langmuir in standard MCF IAs conditions pH 7.4 and 
20ºC. C IgG langmuir adsorption at 4, 20 and 37 °C, pH 7.4. D IgG langmuir adsorption 
at pH 4.8, 7.4 and 10.7, at 20 ºC. The IgG incubation time was 2 hours in all 
experiments described in the figure. The continuous lines in the figure represent the 
values predicted with the Langmuir adsorption model using the least squares solver 
equation. 
 
Antibody adsorption to FEP-Teflon experimental data presented in Figure 2:2 was fitted 
to the Langmuir adsorption model, using the equation (2:4) and the least squares solver 
equation. The parameters 𝜏𝑚𝑎𝑥 .and 𝐾 obtained from the model are presented in Table 
2:1. 
 
𝜏 =  𝜏𝑚𝑎𝑥
𝐾𝑐
1 + 𝐾𝑐
 
(2:4) 
 
Where 𝜏 is the surface coverage in equilibrium, 𝜏𝑚𝑎𝑥 is the number of adsorption sites 
available given by a maximum adsorbed concentration, 𝐾 is the adsorption constant and 
𝑐 the antibody concentration in solution.  
Temperature is one of the factors that most influences protein adsorption, as higher 
temperatures generally increase the adsorbed quantity of protein. 
151
 Surprisingly the 
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amount of antibody adsorbed to FEP-Teflon capillaries did not appear to be affected by 
the temperature in the range of 4 to 37 ºC (Figure 2:2 and Table 2:1). This is an 
advantage for mass production of coated MCF strips as the manufacture set up does not 
require temperature control, lowering the cost of manufacturing and enabling a higher 
degree of freedom for operators.  
In conventional ELISA surfaces antibody adsorption is known to be higher around the 
isoelectric point of IgG (pH 6.8 – 9.0), as electrostatic interactions are minimised 
allowing higher packing densities on the surface.
151
 Nevertheless, Figure 2:2D and 
Table 2:1 shows that adsorption at a pH lower than the antibody isoelectric point 
(pH=4.8) increased the amount of IgG adsorbed onto FEP-Teflon microcapillaries (853 
ng/cm
2
), whereas at a pH higher than the isoelectric point (pH 10.7) the amount 
adsorbed decreases (190 ng/cm
2
) compared to the isoelectric point condition with a Ϯmax 
of 486 ng/cm
2
 (Figure 2:2). This might be explained by protein denaturation at lower 
pH values, which promotes unfolding and aggregation of antibody molecules. Wright et. 
al (1945) reported that at pH 4.95 approximately 50% of the antibody present in 
solution was denatured.
155
  
The antibody adsorption conditions chosen for FEP-Teflon MCF sandwich assays in our 
previous studies
152–154
 were 20 ºC and pH 7.4, and at those conditions the adsorption 
isotherm in Figure 2:2B shows a maximum surface coverage of 404 ng/cm
2 
(approximately 80 µg/ml of adsorbed IgG) for a 200 µm i.d. microcapillaries, which is 
obtained with 400 µg/ml of IgG in solution. This demonstrates a low affinity of IgG for 
the FEP-Teflon surface with an adsorption constant of 0.014 ml/µg (Table 2:1).  
Table 2:1- FEP-Teflon IgG adsorption parameters variation with pH and temperature. 
 Temperature pH 
 4°C 20°C 37 °C 4.8 7.4 10.7 
K (ml/µg) 0.015 0.014 0.016 0.007 0.014 0.019 
Ϯmax (ng/cm
2
) 472 486 472 853 486 190 
R
2
 0.9856 0.9963 0.9891 0.9801 0.9963 0.9412 
 
Based on the dimensions of antibody molecules, Buijs et al.(1995) suggested a 
relationship between the adsorbed amount and the molecular orientation on the surface, 
thus 200 ng/cm
2 would represent a monolayer with antibodies in a “flat-on” orientation, 
260 ng/cm
2
 in an “end on” orientation with Fab fragments in line, and 550 ng/cm2 also 
in an “end-on” orientation with Fab fragments close together and parallel.156 This 
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suggests antibody adsorption to FEP-Teflon at the conditions studied happens by a 
monolayer formation with the maximum adsorbed amount of 404 ng/cm
2
, which 
suggests a packed antibody monolayer with antibodies oriented “end-on”.  
Antibody adsorption to FEP-Teflon was found to be similar to protein adsorption onto 
hydrophobic surfaces and other fluorinated surfaces. A study of protein IgG adsorption 
onto Teflon AF (amorphous fluoropolymers) using optical waveguide light mode 
spectroscopy
157
 showed a maximum surface density of approximately 200 ng/cm
2
 at 40 
µg/ml of IgG solution, where in the FEP-Teflon micocapillaries the adsorbed mass, 
using 40 µg/ml IgG solution, is 220 ng/cm. Another study used a Quartz Crystal 
Microbalance with Dissipation in a Ch3-terminated surface and shows a maximum 
coverage of 468 ng/cm
2
 with 100 µg/ml of IgG in solution. This is 40% higher than the 
surface coverage obtained in the FEP-Teflon MCF (275 ng/cm
2
) using the same IgG 
concentration in solution.
158
 This might be due either to the difference in geometry or 
the surface chemistry, with FEP-Teflon presenting a lower affinity for antibody 
adsorption.  
The reduced affinity to antibodies for hydrophobic surfaces favours the formation of a 
less dense monolayer, which is preferred for sensitive ELISA in miniaturised devices. 
Antibody density on  hydrophilic surfaces yields higher mass adsorbed with the possible 
formation of antibody multilayers.
159
Higher adsorption affinity is promoted by 
electrostatic interactions between antibodies and hydrophilic surfaces. 
159
 Hydrophobic 
surfaces are usually chosen for antibody adsorption onto biosensors as immobilised 
antibodies are more resistant to surfactants and show low desorption due to irreversible 
binding between antibody and surface, which is essential for heterogeneous 
IAs.
158,160,161
 The irreversibility is related to the conformational changes that part of the 
antibody suffer when adsorbed to a hydrophobic surface. These conformational changes 
are reduced in hydrophilic surfaces, therefore antibodies are easier to remove from those 
surfaces. Other studies mentioned antibody denaturation of the Fab region with loss of 
antibody binding capacity to Teflon surfaces.
80,162
  
In order to understand the effect of density immobilised antibodies in antibody-antigen 
binding in the MCF platform, a mouse anti-IgG conjugated with peroxidase was used to 
detect the mouse IgG immobilised at different antibody densities on FEP-Teflon MCF 
capillaries (Figure 2:3). This system intended to mimic antibody-antigen binding. Note 
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that information about antibody orientation cannot be obtained from these results, as 
mouse anti-IgG is able to bind to the whole IgG mouse molecule.  
 
Figure 2:3 - Effect of antibody density on detection zone in antigen-antibody binding 
on FEP-Teflon capillaries. 
 
Three different concentrations of anti-mouse IgG were used and results summarised in 
Figure 2:3. At higher anti-mouse IgG concentrations the signal saturated at around 200 
ng/cm
2
 of adsorbed antibody, while for lower anti-mouse IgG concentration the signal 
increased proportionally to the antibody density. This shows higher antigen 
concentrations are more easily detected in the MCF with a flatbed scanner and a 
chromogenic substrate. A more sensitive detection is achieved by incrementing the 
density of immobilised antibody; however it is important to note that the affinity 
constant between mouse IgG and mouse anti-IgG is very low, therefore higher 
sensitivity requires a higher density of immobilised antibody, once the high avidity must 
compensate the individual low affinity of antibodies. Steric hindrance between 
antibodies is not a problem in this system since anti-mouse IgG can bind to all 
immunoglobulin parts. Although the FEP-Teflon MCF strips were washed with 0.05% 
PBS-Tween before adding the mouse Anti-IgG, based on several repetitions no 
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detectable loss of antibody was detected with the washing. FEP-Teflon microcapillaries 
present a highly hydrophobic surface (123º contact angle), which favours the 
irreversible nature of antibodies on the surface. 
163,164
 
2.4.2. Kinetics of adsorption antibody (IgG) onto FEP-Teflon MCF  
The kinetics of IgG adsorption has not been previously studied, and it influences the 
time required for the coating of FEP-Teflon capillary surfaces. Adsorption time is also 
important for establishing a strong bond with the substrate or influencing the binding 
capacity of the adsorbed antibody.  
The experimental data for antibody adsorption kinetics were fitted to equation(2:5). 
This is the solution of a differential equation given by the difference between the 
adsorption process, the reactant, free binding sites and the desorption process. The 
experimental results and estimated parameters are presented in Figure 2:4 and Table 
2:2, respectively. 
 
 
𝜏 =  
𝐾𝑜𝑛 𝑐
𝑘𝑜𝑛 𝑐 + 𝐾𝑜𝑓𝑓
[1 − exp[−(𝐾𝑜𝑛𝑐 + 𝐾𝑜𝑓𝑓)𝑡]] 
 (2:5) 
  
Where 𝜏 is the surface coverage at time 𝑡, 𝑐 is the antibody bulk concentration, 𝑘𝑜𝑛 is 
the adsorption rate and 𝐾𝑜𝑓𝑓 is the desorption rate.  
Figure 2:4A shows IgG adsorption to FEP-Teflon is surprisingly fast, with Kon in order 
of 10
5
 M
-1
.min
-1 
(Table 2:2). Equilibrium is reached after 5 to 10 minutes incubation and 
independently of the concentration of IgG loading into the microcapillaries. The 
percentage of surface coverage (Φ) is related to a theoretical monolayer with all 
antibodies in the “end on” position, considering the size of the IgG molecule is 14 x 8.5 
x 4 nm with 8.5 nm being the longitudinal axis.
165
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Figure 2:4 - Antibody adsorption kinetics onto FEP-Teflon microcapillaries. 
A Antibody adsorption kinetics with mouse IgG concentrations of 20, 40 and 200 
µg/ml, determined by solution depletion technique. The continuous line represents the 
values obtained by the model described in equation (2:5). B Antibody adsorption 
kinetics with 40 µg/ml of mouse IgG, determined by ELISA, using 0.6 µg/ml of Anti-
IgG peroxidase conjugated as detection antibody. C Kinetics of IgG adsorbed obtained 
by BCA assay (orange bars) and by ELISA (blue bars). The continuous line represents 
the values obtained by the model described in equation (2:5). D IL-1β full response 
curves using 40 µg/ml of capture antibody incubated for 30 and 2 hours (120 minutes). 
The continuous line represents the values obtained by the 4 parameter logistic model, 
commonly used for full response in IAs.  
 
A second method used for determination of the kinetics of antibody adsorption onto 
FEP-Teflon consisted of using anti-IgG conjugated with peroxidase to detect the mouse 
IgG molecules on the surface of the microcapillaries (Figure 2:4B). The MCF strips 
were washed with 1 ml of PBS-Tween before adding the conjugated anti-IgG 
peroxidase. The results are comparable with the ones obtained by the solution depletion 
technique in Figure 2:4A. 
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Table 2:2 - FEP-Teflon IgG adsorption kinetic parameters variation. 
 Kon (M
-1
.min
-1
) Koff (min
-1
) R
2
 
20 µg/ml IgG 9.01x10
5
 1.0666 0.9453 
40 µg/ml IgG 3.09x10
5 0.2968 0.9811 
200 µg/ml IgG 8.45x105 0.9083 0.6444 
 
Both methods showed that maximum antibody adsorption happens within 10 minutes of 
incubation (Figure 2:4C). These findings are applicable to sandwich assays, since IL-1β 
full response curves are similar, with a coating procedure of 30 minutes or two hours’ 
antibody incubation (Figure 2:4D). 
Monoclonal antibodies, commonly used in sensitive IAs, present higher affinity 
compared to polyclonal antibodies used in Figure 2:4B. In order to demonstrate the 
impact of monoclonal antibody adsorption onto FEP-Teflon microcapilaries, a sandwich 
assay was performed using a monoclonal pair of antibodies for IL-1β cytokine (Figure 
2:5).  
 
Figure 2:5 - IL-1β sandwich ELISA in FEP-Teflon capillaries.  
Relation between IL-1β capture antibody (CapAb) concentration and Abs signal (IL-1β 
concentration used was 0.5 ng/ml).  
 
IL-1β sandwich assay signal increased up to 100 µg/ml of CapAb and decreased at 
higher concentrations (Figure 2:5) which could not be seen with the mouse IgG-anti-
IgG system. This difference is related to the fact that IL-1β CapAb is a monoclonal 
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antibody that binds a single epitope in the antigen molecule, therefore a very dense layer 
of immobilised antibody can prevent the binding by steric hindrance. According to Xu 
et al. (2006) the binding capacity of an immobilised antibody is greater below 50% of 
full monolayer coverage, and above this the antigen binding sites of the immobilised 
antibody can become inaccessible to the antigen. In addition, higher bulk concentrations 
decrease the degree of irreversibility of antibodies bond to the surface, with the 
irreversibly adsorbed amount being a maximum 250 ng/cm
2
 on a hydrophilic silicon 
oxide surface.
161
  
Meridith et al. (2012) used a quartz crystal microbalance with dissipation monitoring to 
detect a shift in dissipation value of the crystal almost to zero for antibody mass 
adsorbed below 200 ng/cm
2
, meaning that this initial mass is very attached to the 
surface,
 which suggests antibody “flat-on” orientation. Neutron reflexion studies 
revealed a layer thickness of 4 nm, which is close to the short axial length of an 
antibody for a mass adsorbed of 220 ng/cm
2, also suggesting a “flat-on” orientation.161  
Above 200 ng/cm
2
 these authors showed that the dissipation slope increases, meaning 
new antibodies are adsorbed onto the surface in a less rigid mechanical coupling, 
suggesting “end-on” orientation of molecules. Surprisingly, in this study no decrease in 
antibody binding capacity is found with increasing surface density, suggesting a 
monolayer is achieved at approximately 468 ng/cm
2
, and increases in bulk IgG 
concentration lead to higher dissipation values, suggesting a multilayer formation. 
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The 40 to 100 µg/ml concentrations of antibody in Figure 2:5A correspond to 220 
ng/cm
2
 and 275 ng/cm
2
 respectively, which is slightly above half a full monolayer. The 
conjugation of these studies with these new results from IgG adsorption onto FEP-
Teflon in Figure 2:1B and Figure 2:5A and the performance of sandwich assays in the 
MCF platform suggests the optimum value for sandwich IAs in FEP-Teflon surface 
coverage is a half monolayer (200 to 275 ng/cm
2
). At around this value antibodies start 
adopting vertical orientations and further from this value the packing density starts to 
compromise access to the antigen epitope in the antibody Fab region.  
A further set of experiments aimed to directly compare IgG adsorption onto FEP-Teflon 
microcapillaries with an MCF product from LLDPE and individual glass capillaries.  
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Figure 2:6 - Langmuir and kinetics of IgG adsorption to different capillary surfaces. 
A Microcapillary surfaces used in this study. B IgG adsorption langmuir onto LDPE (19 
bore, ~200 µm i.d.), FEP-Teflon (10 bore, ~200 µm i.d.) and glass (single bore, 580 µm 
i.d.). C IgG adsorption kinetics onto LDPE, FEP-Teflon and glass (40 µg/ml of IgG). 
The % of surface coverage adsorbed was normalised by the theoretical surface area 
available in the different capillary surfaces.  
 
The Langmuir isotherms in FEP-Teflon, LLDPE and glass capillaries showed 
significant differences in respect to the mass of antibody adsorbed when the amount 
adsorbed is normalised by the total surface area of the capillaries (Figure 2:6B and 
Table 2:3). This might be due to different levels in surface hydrophobicity, as FEP-
Teflon presents a higher contact angle (123º) when compared with LLPED (102º) and 
glass (15º).  
Table 2:3 - IgG Adsorption parameters to different capillary surfaces.  
 FEP-Teflon LDPE Glass 
K (ml/µg) 0.014 0.025 0.003 
Ϯmax (%Φ/Total surface area) 8.80 4.15 158.66 
R
2
 0.9963 0.9921 0.9925 
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Some studies reported a higher mass of protein adsorbed onto hydrophilic surfaces, such 
as bare glass, compared to hydrophobic surfaces such as plastic.
163,166
This is in 
agreement with the results in Figure 2:6B. Although glass is capable of adsorbing a 
higher mass of antibodies, these studies
163,166
 also mention the possibility of multilayer 
formation and easy desorption from the glass surfaces. The adsorption isotherm model 
adjusted for glass adsorption presented a more linear shape than those presented for the 
plastic polymers, which suggests continuous antibody adsorption in a multilayer.  
Some hydrophobic surfaces are known to adsorb a lower amount of antibody,
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promoting the formation of a monolayer, with the immobilised antibody strongly 
attached to the surface,
164
 which is essential for performance in heterogeneous IAs. 
There was a major difference in the amount of antibody adsorbed to FEP-Teflon, being 
double the amount adsorbed onto LLDPE. This confirms that the higher hydrophobicity 
of FEP-Teflon favours antibody adsorption. This uniquely combines with the excellent 
optical properties of FEP-Teflon MCF previously reported.
127
 
Adsorption kinetics on FEP-Teflon were also found to be faster than that in LLDPE 
microcapillaries, with equilibirum reached within 10 minutes for FEP-Teflon and glass 
surfaces and 30 minutes for LLDPE (Figure 2:6 and Table 2:4).  
Table 2:4 - IgG Adsorption kinetic parameters to different capillary surfaces (IgG 
concentration = 40 µg/ml). 
 Kon (M
-1
.min-1) Koff (Min
-1
) R
2
 
FEP-Teflon 3.09x10
5
 0.2968 0.9811 
LDPE 1.14x10
5 0.1003 0.9610 
Glass 2.38x10
5 1.1672 0.1083 
2.5. Conclusion 
This study showed that antibody adsorption onto FEP-Teflon microcapillaries results in 
a monolayer with maximum coverage of approximately 400 ng/cm
2
. This can be related 
to a theoretical monolayer with antibodies in a vertical orientation. This surface 
coverage was obtained within 10 minutes as a result of the small diffusion distance in 
the microcapillaries. A full sandwich assay with IL-1β human cytokine showed that the 
signal drops off above ~50% of surface coverage. FEP-Teflon microcapillaries are 
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capable of adsorbing 50% more antibody than LLPED microcapillaries. Glass 
capillaries are capable of adsorbing 90% more than FEP-Teflon and LLPED 
microcapillaries, which suggests that multilayer formation is not desirable for IAs  
This adsorption behaviour of antibodies onto FEP-Teflon along with its excellent 
transparency allows for the performance of sensitive IAs with femtomolar detection of 
analytes (e.g. cytokines) using a simple flatbed scanner as a readout system.  
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3. Impact of HRP enzymatic optimization in sandwich 
ELISA microfluidic systems  
3.1. Abstract 
We developed a simple yet effective method for rapid and very sensitive ELISA 
detection in microfluidic devices using a low-performance optoelectronic detector based 
on maximized HRP enzymatic amplification and a conventional chromogenic substrate 
OPD. Experiments with PSA and IL-1 in a fluoropolymer microcapillary film revealed 
over one order of magnitude increase in sensitivity and 10-fold decrease in incubation 
time required for the enzymatic substrate by increasing the molar ratio of OPD/H2O2 
from 1:3 to 1:1 and OPD concentration from 1 to 4 mg/ml. This is expected to lead to 
the development of affordable microfluidic point of care (POC) tests that are optically 
interrogated using low-cost optoelectronic components by exploring the unique 
amplification capabilities of enzymes and microfluidics devices.  
3.2. Introduction 
Assay miniaturisation is one of the main trends in clinical diagnostics, and several 
studies have succeed in applying microfluidic devices in a range of shapes and detection 
methods 
148,149,167,168
 for rapid and sensitive detection of different analytes for different 
clinical situations. This includes infectious diseases,
169,170 
biomarkers
171
 and food 
allergens
172
 to name a few, and typically requires the ability of detecting molecules in 
the nanomolar to picolomar concentration range. This is achieved with the use of 
expensive detection equipment that is often incompatible with the user requirements for 
POC tests. An alternative approach that surprisingly remains underexplored is to further 
potential the natural “amplification” capability of well-established enzymes173 to yield 
rapid and sensitive detection, using inexpensive and widespread chromogenic 
colorimetric substrates and low-cost optoelectronic components,
174
 such as flatbed 
scanners,
175
 smartphones
176,153
 and other cost effective readout systems.
177
 
It appears established within the scientific community that high-sensitivity detection can 
only be achieved with direct fluorescence labelling of molecules, since fluorophores 
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provide high amplification power required for detecting very low concentrations of 
molecules in biological sample. However fluorescence has main drawbacks in respect to 
microfluidic POC testing, such as scattering noise, crosstalks, misalignment, 
autofluorescence of substrate, and low collection efficiency.
178
 
Our research group is pioneering the application of a low-cost microfluidic material to 
immunoassays (IAs), based on a fluoropolymer Microcapillary Film (MCF).
127
 The 
hydrophobic surface of Teflon-FEP is ideal for immobilising IA reagents in the inner 
surface of the microcapillaries, whereas the refractive index of material similar to that of 
water allows unique signal-to-noise ratios which favours optical simple detection. We 
have recently reported a 13 min colourimetric prostate cancer antigen (PSA) sandwich 
assay from whole blood with limit of detection below 1 ng/ml using both a flatbed 
scanner and a smartphone.
152,
 
153
 Sensitivity was further improved to <0.08 ng/ml with 
the use of a fluorescence enzymatic substrate which to our knowledge was unique in the 
field of microfluidics research. We believe enzymatic amplification combined with 
unique characteristics of microfluidic devices is the key to high-sensitivity POC test 
with low-cost, modest-performance optoelectronic components.
8
 
In this study we present a new method for optimised Horseradish peroxidase (HRP) 
conversion of a very popular chromogenic substrate, o-phenylenediamine 
dihydrochloride (OPD), adapted to microscale enzymatic conversion and enzyme-linked 
immunosorbant assay (ELISA) detection. HRP is one of the most popular enzymes in 
ELISA technique for presenting a very high turnover number. We noticed the 
composition of commercial OPD/H2O2 substrate is adapted to standard laboratory 
systems controlled by diffusion, such as microwell plates,
85,179,180
 where HRP 
performance is sub-optimum. Miniaturisation of ELISA allowed overcoming diffusion 
limitations. Consequently HRP enzyme can be used to produce much higher conversion 
rates of OPD and consequently achieve strong colourimetric signal with reduced 
incubation times. This resulted in a massive improvement in both assay speed and assay 
sensitivity, as supported by our experience with PSA and human IL-1β assay 
development. PSA is the mostly widely used prostate cancer biomarker with a cut off 
value of 4 ng/ml, and its monitorization is a vital tool for disease control.
181,182
 The 
cytokines cut of values are in the order of pg/ml concentrations
183
 and are important 
biomarkers for early detection of sepsis
184,185
 and infectious disease.
186,187
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3.3. Materials and Methods 
3.3.1. Materials 
2,3-diaminophenazine (DAP) and SIGMAFAST™ OPD (o-phenylenediamine) tablets 
were supplied from Sigma Aldrich Ltd (Dorset, UK). 
A Human kallikrein 3/ Prostate Specific Antigen (PSA) ELISA kit was purchased from 
R&D Systems (Minneapolis, USA; cat nº DY1344). The kit contained a monoclonal 
mouse Human Kallikrein 3/PSA antibody (capture antibody or CapAb), a Human 
Kallikrein 3/PSA polyclonal biotynilated antibody (detection antibody or DetAb) and 
recombinant Human Kallikrein 3/PSA (standard).  
Human cytokines reagents were purchased from eBiosciences (Hatfield, UK): IL-1β 
(cat no: human recombinant protein #14-8018; Anti-Human IL-1β biotin #13-
7016;Anti-Human IL-1β purified #14-7018); IL-12p70 (cat no: human recombinant 
protein #14-8129; Anti-Human IL-12p70 biotin #13-7129; Anti-Human IL-12p70 
purified #14-7128); IL-6 (cat no: human recombinant protein #14-8069; Anti-Human 
IL-6 biotin #13-7068; Anti-Human IL-6 purified #14-7069); and Tumor Necrosis 
Factor-α (TNFα) (cat no: human recombinant protein #14-8329; Anti-Human TNFα 
biotin #13-7349; AntiHuman TNFα purified #14-7348). 
ExtrAvidin-Peroxidase (cat. no E2886) was sourced from Sigma Aldrich Ltd (Dorset, 
UK) and High Sensitivity Streptavidin-HRP was supplied by Thermo Scientific 
(Lutterworth, UK; cat no 21130) and used for enzyme detection for IL-1β assay.  
Phosphate buffered solution (PBS, Sigma Aldrich, Dorset, UK; cat. no P5368-10PAK), 
pH 7.4, 10mM was used as IA buffer. The diluent and blocking solution consisted either 
of SuperBlock (Thermo Fisher Scientific, Loughborough, UK; cat. no 37515) or 1 to 
3% w/v protease-free albumin from bovine serum (BSA, Sigma Aldrich, Dorset, UK; 
cat no A3858) diluted in PBS buffer. For washings, PBS with 0.05% v/v of Tween-20 
(Sigma-Aldrich, Dorset, UK; cat no P9416-50ML) was used. 
 Nunc maxisorp ELISA 96-well MTPs were sourced from Sigma Aldrich (Dorset, UK). 
The Microcapillary Film (MCF) was supplied by Lamina Dielectrics Ltd (Billingshurts, 
West Sussex, UK). 
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3.3.2. Methodology 
The miniaturised platform consisted of a 10 bore, 200 µm internal diameter 
fluoropolymer microcapillary film (MCF)
127
 produced by continuous melt-extrusion 
process, which due to its geometrical shape and transparent properties can be easily 
integrated with low cost and easy access readout system, such as a flatbed scanner. 
Comparison of MCF and MTP lower detection limit 
Different concentrations of DAP were detected in the MCF using a flatbed scanner (HP 
ScanJet G4050) and in the 96 well plate using a Microplate Reader (Epoch, Biotek). A 
stock solution of 1 mg/ml of DAP (Sigma-Aldrich, Dorset, UK; cat. no. E2886) was 
prepared in dimethyl sulfoxide (DMSO) (Sigma-Aldrich, Dorset, UK; cat. no.D8418) 
and a 1:2 dilution series in PBS was made to complete the calibration curves. 
Absorbance values were calculated by determining the grey scale peak height for each 
individual microcapillary in the MCF using ImageJ software (NIH, Maryland, USA), or 
using the embedded Gen5 data analysis software for microtiter plate (Epoch, Biotek). 
 Optimisation of Substrate concentration 
In order to find the best combination of OPD/H2O2  concentration, stock solutions of 4 
mg/ml of both OPD and H2O2 concentrations were prepared in deionized water and a 
1:2 dilution series prepared. The solutions were placed in a Nunc MaxiSorp ELISA 96-
well microwell plate using a matrix arrangement (OPD and H2O2 concentrations varied 
along the rows and columns, respectively). EA-HRP was used in solution in a 
concentration of 0.0156 µg/ml.  
Determination of kinetics of enzymatic OPD substrate conversion  
The initial enzymatic rates of HRP conversion of OPD to DAP were determined by 
testing different concentrations of OPD and HRP using both immobilised and 
solubilized enzyme. A start solution with 1 µg/ml of EA-HRP was immobilised by 
overnight incubation in the first well of the first column of the microtiter plate, followed 
by 1:2 dilution solutions in each column. Then, 1:2 dilutions of 1 mg/ml of each 
substrate (OPD and H2O2) were prepared and placed along the rows in the microtiter 
plate, reading immediately the absorbance values with a microtiter plate reader. To 
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understand the role of diffusion, the procedure was repeated with the enzyme in 
solution, by spiking each well with the same quantity of EA-HRP. 
Aquisition of full response curves for Sandwich ELISA in MCF  
Full response curves for PSA and IL-1β were performed in the MCF using different 
concentrations and molar ratios of OPD/H2O2. To obtain the calibration curves, two 30 
cm length MCF strips (strips #1 and #2) were coated with 10 μg/ml of human kallikrein 
3/PSA capture antibody (CapAb) diluted in phosphate-buffered saline  or 20 µg/ml of 
Anti-Human IL-1β purified  (strips #3 and #4). The MCF strips were incubated for 2 
hours at room temperature (20°C) to allow the CapAb to adsorb on the microcapillary 
surface, and subsequently blocked with 1% BSA (strips #1, #2 and #3) or superblock 
blocking buffer (strip #4), for 2 hours at room temperature. The strips were washed 
using PBS with 0.05% (v/v) of Tween-20. Each MCF coated strip was trimmed into 30 
mm long test strips, and each strip incubated with a serial dilution 0-60 ng/ml of PSA 
(recombinant human kallikrein 3/PSA) for 20 min (strip #1 and #2) or a serial dilution 
0-1 ng/ml of IL-1β for 30 min (strip #3) and 0-5 ng/ml in strip #4. Then, 2 µg/ml of 
human kallikrein 3/PSA polyclonal biotinylated antibody or 10 µg/ml of Anti-Human 
IL-1β biotinylated were used as detection antibodies and incubated for 15 min and 10 
min, respectively. EA-HRP in a concentration of 4 µg/ml was incubated for further 15 
min in coated MCF strips #1 and #2 and for 10 min in strip #3. The enzyme used in 
strip #4 (IL-1β assay) was High Sensitivity Streptavidin–HRP with 4 µg/ml, incubated 
for 10 min. Three washing steps were performed afterwards. Subsequently, 1 mg/ml of 
OPD and 1 mg/ml H2O2 (equivalent to molar ratio 1:3) solution was added to strip #1 
(PSA assay) and #3 (IL-1β assay) and 4 mg/ml of OPD and 1 mg/ml H2O2 (molar ratio 
1:1) were added to strips #2 (PSA assay) and #4 (IL-1β assay). The MCF strips were 
scanned as RGB images with a HP ScanJet G4050 (Hewlett-Packard, CA, USA) flatbed 
scanner at 2,400 dpi resolution in transmittance mode in intervals of 2–3 min over 30 
min of incubation.  
Analysis of MCF strips digital images  
RGB digital images were split into 3 separated channels in Image J. The blue channel 
images were used to calculate absorbance values, based on the grey scale peak height of 
each individual capillary of FEP-Teflon MCF as described elsewhere.
127
 Absorbance 
(Abs) was calculated for each individual capillary based on equation (3:1): 
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 Abs =  −log10(
I
I0
) (3:1) 
Where I is the grey scale peak height (transmitted light intensity) and I0 is the 
maximum grey scale value. The absorbance values were averaged across 10 capillaries 
for MCF strip. 
3.4. Results and discussion 
A key aspect that remains clearly underexplored in miniaturization of ELISA tests is the 
incubation of enzymatic substrates, which perhaps is the most crucial, yet powerful, step 
in a colorimetric or fluorescence ELISA. OPD (MW=108.1 g/mol) is widely used as a 
HRP chromogenic substrate by the biggest worldwide manufacturers and suppliers of 
bioanalytical reagents to life sciences laboratories, and typically recommend 0.4 mg/ml 
of OPD and 0.4 mg/ml of H2O2 (MW=34.0 g/mol) or 0.5-1 mg/ml of OPD and 0.3 
mg/ml of H2O2. Nevertheless, datasheets are usually not detailed enough regarding the 
OPD/H2O2 molar ratio, which is of paramount importance for ELISA detection in 
miniaturized tests that are optically interrogated with less sophisticated readout systems. 
We believe enzymatic conversion using off-the-shelf chromogenic substrates is a 
solution for the well desirable portability, sensitivity and low-cost of POC tests for 
detection of molecules in the nanomolar to femtomolar range, which represents the core 
of clinical diagnostics market. 
In order to optimize OPD enzymatic conversion in our novel IA microfluidic 
platform,
152
 which uses a flatbed scanner as a readout system, we studied the 
stoichiometry of HRP conversion of OPD to 2,3-diaminophenazine (DAP) (Figure 
3:1A), realising that two molecules of OPD and one of hydrogen peroxidase (H2O2) are 
necessary for the enzyme to be able to convert OPD (colorless) into DAP (brownish 
color), which yields a theoretical optimal molar ratio of 2:1.  
In more detail, HRP catalyzes the transfer of two electrons from a substrate to hydrogen 
peroxide to produce an oxidized substrate and water. OPD (MW=108.1 g/mol) is one of 
the most popular and sensitive chromogenic substrate for HRP detection. Two 
molecules of this substrate react with one molecule of hydrogen peroxide (H2O2; 
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MW=34.0 g/mol) peroxide and form one molecule of DAP (the oxidized colored 
product) (MW=210.2 g/mol) and water, as shown in  
Figure 3:1A. OPD suppliers usually recommend the concentration of 0.4 mg/ml to be 
used in ELISA and the same concentration of hydrogen peroxide, i.e. a 1:3 molar ratio. 
OPD is ideal for use with low-cost, portable optoelectronic components as the product 
of DAP presents a peak of absorbance at 450 nm, which is ideally aligned with blue 
colour/channel in the illumination source. 
The concentrations of 0.4 mg/ml for both OPD and H2O2 as recommended by the 
suppliers yield a 1:3 OPD/H2O2 molar ratio in sandwich ELISA assays which, 
according to Nicell et. al has an inhibitory effect in HRP catalytic activity by H2O2.
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We compared initially the chromogenic sensitivity and dynamic range of a flatbed 
scanner in respect to DAP detection against a conventional bench-top microplate reader 
(Figure 3:1B). The microplate based detection of DAP was about 256 times more 
sensitive (0.244 pg/ml) than in a 10-bore MCF produced from Teflon-FEP with a 
flatbed scanner (65.2 pg/ml). This links to the much shorter light path distance of 200 
µm microcapillaries compared to 3mm light path distance is a microwell. We noticed, 
however, the DAP scanning in the MCF presented a much broader dynamic range, 
equivalent to 5% to 100% of OPD conversion, whereas the dynamic range for 
microwell is limited to the range of 0.02%-15% conversion. Despite DAP being more 
sensitive in a microwell plate, it lacks quantitation capability for high rates of OPD 
conversion, whereas in the small microcapillaries the Lambert-Beer law is valid on a 
very broad range of equivalent OPD substrate concentrations. We hypothesized 
therefore that substrate concentration should be dramatically increased in order to 
achieve much faster and more sensitive IAs, should HRP be capable of handling such 
high concentrations of OPD and/or H2O2. Consequently, we tested the effect of both 
OPD and H2O2 concentration in the presence of a constant solubilised ExtraAvidin-HRP 
(EA-HRP) concentration and noticed HRP conversion of OPD in the commercial 
formulations is characterized by an inhibition by H2O2 (Figure 3:1C and D). 
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Figure 3:1- Aspects of colorimetric detection in MCF and peroxidase inhibition.  
A HRP conversion of OPD chromogenic substrate. B Response curves for detection of 
DAP (coloured product) in a miniaturised Microcapillary Film (MCF) with a flatbed 
scanner and in a 96 microwell plate (MTP) using a microplate reader. C Initial 
enzymatic conversion rates for different molar ratios of OPD and H2O2. D Initial 
conversion rates of OPD as function of H2O2 and OPD concentration. The concentration 
of EA-HRP was kept constant at 15.6 ng/ml. 
 
The initial rates of OPD conversion, -rs increased with increasing concentration of H2O2 
(inhibitor, [I]) up to a value of 0.5-1.0 mg/ml (Figure 3:1C), beyond which the initial 
rate velocities start decreasing. This enzymatic behavior is coherent with inhibition by 
substrate, in this case H2O2, mathematically described by equation (3:2):
189
  
 
−𝑟𝑠 = −𝑟𝑚𝑎𝑥
[𝐼]
𝐾𝑠 + [𝐼] +
[𝐼]2
𝐾𝑖
 
(3:2) 
 
This experiment also allowed determining the ideal concentration of both OPD and 
H2O2, which were 4 mg/ml and 1 mg/ml, respectively, i.e. equivalent to a molar ratio of 
1:1 OPD/ H2O2. Fitting the substrate enzymatic inhibition model in equation (3:2) a 
value of 0.07 mg/ml and 0.91 mg/ml were obtained for inhibition constant, Ki with 1.0 
mg/ml and 4.0 mg/ml of OPD respectively,  indicating a higher degree of enzyme 
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inhibition with the use of lower OPD concentration. With a molar ratio of 1:3 
OPD/H2O2 used in commercial OPD substrates, the value of –rs obtained was 0.11 
mg/ml.s whereas with 1:1 molar ratio a maximum –rs value of 0.191 mg/ml.s was 
obtained which represents a 1.7 fold increase. 
In Figure 3:1D the impact of OPD/H2O2 molar ratio is further elucidated. In this 
experimental set the concentrations were changed for both OPD and H2O2 in order to 
keep initial OPD/H2O2 molar ratio constant. This revealed OPD substrate is not 
responsible for the inhibition, with the values of –rs increasing as a first order kinetic 
model for low concentration of OPD and clearly trending to a zero order for higher 
concentrations of substrate, which is typical of a non-competitive or mixed inhibition 
kinetic model, mathematically described in equation (3:3):
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 −𝑟𝑠 = −𝑟𝑆,𝑚𝑎𝑥
[𝑆]
𝛼𝐾𝑚+𝛼
′[𝑆]
       (3:3) 
Where Ki and Ki’ are the inhibitor constants representing the inhibition effects and are 
described below, in equations (3:4), (3:5), (3:6) and (3:7): 
 
α = 1 +
[I]
Ki
 
(3:4) 
 
α′ = 1 +
[I]
Ki
′ 
 
(3:5) 
 
Ki =
[E][I]
[EI]
 
(3:6) 
 
Ki
′ =
[ES][I]
[ESI]
 
(3:7) 
This model considers the inhibitor can bind the enzyme or the enzyme-substrate 
complex reducing the overall enzyme activity. The kinetic model parameters were 
found by best-fitting the model in to the experimental data using Solver tool in Excel, 
and are summarized in Table 3:1. These revealed a significant difference in the 
maximum rate of substrate conversion, -rs,max shown in Figure 3:1D, representing a 3.2-
fold increase in maximum rate of conversion of OPD.  
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Table 3:1 - Kinetic parameters (non-competitive/mixed inhibition) for the two different 
molar ratios of OPD/H2O2 studied. 
 1:3 OPD/H2O2 1:1 OPD/H2O2 
-rs,max (mg/ml.s) 0.50 1.61 
Km (mg/ml) 8.39 8.39 
Ki (mg/ml) 5.53 1561.00 
K’i (mg/ml) 5.32 0.39 
 
It is clear from Table 3:1 that the inhibition has higher impact on enzyme kinetics at a 
molar ratio of 1:3. As previously discussed, Km remains approximately constant at both 
molar ratios tested, with the value of -rs,max being strongly affected by the molar ratio. 
This reinforces the non-competitive inhibition model typical of HRP.
190
 Based on 
equation (3:6) and (3:7) the smaller the values of both Ki and Ki’, the more efficient is 
the inhibitor binding either the enzyme itself or the enzyme-substrate-inhibitor complex. 
Comparing the two curves in Figure 3:1D, Ki at 1:1 molar ratio was about 280 times 
higher than the value of Ki at 1:3 molar ratio, suggesting the inhibitor, I (in this case 
H2O2) binds directly to the enzyme. For 1:3 molar ratio, the value of Ki obtained was 
very similar to that of K’i, which again is typical of a non-competitive inhibition,
190
 
where the reaction is only inhibited by the formation of enzyme-inhibitor complex 
(Equation (3:5)).  
Overall, it appears that when in excess H2O2 inhibits HRP enzymatic kinetics by 
reducing the enzyme activity, however it does not affect the affinity of HRP to the 
substrate. This inhibition effect is surpassed by changing the molar ratio initially 
recommended by the manufacturers from 1:3 to 1:1. 
Although molar ratio of OPD/H2O2 revealed paramount to the rate of generation of 
colourimetric signal by affecting HRP kinetics, the diffusion and mass transfer 
limitations need to be taken into account in respect to the speed and magnitude of 
colourimetric signal produced, which ultimately controls both speed and sensitivity of 
the IA. In heterogeneous IA, the enzyme is eventually “immobilised” on the plastic 
surface and consequently the kinetics of substrate conversion is modified because of 
mass transfer limitations. Immobilised enzyme reactions present lower initial velocities, 
due to migration time of substrate molecules to the walls and to possible conformational 
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changes during adsorption process.
191
 This is the typical situation in a microtiter plate, 
where the maximum distance of molecular diffusion is in the range of 3 mm, which can 
represent several minutes for a medium size molecule. Further experiments with 
solubilized enzyme in a microwell (Figure 3:2A) confirmed the increase in the rate of 
colorimetric signal generation with the increase of OPD concentration. Nevertheless, 
experiments with immobilised enzyme (Figure 3:2B) revealed not being advantageous 
to use higher rates of conversion of OPD as this leads to the rapid accumulation of 
product near the plastic wall and fluctuations in the rate of conversion of OPD which is 
not beneficial for IA, where typically the end-point or kinetics rate is expected to be 
linked to the concentration of analyte in the sample. The absorbance values obtained 
were lower than those for solubilized enzyme as, in one hand, the enzyme 
immobilisation process might interfere with enzyme catalytic activity
192
 and, on the 
other hand, the total enzyme molecules available are dependent on the quantity of 
molecules bond to the wall. We calculated the turnover number of the enzyme in this 
specific system by analyzing the velocity rates with the changing of enzyme 
concentration and, assuming that ExtrAvidin contains two molecules of peroxidase, the 
turnover number was 1.95x10
6
 s
-1
. 
In miniaturized ELISA platforms such as MCF, diffusion distances are very short and, 
consequently, an increase in conversion rates of substrate is extremely beneficial. With 
a maximum diffusion distance of 100 µm, substrate conversion with HRP will 
approach the situation shown in Figure 3:2A for solubilized enzyme, which ultimately 
translate into stronger colorimetric signal generated with much shorter incubation times. 
This feature will enhanced signal-to-noise ratios and ultimately improved sensitivities, 
assuming the enzyme is working at maximum activity. Note that when using EA-HRP 
in a sandwich ELISA, it is known that extravidin binds to the biotinylated antibody, 
therefore eliminating the problem of catalytic enzymatic activity reduction due to its 
conformational change. 
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Figure 3:2 - Kinetics of HRP conversion of OPD for varying concentration of 
chromogenic substrate. 
A EA-HRP in solution. B EA-HRP immobilised on plastic surface of a 96 microtiter 
plate well. Concentration of H2O2 was kept constant at 1 mg/ml H2O2, and final 
concentration of EA-HRP immobilised or in solution was kept at 15.6 ng/ml. 
 
To illustrate the multiple benefits of the 1:1 molar OPD/H2O2 and higher OPD 
concentration we have performed multiple PSA and IL-1β sandwich assays optimized 
for the MCF. Figure 3:3 shows the effect of OPD incubation on the performance of 
these two assays. The incubation time required for PSA was reduced in 10-fold when 
compared to the conventional 1:3 molar ratio, and both the signal and sensitivity (or 
lower limit of detection defined as absorbance of blank plus three standard deviations) 
were improved from 11.5 to 0.7 ng/ml. In the case of human IL-1β quantitation the 
sensitivity was much further improved from 100 to 6 pg/ml. The reaction also revealed 
much faster as the signal obtained with just 3 minutes of OPD incubation was about 3-
fold stronger than the signal obtained with 30 minutes OPD incubation with 1:3 molar 
ratio.  
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Figure 3:3 - Comparison between two different OPD and H2O2 molar ratio in MCF 
sandwich assays. 
A  4 mg/ml of OPD and 1 mg/ml of H2O2 (1:3 molar ratio) makes the PSA MCF assay 
10 times faster and with 16x higher sensitivity. B IL-1β assay  improved sensitivity 
from 100 pg/ml to 6 pg/ml with 3 fold reduction in assay time. The times shown relate 
only to the time of incubation of OPD before optical interrogation of the microfluidic 
MCF strips.♦  1:1 molar ratio OPD:H2O2 and ● 1:3 molar ratio OPD:H2O2. 
3.5. Conclusions 
HRP conversion of OPD is characterised by H2O2 inhibition of enzyme activity that 
leads to extended incubation times and weak signals difficult to detection with less 
sophisticated optoelectronic components. By increasing the OPD concentration from 1.0 
to 4.0 mg/ml and OPD/H2O2 molar ratio from 1:3 to 1:1 the value rate of enzymatic 
conversion was increased by 4-fold, which is very beneficial for microfluidic devices 
that contain short diffusion distances. It also avoids the rapid depletion of substrate that 
characterises commercial OPD formulations. A number of sandwich assays with PSA 
and IL-1β detection in fluoropolymer microfluidic MCF strips and a flatbed scanner 
have shown systematically one or more orders of magnitude increase in sensitivity 
and/or speed of the assay. This allows mimicking the performance and reliability of 
sophisticated laboratory detection equipment using low-cost optoelectronic equipment, 
which is expected to trigger the development of affordable POC tests that fully exploit 
the low-cost and unique amplification capabilities of enzymatic ELISA detection.  
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4. The flow effect on assays speed and sensitivity in 
microcapillary immunoassays 
4.1. Abstract  
We present experimental results of effect of flow on antibody-antigen binding in a novel 
microfluidic IA (immunoassay) platform, based on fluoropolymer, the Microcapillary 
Film (MCF). Experimental results were fitted to a kinetic model and the 
association/dissociation rate constants and equilibrium constants estimated, confirming 
the impact of flow in the assays speed and sensitivity. The range of flow rate studied for 
antigen was 10 to 1000 µl/min. From the data presented in this study we conclude that 
assay sensitivity is affected by sample flow rates ≥10 µl/min, since increasing shear 
stress challenges antibody-antigen binding in the microcapillary system, decreasing the 
amount of antigen bond to the immobilised antibody. For high antigen concentration 
systems, flow rates of 10 µl/min will only affect assay speed, without compromising the 
sensitivity.  
Understanding the flow effect is a fundamental step for automation of Microcapillary 
Film (MCF) assays, bringing the technology one step closer to Point-of-Care 
diagnostics.  
 
Keywords: Flow rate, point-of-care, microfluidic, capillary geometry, antibody binding, 
ELISA, automation.   
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4.2. Introduction 
Point-of-care (POC) tests require automation of reagent loading and often the 
replacement of solutions. To design the device and engineer the operating mode it is 
important to understand how fluid flow affects a diagnostic test, commonly performed 
with IAs, using the specificity of antibody-antigen bonding. Therefore, understanding 
the effect of flow on antibody-antigen binding, which will be translated in IA 
performance, such as sensitivity and speed, is fundamental for the development and 
automation of quantitative POC tests. 
Flow rate is fundamental for IA technologies, including lateral flow (LF) and 
microfluidic IAs (IA).
193
 In LF technology, a set of different pads, the detection pad 
with immobilised antibody, the sample pad for sample deposition and the conjugate 
release pad with dried label antibody, are integrated into a test strip to perform a rapid 
sandwich assay. The sample flows along the different pads, due to the hydrophilic 
properties of the porous substrate  the nitrocellulose membrane, mixing the sample with 
the label antibody and transporting the bond and unbound antigen to the test and control 
lines into the waste reservoir.
193
 Currently, competitive and sandwich LF formats are 
able to detect and quantify vitamin-D,
194
 progesterone,
195
 hCG,
196
 prostate specific 
antigen,
197,198
 and hepatitis C virus (HCV).
199
 
Traditionally, LF and IA are performed in one single step. This feature is very useful for 
POC diagnostics, since the test is fast and easy to carry out. However, this feature is 
also one of the main reasons for poor sensitivity of LF technology, because the lack of 
washing steps increases the non-specific binding and does not allow a signal 
amplification step. In addition, LF rely on a wicking effect or with a capillary action, 
defined as the time required for water to travel up and completely fill a 4 cm length strip 
membrane,
193
 which is essential for assay sensitivity. The porosity and the pore size of 
the membrane also determine the flow rate at which the analyte passes the test line; the 
higher the flow rate, the shorter the time for interaction between the immobilised 
antibody and sample analyte, causing the effective analyte concentration to decrease 
with the square of the increase of flow rate and decreasing the sensitivity of the test.
200
 
Analyte residence time is a problem recognized in LF IA and in some paper based IA, 
since there is no flow control strategy, and several researchers have suggested strategies 
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to overcome this technical bottleneck. Rivas et al. (2012)
201
 introduced wax-printed 
hydrophobic pillars onto the nitrocellulose membrane that delays the flow and increase 
vorticity, achieving a 3-fold improvement in sensitivity. Parolo et al. (2012)
202
, 
increased the sensitivity of gold nanoparticles-based LF by changing the size of the 
pads, in order to find a balance between flow speed and sample volume. They 
understood that by changing both conjugation and sample pads sizes in a certain 
configuration, the speed flow in the conjugation pad would not change significantly, 
giving enough time for label antibodies to recognize the analyte. In addition, a larger 
sample pad, meant a larger sample volume and a bigger conjugated pad, meant a larger 
volume of label antibodies, therefore more analyte could be bond to label analyte, 
resulting in the formation of higher number of immune-complexes, which allowed for 
an 8-fold improvement in LF sensitivity.  
The lack of flow control in one step assays, the small test zone area, and small sample 
volume, are some of the LF technological obstacles for sensitivity improvement.  
Adding multiple steps to LF, such as washing and signal enhancement steps in a 
modified two-dimensional paper network format, can increase sensitivity by 8-fold 
when compared to unmodified LF IA technologies. Nevertheless, flow rate and 
therefore analyte residence time in the capture area is still not controllable.
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Microfluidic IA technologies refer to systems where the fluid is manipulated through 
channels with micrometer dimensions. Generally, the microchannel presents a capture 
zone with immobilised CapAb in a limited zone of the channel.
87
 In microfluidic 
technologies flow is easily controlled manually or by pump systems and can be adjusted 
so that analytes have enough time to bind immobilised antibodies and higher analyte 
amount from the sample volume forms antibody-antigen complex, achieving higher 
sensitivities compared to LF. Therefore, flow control is not usually a problem for 
microfluidic IAs, it can avoid antigen depletion from the bulk solution. Hu et al. (2006) 
reported an antigen-antibody binding model in a 20 µm height microchannel, in which 
increment in flow rate decreased the equilibrium binding time, in other words the 
presence of flow would speed up the assay because it would increase the analyte mass 
transport. Slow velocity should just be considered to decrease total sample 
consumption, since sample consumption is proportional to the product of flow velocity 
and the equilibrium time. The flow rates explored in the study varied from 0 to 0.192 
µl/min.203Another study reported similar conclusions, with flow rate range studied from 
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0 to 0.02 µl/min.204 Besides avoiding solution depletion, microfluidic IA can use flow to 
deliver reagents present in a liquid phase, with the inlet often connected with tubes to 
external pumps and reservoirs. High sensitivity microfluidics is related to the possibility 
of performing multiple steps assays, including washing steps (reducing the non-specific 
signal) and signal amplification, which increases the overall signal-to-noise of the 
assay.
7
  
However, sensitivity of microfluidic IAs is usually dependent on sample incubation 
time, with longer incubation times translating into larger amounts of bond analyte 
compared to bulk analyte. This feature is not desirable for point-of-care applications, 
where speed is one of the required conditions being affordable, sensitive, specific, user-
friendly, rapid, robust, equipment-free, delivered (ASSURED).
6
 Also, most of the 
microfluidic external control is not disposable, which does not suit the ASSURED 
point-of-care demands.
205
 Although all microfluidic IA devices developed use liquid 
flow, the effect of flow in antibody binding in microfluidic systems is not well 
understood. In this chapter we aim to explain the effect of flow rate on antibody 
binding, and consequently the flow effect on assays speed and sensitivity, in novel 
microfluidic tests strips manufactured from a fluoropolymer, the Microcapillary Film 
(MCF). The MCF is a plastic flat film with 10 parallel embedded holes, with a diameter 
of approximately 200 µm,  melt extruded from FEP-Teflon.  
Understanding the antibody-antigen kinetics and equilibrium constants, as well as the 
factors that affect the reaction in the MCF IA platform is an important aspect in the 
development of POC tests, which aims at increasing assay speed and sensitivity. Assay 
speed is related to rapid antibody-antigen binding (high association constants, Kon) and 
assay sensitivity is related to analyte capture capacity of the system (high equilibrium 
constants, Keq).  
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4.3. Materials an Methods 
4.3.1. Materials & Reagents 
Purified Mouse IgG, Anti-Mouse IgG (whole molecule) peroxidase conjugated, 
SIGMAFAST
TM
 OPD (o-Phenylenediamine dihydrochloride) tablets, Phosphate 
buffered solution (PBS), Tween-20 and Bovine Serum Albumin (BSA) were purchased 
from Sigma-Aldrich (Dorset, UK). 
The IA buffer used was 10 mM PBS at pH 7.4. The blocking solution consisted of 3% 
w/v protease-free BSA diluted in PBS buffer and the washing solution was PBS with 
0.05% v/v. 
The MCF used was fabricated from fluorinated ethylene propylene co-polymer using a 
melt-extrusion process by Lamina Dielectrics Ltd. (Billinghurst, West Sussex, UK). 
FEP-Teflon MCF presents 10 parallel microcapillaries with mean 0.2 mm hydraulic 
diameter.  
MCF strips were connected to Vici M6 pumps, supplied from Valco International 
(Parkstrasse 2, CH-6214 Schenkon). Sets of 30 cm length MCF strips were glued to a 5 
mm i.d., ¼’’ o.d. High-Density Polyethylene (HDPE) tubing with slow setting epoxy.  
4.3.2. System overview and kinetic model 
Capture antibodies were immobilised on the overall surface area of the 10 bore 200 µm 
diameter FEP-Teflon MCF shown in Figure 4:1B. The MCF presents a large surface for 
antibody immobilisation (each 4 cm strip presents 0.25 cm
2
 of surface area available per 
capillary) when compared with capture areas of reported microfluidic channels, e.g. 
fused silica capillary micro-reactor with 3.1x10
-2
 cm
2
, spotted antibodies onto an open 
PDMS with  3x10
-2
 cm
2
 and a reaction chamber with 1x10
-3
cm
2
. 
56,147,206
 
The flow within the MCF capillaries is laminar with a parabolic profile for flow profile 
for all the flow rates studied, 10 to 1000 µl/min, with Reynolds numbers of varying 
between 0.1 and 100, respectively.  
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The antibody-antigen kinetics were fitted to a theoretical IA mathematical model that 
aims to describe the role of transport of analyte in a microchannel (convection and 
diffusion), the kinetics of binding between the analyte and the capture antibodies, and 
the surface density of the capture antibody (CapAb) on the assay. Equation (4:1), was 
solved analytically for a constant analyte concentration and used for estimating the rates 
of association (Kon) and dissociation (Koff) of antibody binding in the MCF system.
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𝛷 =
𝑘𝑜𝑛  𝛷𝑚𝑎𝑥  𝐶
𝑘𝑜𝑛  𝐶 + 𝐾𝑜𝑓𝑓
(1 −  𝑒−(𝐾𝑜𝑛  𝐶+𝐾𝑜𝑓𝑓)𝑡 
(4:1) 
 
Where Φ is the surface density at time t, C is the analyte concentration, Kon is the 
association rate, Koff is the dissociation rate, and Φmax is the maximum surface coverage, 
which in our system was given by the highest absorbance obtained.  
4.3.3. Flow effect determination on antibody binding in FEP-Teflon microcapillaries 
For optimization of immobilised antibody in high analyte concentration systems, mouse 
IgG solutions with 0, 0.1, 1 and 10 µg/ml were aspirated into different 4 cm MCF strips 
and incubated for 2 hours at room temperature. The solution inside the strips was 
replaced by 3% BSA blocking solution, which was left to incubate for an additional 2 
hours at room temperature. The strips were then washed again with 1 ml PBS-tween 
solution. A dilution of 1/1000, corresponding to 1 µg/ml of anti-IgG conjugated to 
peroxidase was added to each strip and incubated for 10 minutes. Each strip was washed 
again with 1 ml PBS-Tween and 1 mg/ml of OPD/H2O2 substrate aspirated and left to 
incubate for 10 minutes. The strips were imaged using a flatbed scanner (HP G4050) in 
transmittance mode, with a minimum resolution of 2,400 dpi.  
After determining the optimum concentration of immobilised antibody, four 30 cm 
MCF strips were filled with 10 µg/ml of mouse IgG diluted in PBS solution, and left for 
2 hours at room temperature for adsorption of antibody. The strips were then blocked 
with a solution for 2 hours at room temperature. The MCF strips were washed with 
PBS-Tween and emptied before being connected to the Vici pump, by injecting air with 
a syringe attached to a silicone tube. The MCF capillaries were filled with 1 µg/ml of 
Anti-IgG peroxidase conjugated at 10000 µl/min for 2 seconds, and then, each 30 cm 
MCF strip was continuously infused with anti-IgG at variable flow rate, 10, 100 and 
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1000 µl/min and 4 cm MCF strips were trimmed from the strip at regular time intervals 
of two minutes following the first minute: 1, 2, 4, 6, 8 and 10 minutes, and quickly 
washed with 1 ml of PBS-Tween solution (Figure 4:1C). One of the MCF strips was 
used as a control, where the incubation of anti-IgG was performed in the absence of 
flow, therefore incubation was done in the absence of flow. The MCF strips were then 
filled with 1 mg/ml of OPD substrate and left to incubate for 10 minutes. Digital images 
of the strips were taken by a flatbed scanner and analysed by ImageJ (NIH, Maryland, 
USA) software.  
In order to test the flow effect in low analyte concentration systems a 1:2 serial dilution 
with an initial anti-IgG dilution 1µg/ml was prepared, and aspirated and incubated for 
10 minutes in 4 cm long MCF strips coated 10 µg/ml of mouse IgG and blocked with 
3% BSA for two hours at room temperature, as described previously. After 10 minutes 
incubation of Anti-IgG, the strips were washed and filled with 1 mg/ml of OPD 
substrate for 10 minutes, before being imaged with a flatbed scanner.  
For immobilised antibody concentration optimization in low analyte systems, 8 MCF 
strips were filled with 0, 0.1, 1, 10, 20, 40, 80, 100 µg/ml of mouse IgG and left to 
incubated at room temperature for 2 hours. Blocking and washing procedures were the 
same as previously described. A 0.06 µg/ml solution of anti-IgG was aspirated and 
incubated for 10 minutes in the different MCF strips, followed by a washing with PBS-
Tween and 10 minutes incubation with 1 mg/ml OPD substrate. The strips were then 
imaged with a flatbed scanner. 
In order to test the flow effect on antibody binding, two 30 cm MCF strips were 
incubated with 100 µg/ml of mouse IgG for 2 hours at room temperature. Blocking and 
washing procedures were the same as previously described. A 0.06 µg/ml dilution of 
Anti-IgG was added to the 30 cm MCF strips. In one of the strips used as control, the 
incubation occurred in the absence of flow and in the other strip the incubation was 
with10 µl/min. The MCF strip was trimmed at varying time intervals as described 
above: 1, 2, 4 6, 8 and 10 minutes (Figure 4:1). Each trimmed strip was washed with 1 
ml of PBS-Tween and 1 mg/ml of OPD substrate was added and incubated for 10 
minutes. The strips were then imaged with a flatbed scanner.  
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Figure 4:1 – In flow MCF flow IA. 
A 100 cm long MCF strip. B Diagram of microcapillary IA configuration in laminar 
flow. C Experimental set up used for MCF flow experiments.  
Table 4:1- Anti-IgG volume passed in 4 cm MCF strip/minute. 
4.3.4. Image analysis of MCF strips  
Digital RGB images were split into 3 separated channels images in Image J software. 
The blue channel images were used to calculate absorbance values, based on the peak 
grey scale height for each individual capillary as described elsewhere.
127,152
 Absorbance 
was calculated according to (4:2) 
 Abs =  −Log10 (
I
I0
) (4:2) 
 Total volume of IgG passed through the 4 cm long 
strip per minute of experimental time 
No Flow  13 µl 
10 µl/min 13 µl + 10 µl 
100 µl/min 13 µl + 100 µl 
1000 µl/min 13 µl + 1000 µl 
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I is the transmitted light and corresponds to I0 minus peak height and I0 is the baseline 
grey scale value (emitted light). The absorbance values presented here correspond to 
average of absorbance values from 10 capillaries on each MCF strip.  
4.4. Results and Discussion 
Understanding the effect of flow in microfluidic sandwich IAs is fundamental for 
developing rapid, sensitive and robust miniaturized diagnostic tools. Few diagnostic 
biomarkers have high clinical thresholds, such as hCG, used for pregnancy with a cut-
off value of 0.5 mg/mL
207
 and CRP protein, a cardiac biomarker, which 1 µg/ml 
indicates the low risk of future cardiovascular complications.
208
 The majority of 
biomarkers requires quantitation at very low concentration, such as cytokines in sepsis 
diagnostic, where 17 to 70 pg/ml cytokines (e.g. IL-6, TNFα, IL-10) levels can predict a 
particular disease and thereby help to select the appropriate treatment.
184,209
 Also, 
troponin used in cases of heart failure has for cardiovascular diseases prediction 
demands equivalent to a clinical threshold of ≤ 40 pg/mL.17 Therefore, POC tests have 
to be able to measure analyte concentration in a broad range of concentrations, besides 
integrating all the ASSURED conditions. 
There is limited understanding on the effect of flow on sensitivity. In the present chapter 
the effect of flow on antibody binding was studied for high and low analyte 
concentrations, using mouse, a mouse IgG and anti-IgG-HRP system to mimic 
antibody-antigen interaction. The use of this system is prevalent in direct IAs, since it 
shows diffusion and rate constants similar to many antibody-antigen interaction.
210
  For 
high concentration of analyte (1 µg/ml of Anti-IgG) mouse IgG was immobilised in the 
FEP-Teflon MCF at a density of about 50 ng/cm
2
, which represents around 12.5% of an 
“end-on” antibody monolayer.  
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Figure 4:2 – Flow effect on antibody binding in the FEP-Teflon MCF at high antigen 
concentration regimes (1 µg/ml nti-IgG). 
A MCF optimization of immobilised mouse IgG for 1 µg/ml of Anti-IgG. B Kinetics of 
IgG and Anti-IgG binding at continuous flow rates from 0 to 1000 µl/min, for 1 µg/ml 
analyte concentration, considering the total absolute absorbance signal. C Non-specific 
Anti-IgG binding kinetics (negative control) at different flow rates (from 0 to 1000 
µl/min) for 1 µg/ml of Anti-IgG. D Kinetics of IgG and Anti-IgG binding at different 
flow rates (from 0 to 1000 µl/min), for 1 µg/ml analyte concentration, considering the 
absorbance signal related only to antibody-antigen specific binding (Specific signal = 
Total absorbance – Negative control absorbance). 
The antibody-antigen equilibrium can be described by equation (4:3),  
 CapAb + Ag   CapAb-Ag (4:3) 
where CapAb, is the concentration of immobilised antibody (mouse IgG); Ag is the 
concentration of antigen (Anti-IgG); and CapAb-Ag is the concentration of antibody-
antigen complex.  
It was found that flow slightly delays the time to reach equilibrium (Figure 4:2B), 
presenting a Kon of 6.97 x 10
6
 M
-1
s
-1 
and a Koff 4.42 x10
-2
 s
-1
 in the absence of flow and 
Kon of 1.48 x 10
6
, 1.83 x 10
6
 and 1.8 x 10
6
 M
-1
s
-1
, for anti-IgG incubation with 10, 100 
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and 100 µl/min flow rate, respectively (Table 4:2). These values are comparable to 
those found in literature for the same antibody pair. 
211,212
 
Table 4:2 – Kinetic parameters of antigen antibody binding with flow in antigen excess 
systems. 
  Total Signal Background 
Signal 
Specific Signal 
No flow 
Kon (M
-1s-1) 6.97x106 4.88x106 6.97x106 
Koff (s
-1) 2.77x10-2 0.3263 4.42x10-2 
KA (M
-1) 2.52x108 1.50x107 1.58x108 
R2 0.99315 0.99812 0.99184 
10 
µl/min 
Kon (M
-1s-1) 1.90x106 4.40x106 1.48x106 
Koff (s
-1) 5.38x103 0.15404 8.88x10-3 
KA 3.54x10
8 2.86x107 1.67x108 
R2 0.98559 0.99444 0.98495 
100 
µl/min 
Kon (M
-1s-1) 1.83x106 9.79x106 1.83x106 
Koff (s
-1) 5.61x10-3 0.26635 1.81x10-2 
KA 3.26x10
8 3.67x107 1.01x108 
R2 0.99015 0.98011 0.97774 
1000 
µl/min 
Kon (M
-1s-1) 1.83x106 1.57x107 1.83x106 
Koff (s
-1) 4.59x10-3 0.25749 2.56x10-2 
KA 3.98x10
8 6.09x107 7.13x107 
R2 0.981044 0.99812 0.77352 
 
In the absence of flow the maximum absolute signal, therefore maximum sensitivity, is 
reached in less than 1 minute, while in the presence of flow the equilibrium is reached 
after 4 minutes. There were no differences observed between the different flow rates 
studied, (Figure 4:2B). It is important to mention that the absolute signal results from 
anti-IgG bond specifically to the immobilised antibody, but also to any anti-IgG capable 
of binding directly to the wall of the microcapillaries. In order to obtain only the 
specific signal the experiments were repeated without immobilised mouse IgG, and 
MCF strips only blocked with 3% BSA. Background signal increased with increase of 
incubation time of antigen of and with the increment in flow rate (Figure 4:2C), 
presenting Keq of 1.50 x 10
7
 M
-1
 in the absence of flow and 2.86 x 10
7
, 3.67 x 10
7
 and 
6.09 x 10
7
 M
-1
 for 10, 100 and 1000 µl/min, respectively. The association rate constants 
were also higher in the presence of flow in stagnant conditions (Table 4:2).  
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This increase in the non-specific signal at the MCF assays results in a drop in the signal-
to-noise ratio of the assay, therefore reduced sensitivity of the assays. In brief, for high 
analyte concentration system the presence of flow delays the antibody-antigen binding, 
but also promotes direct binding of label IA reagents to the capillary walls, reducing the 
specific binding for flow rates range at 100 and 1000 µl/min (Figure 4:2 and Table 4:2).  
The increment in assay time and reduction sensitivity, in flow, can be explained by the 
effect of shear in the microcapillary walls, which increases with the flow rate. 
According to Figure 4:1C and Table 4:1, with 10 µl/min flow rate the 3 initial MCF 
strips, corresponding to times 1, 2, and 4 minutes, did not have Anti-IgG solution 
replacement, which means that the initial filling solution was just being dragged along 
the capillary, decreasing the mouse IgG-Anti-IgG complex formation. However, since 
the antigen concentration is high and the antigen solution is being replaced with fresh 
solution, the equilibrium is maintained with the absence of flow and 10 µl/min. Shear 
can affect assay signal and sensitivity in three-fold. Firstly, the increment of shear stress 
close to the capillary wall promotes the decrease of boundary layer thickeness 
decreasing consequently the residence time of analyte in the system; secondly by 
promoting removal of antigen from the antibody-antigen complex; thirdly, by 
incrementing the boundary layer instability, which difficults the bonding between 
antibody and antigen.  
Based on the fact that anti-IgG incubation at 10 µl/min appeared to not change the 
equilibrium constant (Keq) (no flow conditions Keq =1.58E x108 M-1and 10 µl/min 
Keq =1.67 x 108 M-1,Table 4:2), this flow rate was used for analysing the kinetics of 
antibody-antigen binding for mouse IgG and Anti-IgG. The concentration of CapAb 
was optimized for low antigen concentration, 60 ng/ml (Figure 4:3A) and it was found 
that instead of 10 µg/ml, the optimum concentration was 100 µg/ml, which corresponds 
to approximately 70% of “end-on” antibody monolayer, as mentioned in chapter 2. 
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Figure 4:3 - Flow effect on kinetics of antibody binding in the MCF at low antigen 
concentration (60 ng/ml).  
A Optimisation of immobilised concentration of mouse IgG B Kinetics of IgG and Anti-
IgG binding in the absence and in the presence of flow (Q=10 µl/min), considering the 
total absolute absorbance signal,. C Non-specific Anti-IgG binding kinetics 
(background development) in the absence and presence of flow (10 µl/min) for 0.06 
µg/ml of Anti-IgG. D Kinetics of IgG and Anti-IgG binding in the absence and presence 
of flow (10 µl/min), considering Specific signal = Total absorbance – Background 
signal. 
 
With a small antigen concentration of 60 ng/ml of anti-IgG, the association rate constant 
(kon) dropped from 6.11 x 106 M-1s-1 in the absence of flow to 1.67 x 106 M-1s-1 at 
10 µl/min and the equilibrium constant (Keq ) dropped from 5.64 x 108 M-1 to 2.0 x 
108 M-1 respectively (Figure 4:3B). These best fitted constants are summarised in 
Table 4:3. 
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Table 4:3 – Kinetic parameters of antigen antibody binding with flow in antigen limited 
systems. 
  Total Signal Specific Signal 
No 
flow 
Kon (M
-1s-1) 6.62x106 6.11x106 
Koff (s
-1) 8.88x10-3 1.08x10-2 
KA (M
-1) 7.46x108 5.64x108 
R2 0.8812 0.8879 
10 
µl/min 
Kon (M
-1s-1) 2.19x106 1.67x106 
Koff (s
-1) 8.40x10-3 8.35x10-3 
KA (M
-1) 2.60x108 2.00x108 
R2 0.79490 0.81943 
 
This shows that in high sensitivity systems, for flow rates as small as 10 µl/min assay 
time is increased, increasing up to 4 minutes the time to reach the equilibrium. Assay 
sensitivity also reduced in low analyte systems, since the maximum signal in continuous 
flow is lower than the one obtained with antigen incubation in the absence of flow. The 
background increment was not significant, due to the low concentration of the analyte 
(Figure 4:3C), therefore in low analyte concentration systems the decrease observed on 
assay sensitivity is directely related to the shear effect on antibody-antigen binding. 
Parsa et al. (2008) reported an antibody-antigen binding numerical model in a PDMS 
microchannel with h=50 µm and w=500 µm and a binding surface of 100-1500 µm2. In 
this model for unlimited sample and incubation time (approximately 10 hours) the 
analyte capture flow rate was not affected, however when time decreased to 5 or 10 
minutes, the captured analyte decreased with the incubation time, but still increased 
within flow rates from 0.1 to 100 µl/min. The negative effect of flow was only evident 
in time and sample volume constraint, where the analyte capture decreased with the 
flow rate, being almost zero at 100 µl/min for the range of sample volume studies (1 to 
15 µl). The captured area used in the numerical simulations was 0.0005 cm2.  This flow 
effect was validated with experimental data with mouse IgG and anti-IgG system, where 
the fluorescent signal was proportional to the bond complex, but decreased with the 
flow rate from 0.1 to 100 µl/min.210 In the Fep-Teflon MCF, the initial sample volume 
inside the capillaries was13 µl for a capture area of 2.5 cm2 (corresponding to 4 cm long 
MCF strip) and the maximum incubation time tested was 10 min. Therefore, the flow 
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effect observed in the MCF antigen incubation is coherent with the model described by 
Parsa et al (2008), whose reported flow rates ≥ 1 µl/min can decrease the capture 
analyte of a system. The experimental results presented in the same study show a 
decrease in analyte capture from flow rates to ≥ 0.1 µl/min. Zimmermann et al. (2005) 
reported a microfluidic antibody-antigen binding model in which the analyte capture 
would increment with flow rates of  ≤ 0.02 µl/min. and Hu et al. (2006) reported the 
same finding for flow rates at  ≤ 0.2 µl/min. These flow rates are 500 times and 50 times 
smaller than the ones used in the MCF flow antigen incubation studies, explaining the 
different conclusions about the flow effect for these models and the MCF flow 
experimental results.  
In general, flow has a significant impact on assay sensitivity not only for LF technology 
but also in microfluidic devices. Consequently, several sensitive microfluidic IAs 
required stopped flow during antigen incubation. For example, IL-4 biomarker was 
measured with a Lower Limit of Detection (LLoD) of 0.2 pg/ml and PSA presented a 
LLoD 16 pg/ml in a microfluidic microplate, both requiring 20 minutes stagnant 
incubation of sample.
66
 Other microfluidic devices used polyesterene beads with 
immobilised CapAb inside an immunopillar chip, reported LLoD around 100 pg/ml of 
CRP, AFP and PSA, with 5 min sample incubation.
58
 Flatbed Scanner colorimetric 
MCF IAs have presented a LLoD’s in femtomolar range with cytokines detection154 and 
LLoD of < 1 ng/ml PSA in 2 min with stagnant sample incubation.
152
 A glass capillary 
immunoasensor with portable fluorescence detection reported an LLoD of 1 ng/ml for 
PSA and 5 ng/ml for AFP, with 20 min continuous sample incubation at 50 µl/min.69 
Although antibodies immobilised layer and detection modes are important for assay 
sensitivity, flow rates during sample (analyte) incubation times also play an important 
role. When same biomarkers are incubated for longer time the LLoD systematically 
increases at Q=50 µl/min. This is coherent with the data presented in this study, which 
shows at flow rates larger than 10 µl/min the analyte capture decreases which involves a 
decrease in equilibrium constants (Figure 4:3D and Table 4:3). Flow rate impacts on 
sensitivity and according to this data it also impacts on the antibody-antigen binding 
kinetics. Sandwich assays performed in microfluidic IAs used capillary pumps to 
control the flow rate in the range of 0.028 to 0.2 µl/min.213 Cesaro-Tadic et al. (2004) 
reported tumor necrosis factor α (TNF- α) microfluidic assay with a LLoD of 20 pg/ml 
with 12 minutes sample incubation time at 0.03 µl/min (30 nL/min) using capillary 
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pumps.
50 Gervais et al. (2009) reported a microfluidic fluorescent CRP one step 
sandwich assay with 1 ng/ml detection limit within 14 min at 0.082 µl/min (82 nL/min) 
also using a capillary pump. The main drawback of such microfluidic sandwich assays 
appeared to be the use of high resolution and expensive readout equipment, i.e. such as 
fluorescente microscopes. Recently, Mohammed et al. (2014) reported a LLoD of 24 
pg/ml of Troponin I involving sample incubation time of 4 minutes with capillary flow 
where the reaction chamber geometry decreases the flow velocity, increasing the 
residence time of analyte in the system. The signal was obtained using a house build 
and fully enclosed fluorescent reader.
73
  
In summary, microfluidic IA devices present, in general a higher sensitivity than LF 
assays due to good flow control with external devices, such as pumps or manual 
syringe. However, IA yet the flow has a substantial negative effect on sensitivity which 
requires detailed consideration when automating microfluidic IAs.  
4.5. Conclusion 
LF technology offers simplicity and speed in diagnostics; however this technology lacks 
the sensitivity essential for some important diagnostic diseases such as sepsis and 
cardiovascular diseases. This reduced sensitivity is mainly due to a lack of flow control 
in one step, LF IA. Microfluidic technology offers sensitive IAs with the possibility of 
flow control; however, understanding the effect of flow on antibody-antigen binding 
over a broad range of flow rates in microfluidic platforms is important for automation 
and design of POC tests.  
In the present study it was concluded that sample incubation in FEP-Teflon MCF strips 
requires a flow rate below 10 µl/min, and preferably below 0.1 µl/min if the assay 
requires quantitation of low analyte concentrations. For high analyte systems a flow rate 
of 10 µl/min can be used yet extended incubation times are required to avoid any impact 
on assay sensitivity. Future work will consist in validation of these broad conclusions, 
with different sandwich assays, with different orders of magnitude of LLoD, e.g. the 
PSA, Cytokines and cardiac biomarkers assays in the MCF platform.  
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5. A Lab-in-a-briefcase for rapid PSA screening from 
whole blood 
5.1. Abstract 
We present a new concept for rapid and fully portable Prostate Specific Antigen (PSA) 
measurement, termed “Lab-in-a-Briefcase”, which integrates an affordable microfluidic 
ELISA platform utilising a melt-extruded fluoropolymer Micro Capillary Film (MCF) 
containing 10 bore, 200 m internal diameter capillaries, a disposable multi-syringe 
aspirator (MSA) plus a sample tray pre-loaded with all required immunoassay (IA) 
reagents, and a portable film scanner for colorimetric signal digital quantitation. Each 
MSA can perform 10 replicate microfluidic IA on 8 samples, allowing 80 measurements 
to be made in less than 15 minutes based on semi-automated operation and no 
requirement of additional fluid handling equipment. An assay was optimised for 
measurement of a clinically relevant range of PSA from 0.9 to 60.0 ng/ml in 15 minutes 
with CVs in the order of 5% based on intra-assay variability when read using a 
consumer flatbed film scanner. The PSA assay performance in the MSA remained 
robust in the presence of 1:2 diluted and non-diluted human serum and whole blood, 
where matrix effect could be overcome by extending the incubation times of the 
samples beyond 2 min. The PSA "Lab-in-a-briefcase" is particularly suited to a low-
resource health setting where diagnostic labs and automated IA systems are not 
accessible, by allowing PSA measurement outside the laboratory using affordable 
equipment. 
5.2. Introduction 
Prostate cancer is the second most common cause of cancer and the sixth leading cause 
of death by cancer among men population worldwide.
214
 Currently Prostate Specific 
Antigen (PSA) is the most reliable tumor biomarker for prostate cancer diagnosis and 
for monitoring disease recurrence after treatment. The highest prostate cancer incidence 
rates have been estimated to occur in the highest resource areas of the world, however 
higher mortality rates are seen in low- to medium-resource areas of South America, the 
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Caribbean, and sub-Saharan Africa.
214
 Two possible reasons for high mortality rates in 
low resource settings are lack of early detection and absence of appropriate diagnostic 
testing, alongside limited treatment options. 
PSA serum concentration in healthy males is in the range of 0-4 ng/ml and increases in 
men with prostate cancer.
12
 Several studies of screened populations showed individuals 
with PSA levels in the range of 4–10 ng/ml had a 22-27% likelihood of developing 
cancer, with those with PSA levels of ≥10 ng/ml having a risk increasing to 67%.215,216 
The Food and Drug Administration (FDA) approved the determination of PSA serum 
levels to test asymptomatic men for prostate cancer, in conjugation with digital rectal 
exam (DRE), in men aged 50 year-old or older with a cutoff blood PSA value of 4 
ng/ml.
182,181
 However, some organizations and studies advise undergoing periodic PSA 
screening from the age of 40 for African American men and men with prostate cancer 
family history.
217 
After diagnosis and treatment of primary disease, regular PSA 
measurements are also routinely used to monitor disease progression and inform clinical 
decision making. Prostate cancer recurrence is investigated when the PSA blood levels 
reach 0.4 ng/ml in patients with radical prostatectomy treatment,
218,219
 and 2 ng/mL 
above the post-treatment PSA nadir (absolute lowest level of PSA after treatment) for 
patients submitted to radiotherapy.
220,221
 
Although the efficacy of cancer screening programs is generally complex recent studies 
have suggested that PSA screening may be able to decrease prostate cancer 
mortality.
222,223
 
PSA levels are commonly quantified in blood samples in laboratories by sandwich 
enzyme-linked immunosorbent assay (ELISA). The microtiter plate (MTP) remains a 
common platform for ELISA in diagnostic laboratories offering several advantages 
including established methods and wide range of reagents and kits, alongside wide 
availability of plate readers, automated plate handling instruments and plate washers. 
MTP-based ELISA is highly quantitative and sensitive enough to reach a low Limit of 
Detection (LLoD) in the picomolar range.
224
 However, MTP ELISA cannot be 
performed outside the laboratory, requires long incubation times and must be performed 
by trained personnel. These limit the suitability of MTP for the ever increasing demand 
for measurement of biomarkers such as PSA
225,226
 and prevent PSA screening or 
monitoring in low resource areas where diagnostic laboratories have limited capacity.
227
 
A rapid, inexpensive, portable and quantitative ELISA platform is therefore urgently 
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required for both high and low resource health systems, in order to simplify PSA 
screening and monitoring. This should integrate simple manual fluid handling with a 
simple signal measurement system and avoid the need for expensive instrumentation.  
One approach to point-of-care PSA quantification is to develop a fully quantitative 
lateral flow assays, for example by using fluorescence detection
228
 or scanning band 
intensity of colorimetric lateral flow strips.
197
Although lateral flow assays have the 
assay speed, simplicity, low cost and portability appropriate for point-of-care 
diagnostics, the suitability for quantitative applications remains unclear, and so they 
remain most suited to qualitative diagnostic tests.
229
 Lateral flow systems also lack the 
capacity to perform multiple replicate tests in a single assay, preventing the use of 
internal standard reference assays alongside the sample. 
Recently microfluidic devices have overcome several limitations of MTP for 
performing ELISA by capturing the analyte on the surface of a microchannel or using 
particles entrapped inside the microchannels to increase the surface-to-volume ratio and 
reduce diffusion distances, resulting in greatly reduced assay times.
148
 Many 
microfluidic IA systems have been reported for detection of a wide range of analytes, 
including measurement of cancer biomarkers such as PSA.
66,230
 Major remaining 
challenges for microfluidic devices include controlling fluid flow and developing 
simple inexpensive detection systems. For example, power-free Lab-on-a-Chip PSA 
measurement in serum was achieved by manually moving magnetic particles through a 
device using a permanent magnet.
70
 Mobile phone cameras were used for colorimetric 
signal quantitation.
70,194
 However, the inability of using several replicates in the same 
run might compromise assay precision, and these devices do not have the capacity for 
running internal reference samples alongside sample. A major drawback for most 
microfluidic devices also remains the high fabrication cost preventing rapid product 
development from laboratory prototypes. 
We propose here a new “Lab-in-a-briefcase” concept for rapid, manual, portable and 
cost-effective PSA screening, based on an affordable miniaturized ELISA platform that 
utilises a melt-extruded MicroCapillary Film (MCF).
117
 We developed a manually 
operated device capable of performing 80 microfluidic quantitative ELISA tests in <15 
minutes and read using a flatbed scanner. Standard reference curves and sample 
replicates are measured simultaneously, allowing internal assay calibration. The entire 
system can be carried in a small briefcase, a handbag or a laptop case and the assay can 
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be performed by a single operator with minimal training, and requires no additional 
equipment or instrumentation. We present here optimization and performance data for 
this new system that demonstrates its ability to measure clinically relevant PSA 
concentrations in human serum and whole blood over a range of operating temperatures. 
This portable microfluidic system has the potential to give large population access to 
affordable PSA screening and monitoring. 
5.3. Materials and Methods 
5.3.1. Reagents and Materials 
A Human kallikrein 3/ Prostate Specific Antigen (PSA) ELISA kit was purchased from 
R&D Systems (Minneapolis, USA; cat nº DY1344). The kit contained a monoclonal 
mouse Human Kallikrein 3/PSA antibody (capture antibody), a Human Kallikrein 
3/PSA polyclonal biotynilated antibody (detection antibody) and recombinant Human 
Kallikrein 3/PSA (standard). ExtrAvidin-Peroxidase (cat. nº E2886), SIGMAFASTTM 
OPD (o-Phenylenediamine dihydrochloride) tablets (cat. nº P9187), o-
Phenylenediamine dihydrochloride (cat. nºP1526-25G), urea hydrogen peroxide (cat. nº 
289132), phosphate-citrate buffer tablets, pH 5.0 (cat. no P4809) were sourced from 
Sigma Aldrich Ltd (Dorset, UK). 3, 3’, 5,5’ Tetramethylbenzidine (TMB) (cat. nº 
DY999) from R&D Systems (Minneapolis, USA) was also used as an alternative 
enzymatic substrate. High Sensitivity Streptavidin-HRP was supplied by Thermo 
Scientific (Lutterworth, UK; cat no 21130) and used for enzyme detection. 
Phosphate buffered solution (PBS, Sigma Aldrich, Dorset, UK; cat. no P5368-10PAK), 
pH 7.4, 10mM was used as IA buffer. The diluent and blocking solution consisted either 
of SuperBlock (Thermo Fisher Scientific, Loughborough, UK; cat. no 37515) or 1 to 
3% w/v protease-free albumin from bovine serum (BSA, Sigma Aldrich, Dorset, UK; 
cat nº A3858) diluted in PBS buffer. For washings, PBS with 0.05% v/v of Tween-20 
(Sigma-Aldrich, Dorset, UK; cat no P9416-50ML) was used. Nunc maxisorp ELISA 
96-well MTPs were sourced from Sigma Aldrich (Dorset, UK). Normal Human Serum 
Off the Clot, from a single female donor Post-Menopausal (product code S1221) was 
supplied by SunnyLab (Broad Oak Road, Sittingbourne, UK). The whole blood used 
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was obtained from umbilical cord through NHS England, collected into a bag with 
added citrate phosphate dextrose (CPD) as anticoagulant. 
5.3.2. “Lab-in-a-briefcase” components 
The "Lab-in-a-briefcase” (Figure 5:1) comprises four components: 1) a set of 15 x 12 x 
1 cm
3
 disposable Multiple Syringe Aspirator (MSA) devices, each of which can perform 
10 replicate ELISA tests on each of 8 samples; 2) customised microwell plates pre-
loaded with reagents that interfaces with the MSA; and 3) a portable USB powered film 
scanner for colorimetric signal quantitation; and 4) a portable computer for real-time 
data analysis. If required, diluent plus disposable pipettes can be included for diluting 
samples to increase assay dynamic range. The overall dimension of this portable lab can 
be 40 x 30 x 15 cm
3
 and weighting up to 3 kg.  
 
Figure 5:1 - Main components of “Lab-in-a-briefcase” for PSA screening. 
 
Each MSA device includes unique design features that minimizes the possibility of 
operator error (e.g. asymmetric edges and a single thumb-wheel to control sample and 
reagent aspiration). The fluid aspiration within the MSA cartridge is driven by 8 plastic, 
1ml syringes driven by a simple thumb-wheel and central threaded rod. Each syringe is 
connected to a single 30 mm long strip of fluoropolymer MCF containing 10 bore, 
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200µm internal diameter microcapillaries pre-coated internally with monoclonal CapAb 
(Figure 5:2). The MSA combines with a customized microwell plate, loaded with 
reference standard samples, assay reagents and wash buffer, plus empty sample wells 
for clinical samples. One MSA device plus microwell plate can analyse 8 independent 
samples, allowing the option of comparing a single sample with 7 reference samples, or 
as many as 4 samples with 4 reference samples. 
MCF is a long, continuously manufactured plastic film containing a parallel array of 
microcapillaries with controlled size and shape, resulting from air aspiration/injection 
through a specially designed melt-extrusion die.
117
 The surface characteristics 
(hydrophobic) and the geometry of the fluoropolymer MCF (flat film) make it a reliable 
platform for IA techniques, including ELISA.
127
 The "Lab-in-a-briefcase" uses a MCF 
ribbon produced from fluorinated ethylene propylene (FEP-Teflon), containing 10 
embedded capillaries with a mean hydraulic diameter of 206 ± 12.2 µm manufactured 
by Lamina Dielectrics Ltd (Billingshurts, West Sussex, UK). The external dimensions 
of the fluoropolymer MCF used in this study were 4.5 ± 0.10 mm wide by 0.6 ± 0.05 
mm thick. 
The hydrophobicity of MCF fluoropolymer allows the antigen and antibodies to be 
immobilised on the inner surface of the microcapillaries by passive adsorption.
127
 MCF 
extruded from FEP has exceptional optical transparency because its refractive index of 
1.34 to 1.35
231
 matches the refractive index of water (1.33), allowing simple optical 
detection of colorimetric substrates
127
  
5.3.3. PSA Sandwich ELISA in the fluoropolymer MCF 
For each duplicate run using the MSA, the inner surface of the microcapillaries in a 50 
cm long fluoropolymer MCF was coated with Human Kallikrein 3/PSA capture 
antibody (CapAb) within a concentration range of 10-40 µg/ml in phosphate saline 
buffer (PBS). This solution was incubated overnight at 4ºC or for a minimum of 2 hours 
at room temperature (20 
o
C). The MCF surface was then blocked using the IA diluents, 
1 to 3% BSA/PBS or SuperBlock Solution, for at least 1 hour at room temperature, after 
which the MCF was washed and trimmed to produce eight 30 mm long fluoropolymer 
MCF test strips which were inserted into the push-fit seal and then fitted into the MSA.  
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Recombinant PSA protein standards loaded into the sample wells of the plate were 
aspirated into MCF strips in the MSA cartridge with 6 full revolutions of the central 
wheel (Figure 5.2), and cartridge left in the plate with MCF immersed in samples for 
incubation. Each wheel rotation draws up 13 µl through the MCF test strips, thus 6 turns 
correspond to 78 µl of reagent per 10 bore assay strip. This volume was in great excess 
compared to the small internal volume of each 30mm strip (approximately 10 µl) to 
ensure complete solution replacement, which allowed skipping washing steps in the 
sandwich IA. 
The MSA cassette was then moved to the next row of wells in the MSA plate containing 
biotinylated detection antibody (DetAb) within the range 0.5-2 µg/ml in PBS. The 
solution was aspirated with 6 turns of the wheel and incubated for required time. 
Subsequently this procedure was repeated for the enzyme conjugate (ExtrAvidin 
Peroxidase and High Sensitivity Streptavidin-HRP). Finally, the MCF test strips were 
washed 3 to 4 times with PBS-T (washing buffer) using 6 turns of the thumb wheel per 
wash. 
The enzymatic substrate (OPD or TMB) was then aspirated into the MCF strips and the 
MSA containing the MCF strips was laid flat on a HP ScanJet G4050 Film Scanner, and 
RGB images with 2,400 dpi resolution scanned in transmittance mode (Figure 4:4) were 
taken at a given time interval. The MSA provides good alignment of the test strips with 
the glass surface of the scanner, at a distance within the focal distance of the linear 
CMOS detector (about 6 mm). The volume of the 1 ml disposable syringes was 
sufficient to deliver homogeneous aspiration of each IA reagents and good washing 
before the addition of the colorimetric substrate. RGB images of the fluoropolymer test 
strips array were then taken every 2 to 5 min for up to 30 minutes, and analysed using 
ImageJ (NIH, Maryland, USA) to quantify absorbance on each individual capillary 
(Figure 4:4) from the grey scale pixel intensity. The RGB image was split into red, 
green and blue channels, and for OPD substrate the blue channel was used as it 
provided maximum light absorption, whereas with TMB the red channel showed the 
highest absorbance. 
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5.3.4. PSA Sandwich ELISA optimization the fluoropolymer MCF 
Assay optimization studies were done according to an experimental matrix which 
consisted in analyzing the effect of 7 factors: CapAb concentration, DetAb 
concentration, DetAb incubation time, PSA incubation time, enzyme concentration, 
enzyme incubation time, and matrix effect. All factors were optimized according to the 
maximum signal-to-noise ratio and total assay time (Figure 5:2 and Figure 5:5A). 
Kinetic studies, involving optimum incubation times, were performed using the 
optimized concentrations of 40 µg/ml CapAb, 1 µg/ml of DetAb; 1 µg/ml of high 
sensitivity streptavidin, and 4 mg/ml o-phenylenediamine dihydrochloride (OPD) with 1 
mg/ml Hydrogen Peroxide.  
The matrix effect was studied after the assay optimization process (Figure 5:5A). It was 
tested by performing in parallel three different PSA full response curves, one with 
buffer solution spiked with diluted concentrations of recombinant proteins (0% serum) 
and the others diluting the PSA standards in 100% and 50% (in PBS) female serum, 
respectively within a total assay time ≤15 minutes. To complement the study of sample 
matrix on PSA sandwich assay other set of experiments where PSA standards were 
spiked in non-diluted serum and whole blood matrices were performed. Resulting 
absorbance values were compared to absorbance values of PSA standards diluted in 
buffer. To finalize matrix effect studies sample incubation time was increased to ≥10 
minutes and two PSA assays were performed in parallel, one in buffer (0% serum) and 
the other in non-diluted serum (100% serum) in a total assay time ~30 minutes. For the 
purpose of this comparison, the assay conditions were: 10 µg/ml CapAb incubated 
overnight at 4ºC, 2 µg/ml of DetAb incubated for 10 minutes, 4 µg/ml of Extravidn 
Peroxidase incubated for 10 minutes, 4 mg/ml of o-phenylenediamine dihydrochloride 
(OPD) and 1 mg/ml with Hydrogen Peroxide incubated for 3 minutes. 
The 4 Parameter Logistic (4PL) mathematical model was fitted to experimental data by 
the minimum square difference for each full PSA response curve. The lower limit of 
detection (LLoD) was calculated by the mean absorbance of the blank plus three times 
the standard deviation of the blank samples. 
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5.3.5. PSA IA Optimization in the MCF 
The effect of CapAb concentrations (10, 20 and 40 µg/ml) and DetAb concentrations (0, 
0.5, 1 and 2 µg/ml) on colorimetric signal was tested by comparing absorbance values 
obtained in test strips incubated with 0 ng/ml (negative control), 1.5 ng/ml (lower end) 
and 30 ng/ml (upper end) recombinant protein diluted in the assay buffer. Since the 
optimum CapAb and DetAb concentrations were established, the effect of DetAb 
concentration and DetAb incubation times (0, 2.5, 5, 10 minutes) was fully tested using 
4.0 ng/ml of recombinant protein. A third set of experiments was performed which 
aimed optimising the conditions for the enzyme complex, High Sensitivity Streptavidin-
HRP (0, 1, 2 and 4 µg/ml). All core sandwich PSA IA steps were optimised in respect to 
maximum signal-to-noise ratio. 
A chromogenic OPD enzymatic substrate was used, which consisted in 1 mg/ml OPD 
and 1 mg/ml H2O2 (enhanced recipe) or 4 mg/ml OPD and 1 mg/ml H2O2 (fully 
optimised recipe); note the manufacturer recommended 0.4 mg/ml OPD and 0.4 mg/ml 
of H2O2 for ELISA in MTPs. Horseradish peroxidase is an enzyme with a large 
turnover, therefore we have found that higher concentrations of OPD and/or H2O2 
results in one order of magnitude increases in absorbance in the microcapillaries, where 
the diffusion of a small molecule such as OPD and DPA across the whole diameter of 
the capillary can happen in few seconds. 
5.3.6. PSA IA in the Microtiter Plate (MTP) 
The protocol recommended by ELISA kit manufacturer was followed for PSA assay 
detection in a 96-well MTP which is summarized in Table 5:1. The OPD was added to 
each well, slightly mixed and absorbance measured at 450 nm using the Epoch 
(BioTek) microplate reader. In this instance no stop solution was used, in order to 
compare directly the colorimetric data obtained in the MCF strips with the flatbed film 
scanner. Absorbance values were expressed as cm
-1
 based on a light path length of 0.30 
cm for a 96 microtiter plate well.  
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Table 5:1 - Experimental conditions used for sandwich ELISA detection of PSA in a 96 
well MTP. 
Step Concentration Incubation Time Volume (per well) T (ºC) 
CapAb 1 µg/ml overnight 100 µl 4 
Washing -  4*100 µl 20 
Blocking (BSA) 1% (w/v) 2 hours 300 µl 20 
Washing -  4*100 µl  20 
PSA standards 0.9-60 ng/ml 120 minutes 100 µl 20 
Washing -  4*100 µl 20 
DetAb 0.2 µg/ml 120 minutes 100 µl 20 
Washing -  4*100 µl 20 
Enzyme (Extravidin) 1 µg/ml 20 minutes 100 µl 20 
Washing -  4*100 µl 20 
Substrate (OPD) 0.4 mg/ml 30 minutes 100 µl 20 
5.3.7. Measurement of Absorbance, Absorbance Ratio and Intra-assay variability in 
MCF strips 
The absorbance (Abs) in the MCF strips was measured from the grey scale pixel 
intensity of scanned images using image analysis. This consisted in running a profile 
plot across the greyscale images of the MCF strips (blue channel) and measuring the 
baseline grey scale pixel intensity across each strip (I0) and the peak height (I) at the 
center of each capillary, from where Abs could be directly determined by equation (5:1).  
 Abs=-log(I/I0) (5:1) 
This procedure was repeated for each individual capillary on each separate MCF strip. 
Response curves for PSA performed in the MCF strips were compared to those 
performed in the MTP by considering a mean light path distance of 200 m for each 
capillary in the MCF strips.  
In order to understand signal variability across the different microcapillaries within the 
same MCF strip (intra-assay variability), MCF strips were immersed in liquid nitrogen, 
sliced with a razor blade and observed using a long distance microscope (Nikon 
SMZ1500). The mean hydraulic diameter, and width (w) and height (h) for each 
capillary (Figure 5:3) was then measured using Image J software. For each strip at least 
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10 slices were analysed at 30 mm intervals which corresponds to the distance of the pre-
coated MCF strips required to operate the MSA. 
In parallel, MCF strips from the same batch were filled with a 1:2 dilution series of 2 
mg/ml of 2,3-diaminophenazine (DAP), the colored product resulting from the 
enzymatic conversion of the chromonogenic OPD substrate. The MCF strips were then 
scanned using same film scanner and absorbance values determined by image analysis 
using Image J. This allowed normalizing Abs values in respect to DAP reference 
solution, which was expressed in this paper as Absorbance Ratio (Abs ratio) values: 
 
Abs ratio =
𝐴𝑏𝑠𝑃𝑆𝐴
𝐴𝑏𝑠𝐷𝐴𝑃
 
(5:2) 
 
5.3.8. Robustness studies for PSA sandwich ELISA in the MCF 
The effect of temperature on the PSA assay performance was tested by running full 
response curves using the optimised PSA protocol and all reagents brought to the 
operating temperature of 4, 20 or 37 °C.  
The intra-assay variability studies was accomplished by measuring the absorbance of 
lower, middle and upper range of PSA values (3.75, 7.5 and 30 ng/ml PSA) in the 10 
capillaries of one MCF strip. These values were already normalized by DAP 
absorbance, which means that the variability obtained is only intrinsical to the assay and 
it does not depend of the platform geometry variation.  
The inter-assay variability was determined by performing PSA assay in the MCF for 
three PSA concentrations: 3.75, 7.5 and 30 ng/ml (lower, middle and higher range) in 
three different days and using different MSA devices. The absorbance was measured for 
20 samples (n=20) of each PSA concentration studied.  For every PSA concentration the 
inter-assay variability was obtained by calculating the coefficient of variation (CV) 
between the absorbance of 3 independent PSA sandwich assay runs. 
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5.4. Results and discussion 
5.4.1. Optimisation of manual and portable Lab-in-a-briefcase ELISA  
The inexpensive microengineered MCF material was first presented as a miniaturised 
IA platform for low cost microfluidic direct ELISA
127
, but the majority of IA require a 
sandwich format including an immobilised CapAb. To demonstrate the potential of the 
melt-extruded microfluidic material MCF for delivering affordable, sensitive, clinical 
testing using a sandwich protocol, we developed a complete ELISA system that shares 
many benefits with MTP assays but in a portable kit requiring no additional equipment 
or any complex fluid handling. The core of this system is a manually driven multi-
syringe device, termed a MSA, combined with a customized microwell plate, that 
together aspirate samples and all required reagents sequentially through MCF strips to 
perform a full sandwich ELISA (Figure 5:2). The different geometry, size, and surface-
to-area ratio of MCF leads to significant differences in optimal ELISA assay conditions 
when compared to MTP assays, specifically higher reagent concentrations combined 
with shorter incubation times. Initial studies therefore focused on identifying the 
optimal assay conditions for the required sensitivity and for fast total assay times 
(Figure 5:2) and were based on the optimal signal-to-noise ratio of the assay. 
A concentration of 20 µg/ml of CapAb and 2 µg/ml of DetAb (detection antibody) 
resulted in the highest absorbance signal for the assay as shown in Figure 5:2 however it 
also resulted in higher background signals (strip with 0 ng/ml of recombinant protein) 
with incremental CapAb concentrations for all range of DetAb concentrations tested. 
With 40 µg/ml of CapAb the concentration of DetAb significantly affected the 
background signal. This happened because the detection antibody is polyclonal, so it 
can bind directly to the CapAb or to other proteins on the fluoropolymer surface 
significantly increasing the background signal. The best signal-to-noise ratio was 
therefore obtained with 40 µg/ml of CapAb and 0.5 µg/ml of DetAb. This was also 
valid for 1.5 ng/ml and 30 ng/ml PSA (lower and upper limits, respectively, of PSA 
studied range), based on 5 minutes substrate incubation time. The large surface-area-to-
volume ratio in the 200 m MCF allows coating the plastic fluoropolymer surface with 
a concentration of CapAb more than 10x higher than on a 96-well plate. This can 
potentially improve the sensitivity of the assay in the MCF, as the kinetics of antigen-
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antibody binding is favored by high surface density of CapAb molecules. This is only 
possible until a given surface coverage, above which the antibodies binding capacity 
decreases for reason well established in literature.
158
 
In a further set of experiments a MCF reel was coated with 40 µg/ml of CapAb varying 
the DetAb concentration and DetAb incubation time. Then, the full sandwich assay was 
completed using 4 ng/ml of recombinant protein. Figure 5:2B shows that for all DetAb 
concentrations studied the absorbance values increased until 1 µg/ml of DetAb. The 
highest absorbance signals were obtained for 5 minutes incubation time of DetAb, 
followed by 10 minutes and 2.5 minutes. The background signal increased with the 
increase in the concentration and incubation time of the DetAb, being 10 minutes 
incubation and 2 µg ml of DetAb the conditions resulting in higher background signals. 
Figure 5:2B shows that 1 µg/ml of DetAb incubated for 5 minutes resulted in the 
highest signal-to-noise ratio with 40 µg/ml of CapAb. The use of a detection 
monoclonal antibody would increase the sensitivity of the assay, however this issue can 
be easily overcome by varying the concentration and incubation time for the DetAb. 
In respect to the enzymatic complex, the highest signal was obtained with 4 µg/ml of 
High Sensitivity Streptavidin-HRP with 5 minutes incubation (Figure 5:2C), however it 
is important to take in consideration that these conditions also led to the highest 
background signal. The presence of colorimetric signal at 0 µg/ml of enzyme showed 
enzymatic conversion of OPD in the absence of enzyme which might have been induced 
by the transmitted light in the flatbed scanner.  
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Figure 5:2 - Optimisation of PSA sandwich assay conditions in the fluoropolymer MCF 
platform using the MSA.  
A Signal, background and signal-to-noise ratio of MCF PSA assay with varying 
concentartions of capAb and detAb concentration, using 1.5 ng/ml of recombinant 
protein and 4 µg/ml of Extravidin Peroxidase. B Signal, background and signal-to-noise 
ratio of MCF PSA assay for varying concentrations and inbuation times for detAb 
(capAb 40 µg/ml; 4 ng/ml recombinant protein; 4 µg/ml Extravidin Peroxidase. C 
Signal, background and signal-to-noise ratio of PSA assay with varying Enzyme 
concentration and Enzyme incubation times (40 µg/ml of capAb; 3.75 ng/ml of PSA 
concentration; 1 µg/ml of detAb concentration; High sensitivity streptavidin-HRP). 
5.4.2. Effect of MCF dimensions on assay signal 
Having established optimal assay conditions, the next focus was on understanding assay 
variability. One of the main challenges in microfluidic IA is to maintain the sensitivity 
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and precision of gold standard MTP methodology, whilst achieving a major reduction in 
total assay times. The cost-effective continuous melt extrusion process used to produce 
MCF offers the potential for low device cost, but has the potential for small variation in 
the shape and diameter of the microcapillaries along the plastic film and across each 
film strip. The extent of variation and effect of variations in geometry of 
microcapillaries on assay performance have not previously been reported, and were 
studied here by measuring MCF geometry both directly and also indirectly by imaging 
dye solutions within MCF strips.  
According to the Lambert-Beer law, Abs is linked to the extinction coefficient of a 
substance, 𝜖, concentration, c and light path distance, l. Small differences in the shape 
or size of microcapillaries will therefore affect absorbance independently of assay signal 
if path distance l changes (Figure 4.4), which could increase assay variability both from 
capillary to capillary across a single MCF strip, or between strips taken from film 
batches with variable dimensions. Initially, the mean hydraulic diameter and capillary 
height h for each capillary was measured using an optical microscope in 10 replicate 
thin samples cut from MCF strips (Figure 5:3A). Although informative, this was a 
difficult and laborious task because the fluoropolymer MCF material was soft and could 
be deformed during sample slicing, potentially increasing the variability of measured 
geometry. A second non-invasive method to measure variation in capillary geometry 
was therefore developed whereby MCF strips were filled with solutions of fixed 
concentrations of DAP, the coloured product resulting from HRP enzymatic conversion 
of the chromogenic OPD substrate, and scanned using same settings as PSA strips. 
From the known extinction coefficient of these solutions, variation in capillary height h 
could therefore be measured from Abs values calculated from the scanned images. As 
expected, when measured capillary height was compared to absorbance, a correlation 
between Abs values for DAP was seen with h (Figure 5:3B). When a single DAP 
reference strip was used to provide reference absorbances, and a normalized absorbance 
ratio calculated (using Equation 2), the effect of small differences in pathlength distance 
on PSA assay absorbance was eliminated resulting in a significant decrease on the intra-
assay variability across the entire concentration range (Figure 5:3C). 
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Figure 5:3 - Correlation between capillary height (h) and absorbance (Abs) variability 
across a 10 bore fluoropolymer MCF material.  
A Variation in h across and along the MCF strip (error bars represent 2 standard 
deviations from multiple measurements along 1m long MCF strip). B Correlation 
between h and DAP absorbance. C Coefficient of Variation (CV) of absorbance values 
for different PSA concentration, before and after normalisation with DAP absorbance; 
CV is obtained from the ratio between the Relative Standard Deviation (STDEV) 
absorbance along 10 capillaries for a given PSA concentration and the mean value of 
absorbance in the same 10 capillaries.  
5.4.3. Kinetics of ELISA in MCF capillaries 
Quantitative heterogeneous IA usually require extended incubation times to attain the 
antibody-antigen binding equilibrium. These are dependent on the reagents mass 
transfer and kinetic limitations.
232
 The long incubation times required for sandwich PSA 
IA in the MTP are linked to the long diffusion distances in the plastic wells that can be 
dramatically reduced in a miniaturized system. Kinetic studies for each core sandwich 
ELISA step in the fluoropolymer MCF after assay optimization confirmed the very 
short times required to achieve full signal response in a system with a diffusion distance 
15 times smaller. An incubation time for recombinant protein of 2 min was found 
sufficient in the MCF, whereas for DetAb and enzyme conjugate no benefit was seen in 
extending incubation times beyond 5 min (Figure 5:4). In respect to the enzymatic 
chromogenic substrate (OPD) incubation times up to 10 min followed a zero order 
reaction (Figure 5:4(iii)) which is ideal for obtaining a broad dynamic range in IA, as an 
early reading can provide good assay performance for higher concentrations, and in 
contrast low concentrations with weak initial signal can be more clearly measured. As 
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expected for enzyme assays, measurement of reaction rate rather than endpoint 
absorbance can also provide good indication of sample concentration. 
Many microfluidic platforms reported successful quantitation of biomarkers over a 
certain dynamic range with total assay time ranging from 2 minutes to several 
hours.
147
,233,
101
 The MCF ELISA can successfully quantify PSA in diluted human serum in 
15 minutes, requiring <5 minutes sample incubation time (Table 5:2). This total assay 
time could also be achieved by the Immuno-pillar chip and a capillary driven device 
using PDMS substrate, which were able to run human serum sandwich assays, 
presenting similar MCF sensitivity, within 12 and 14 minutes total assay time 
respectively.
58,56
 Although, time competitive these devices are tailored to single sample 
and single test, in contrast to the independent 8 samples measured 10 times each in the 
MSA. In addition these microfluidic devices use fluorescence microscopes for signal 
detection, which allows the high sensitivity of the assays, but also increases the cost and 
difficulties for platform operator, characteristics not suitable for POC applications. 
Colorimetric detection by a flatbed scanner or other portable device (e.g. smartphone 
camera) is ideal for POC settings. It is easy-to-use, portable, user-friendly, rapid and 
cost effective detection strategy.
234,148
 So far no other microfluidic platform has reported 
a fully quantitative sandwich IA in ≤15 minutes using biological samples and 
colorimetric detection by a flatbed scanner. 
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Figure 5:4 - Kinetic study of all assay steps illustrating minimum incubation times 
required for signal saturation with 3.75 ng/ml of PSA recombinant protein. 
 
Table 5:2 - Incubation times of ELISA reagents in the standard Microtiter Plate (MTP) 
and in the novel Microcapillary Film (MCF).  
 Time (min) 
Assay Step MTP MCF 
PSA Incubation 120 2 
DetAb Incubation 120 5 
Enzyme Incubation 20 5 
Enzymatic Substrate 
Incubation 
20-30 1.5- 3 
 
Total 280 13.5-15 
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5.4.4. Assay performance with biological samples 
IA performance can often be affected when human samples are tested, with the high and 
variable concentration of unrelated proteins, lipids, and other biomolecules plus changes 
in viscosity often producing unwanted background or loss in signal.
235
,236,
237
 Identifying 
these interferences and managing them is fundamental for sensitive and reproducible 
IA.
237
 Managing matrix effects becomes even more urgent in POC settings, where the 
sample processing needs to be minimized or eliminated to speed up the testing 
process.
234
  
After PSA assay optimization (Figure 5:5A) the PSA assay was tested with 100% 
human serum. The full PSA response curve obtained presented a loss in absolute 
absorbance signal without a significant loss in sensitivity compared to buffer (Figure 
5:5B and (Table 5:2). This observation showed however that the biological matrix was 
interfering with the assay. A further set of experiments compared performance in 100% 
human serum with 100% whole blood as sample matrices for the PSA standards. The 
results showed that the absorbance values are similar for serum and for the whole blood, 
but still lower that the ones performed in buffer for concentrations (Figure 5:5C). These 
observations confirm that the PSA MCF assay presents the same performance in serum 
and in blood simplifying sample preparation process, by eliminating the need of sample 
preparation. To our knowledge this finds no precedent in microfluidic devices. 
Therefore, an attempt to reduce matrices interferences was done by diluting the human 
serum 1:2 and using the diluted serum as the sample matrices for full response curves of 
PSA MCF sandwich assay as it has been reported in other microfluidic IA studies.
238
 In 
that case, the absolute Abs values and sensitivity of PSA assay in buffer and diluted 
serum were similar for 15 minutes total assay time (Figure 5:5D). This means that 
sample dilution can be used to overcome the matrix effect.
239,238
 Other attempt to 
overcome the matrix effect consisted in increasing sample incubation times, so the PSA 
(26 KDa protein
240
) protein could have time to diffuse through the matrix viscous liquid 
and bind to the immobilised antibody on the capillary walls. These experiments 
performed in 100% serum showed that with 15 minutes sample incubation no difference 
was noticed between the PSA absorbance values in buffer and in non-diluted serum 
(Figure 5:5E). These results suggest that matrix effect in PSA MCF system is due to a 
viscosity increment in the PSA diluent and not to the presence of specific proteins in the 
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matrix.
235
 At 20 °C the viscosity of buffer is approximately 1 mPa.s whislt he viscosity 
of serum is known to be higher.
241
 The diffusion coefficient of a spherical particle 
through liquid with low Reynolds number is directly proportional to diffusion time and 
inversely proportional to viscosity. This can justify the need for higher sample 
incubation times for assays performed in non-diluted biological samples and the same 
absorbance values for 1:2 diluted serum samples with 2 minutes sample incubation. 
Therefore to overcome viscosity effect of non-diluted serum an extended sample 
incubation time should be considered, otherwise the sample would need to be diluted 
1:2 to match he viscosity to that of the buffer. The absorbance values of PSA assay in 
the whole blood were similar to the ones performed in non-diluted serum, despite blood 
viscosity was reported to be  between 3.36 and  5.46 mPa.s.
241
 The larger viscosity of 
blood compared to serum relates to the viscoelastic properties of red blood cells, which 
appears not to interfere to protein diffusion in the liquid matrix (i.e. blood 
serum).Consequently, whole blood samples can be used in the PSA sandwich ELISA in 
the MCF platform as long as the minimum of 10 minutes sample incubation is 
undertaken or blood sample is diluted in 1:2. Overall, the PSA assay in the MCF was 
fully quantitative in the current clinical range (>4 ng/ml),
242,243
 and in lower proposed 
ranges (2.6 to 4 ng/ml) (Figure 5:5 and Table 5:3),
244,181
 presenting LLoD below 0.9  
ng/ml of recombinant protein (Table 5:3) with a precision varying from 3 to 9% based 
on the intra-assay variability in buffer and  in biological samples. The LLoD was 
calculated by adding 3 times the blank standard deviation to the mean blank absorbance, 
the absorbance value obtained was transformed in a PSA concentration using the 4PL 
mathematical model. The cross-correlation coefficient, R
2
 between the 4PL model and 
the experimental data is also shown inTable 5:3. 
Given that variation in capillary geometry across the MCF strip had already been 
identified as a significant component of assay variance (Figure 5:3C), it was possible to 
reduce assay variability by normalizing absorbance values. This was done by dividing 
each capillary absorbance by the average of absorbance of a reference solution of DAP 
strip in the same capillary number, obtaining absorbance ratio (Figure 5:5).  
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Figure 5:5 - PSA sandwich ELISA in MCF platform using the MSA device. 
A Optimisation process and selected experimental conditions. B MCF PSA assay 
response curves in 0% and 100% human female serum, spiked with recombinant protein 
using total assay time of 15 minutes. C PSA sandwich assay in buffer, non-diluted 
serum and whole blood in 15 minutes total assay time (<5 minutes sample incubation 
time). D MCF PSA assay response curves in 0 and 50% Human Female Serum, spiked 
with recombinant protein in 15 minutes total assay time (<5 minutes sample incubation 
time). E PSA sandwich assay in 0 and 100% buffer in ~ 30 minutes total assay time (15 
minutes sample incubation).  
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Table 5:3 - Parameters of fully-optimised response curves in the MCF using MSA 
device. 
Assay Parameter 0% Serum 50% Serum 100% Serum  
Dynamic Range 0.9–60.0 ng/ml 
(R2 = 0.9988) 
0.9 – 60.0 ng/ml 
(R2 =0.9981) 
0.9 – 60.0 ng/ml 
(R2 = 0.9988) 
 
Sensitivity (LLoD) <0.9 ng/ml <0.9 ng/ml  <0.9 ng/ml   
Precision 5% at 3.8 ng/ml  9% at 3.8 ng/ml 7% at 3.8 ng/ml   
 
Since optimized conditions were established for the MCF (Figure 5:5A), full PSA 
response curves were performed and compared to a 96-well microtitre plate. 
Performance of the two platforms was comparable (Figure 5:6), despite the >94% 
reduction in assay time in the MCF platform (Table 5:2). A major difference between 
assays in the MCF and the MTP is that the former only requires one washing step 
(before adding enzymatic substrate), while the MTP involved several washes after each 
incubation step. The assay sensitivity in the MCF was not affected by removal of 
washing steps, which reduced the total number of steps required, bringing sandwich IA 
closer to point-of-care (POC) devices. The normalized Abs/cm signal in the MTP 
(Figure 5:6) was almost 50-fold lower than in MCF platform using the optimised IA 
conditions, a reflection of the shorter pathlength of the microcapillary assay and 
optimized MCF assay conditions. 
 
Figure 5:6 – Comparison of MCF vs MTP PSA colorimetric IA. 
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MTP PSA assay was performed using conditions  suggested by manufacturer and 
summarised in Table 5:1; MCF PSA assay was performed in the optimised conditions 
(Figure 5:5A and Figure 5:2). 
5.4.5. Robustness of PSA sandwich ELISA in the MCF using MSA devices 
POC testing devices should ideally present robust performance on a range of 
temperatures, as temperature fluctuations are difficult to control outside laboratory 
setting. Temperature has been reported to affect IA performance in terms of linear 
range, precision and limit of detection.
245,246
 A separate set of experiments explored the 
effect of temperature on PSA sandwich assay performance. Consequently, PSA full 
response curves were performed with reagents pre-stabilized at 4, 20 and 37 ºC in the 
MSA with a reduction in the absolute values of absorbance for 4 ºC (related to lower 
HRP enzymatic activity), but limited impact in respect to the LLoD or linearity of the 
PSA IA. In general, temperatures around 20 ºC favored the sensitivity and precision of 
the assay (Figure 5:7A). Similar results were found by Imagama M. et al (1982) where 
the lowest non-specific binding and the highest specific binding were obtained by 
incubation at 20°C when compared with incubation at 37°C.
246
 Although temperature 
presents minimum impact on assay performance, the MSA allows performing a full 
response curve at the same conditions of a given biological sample, therefore providing 
an internal calibration ideal for POC settings.
234
 
133 
 
 
Figure 5:7 - Robustness of PSA sandwich assay in the MCF.  
A Effect of temperature on the performance of PSA IA in the MCF  i) 4ºC;ii) 20ºC;iii) 
37ºC.B Intra-assay variability studies in lower, middle and upper range of PSA response 
curve i) Absorbance ratio per capillary ii) Coefficient of variation calculated by the ratio 
of standard deviation of 10 absorbance values by the average of those values. C Inter-
assay variability studies for lower, middle and upper range of PSA assay using different 
MSA devices i) Inter-assay variability per day and ii) Coefficient of variation calculated 
by the ratio of standard deviation of 20 absorbance values by the average of those.  
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A further set of experiments aimed at specifically studying the precision of PSA assay 
in the MCF at 20°C. This experiments showed an intra-assay precision <7% in the 
lower, middle and upper range of the PSA response curve (Figure 5:7B). Note that 10 
samples corresponding to 10 capillaries were analyzed in this process, being the CV 
calculated by the ratio between the standard deviation of Abs values with the 
absorbance average of the 10 samples. The inter-assay variability was determined by 
performing the assay in three different days and using three different MSA devices. A 
total of 20 samples was analysed in order to calculate CV values. The results showed 
<20% of inter-assay variability (Figure 5:7C) which is within the value accepted (25% 
of variation) for validation of heterogeneous IA according to a pharmaceutical industry 
perspective.
30
  All absorbance values were previously normalized by DAP absorbance 
eliminating the effect of capillary geometry variation in the determination of intra and 
inter-assay variability. 
5.5. Conclusions  
We presented a new “Lab-in-a-briefcase” concept for sandwich IA employing 
inexpensive, compact components for POC and field diagnostics detection, and 
demonstrate system performance for the important cancer biomarker PSA (prostate 
specific antigen) from human serum and whole blood. This portable lab, with 40 x 30 x 
15 cm
3
, uses a miniaturised ELISA platform, fluoropolymer MCF which offers rapid, 
low volumes and cost-effective assays, comparable to MTP ELISA. The flat geometry 
of the plastic film combined with optical clarity of the fluoropolymer material provides 
the opportunity for a simple optical detection using USB powered film scanners. A 
simple and efficient MSA is used to simultaneously fill 8 pre-coated MCF test strips or 
80 capillaries using an array of 1 ml disposable plastic syringes. The components of our 
portable lab allow the use of conventional ELISA and commercialized assay chemistry 
on the field, outside the laboratory setting. As a proof-of-concept the PSA ELISA 
detection using the lab components was performed in 15 minutes in biological samples 
with a LLoD of <0.9 ng/ml PSA and 3 to 10% intra-assay variability. This means PSA 
MCF ELISA was 20x faster than the standard MTP ELISA, whilst maintaining similar 
assay performance in respect to precision and LLoD. This has the potential of enabling 
PSA screening into patient home or into remote areas. Future improvement to the “Lab-
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in-a-briefcase” for PSA screening can be achieved by further miniaturising all 
components or interfacing to wireless, smartphone technology for simple-optical signal 
quantitation.  
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6. Portable smartphone quantitation of prostate specific 
antigen (PSA) in a fluoropolymer microfluidic device 
 
6.1. Abstract 
We present a new, power-free and flexible detection system named MCFphone for 
portable colorimetric and fluorescence quantitative sandwich IA detection of prostate 
specific antigen (PSA). The MCFphone is composed by a smartphone integrated with a 
magnifying lens, a simple light source and a miniaturised IA platform, the 
Microcapillary Film (MCF). The excellent transparency and flat geometry of 
fluoropolymer MCF allowed quantitation of PSA in the range 0.9 to 60 ng/ml with < 7 
% precision in 13 minutes using enzymatic amplification and a chromogenic substrate. 
The lower limit of detection was further improved from 0.4 to 0.08 ng/ml in whole 
blood samples with the use of a fluorescence substrate. The MCFphone has shown 
capable of performing rapid (13 to 22 minutes total assay time) colorimetric quantitative 
and highly sensitive fluorescence tests with good %Recovery, which represents a major 
step in the integration of a new generation of inexpensive and portable microfluidic 
devices with commercial IA reagents and off-the-shelf smartphone technology. 
6.2. Introduction 
Decentralization of diagnostic testing to near the patient sites is both a trend and a need 
in clinical diagnostics. IA platforms (the most common laboratory bioanalytical tool) 
and detection systems must therefore be adapted for point-of-care (POC) testing, which 
requires the ability to design affordable, portable, and user-friendly IA systems capable 
of rapid and sensitive detection using well established IA chemistries. 
Diagnostic tests are routinely used to diagnose and select treatment options for many 
critical health conditions, including cardiovascular diseases, sepsis, ovarian and prostate 
cancer, demand quantitation of one or multiple analytes. 
247–250
 Agglutination and lateral 
flow assays are the most widely used POC IA tests, however these formats are usually 
qualitative or semi-quantitative, lacking both the sensitivity for many important 
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biomarkers and the ability to perform multiplex analysis.
234
 This has driven the 
development of microfluidic IA platforms,
8
 combining minimal diffusion distances and 
high surface-area-to-volume ratios for improved performance, with the use 
microchannels or beads for rapid and sensitive detection of analytes from small sample 
volumes. 
Optical detection is often preferred in POC testing, as it can rapidly and simply provide 
high-resolution microscopic and macroscopic information.
251,252
The recent fall in cost 
of optoelectronic components now offers cost benefits for portable detection systems. 
Two most common optical detection techniques used in microfluidic IAs are 
fluorescence and chemiluminescence, due to their excellent sensitivity.
148
 However, the 
readout equipment used to detect these signals is complex and expensive, typically 
requiring a fluorescence or confocal microscope or high-sensitivity optical sensors, and 
therefore not portable or cost-effective for POC use.
253
 The opportunity for using simple 
portable optical detection in microfluidic diagnostics has recently arisen because of the 
rapid expansion in consumer electronics such as high-performance smartphones 
cameras that are now ubiquitous, and have driven down the price of high performance 
digital image sensors combined with portable computers.
251
 Smartphones are portable, 
widely available, user-friendly and low cost, and are therefore suitable for integration 
into a microfluidic platform for POC diagnostics. 
Examples of microfluidic diagnostic tests based on smartphone measurement include 
colorimetric detection of Salmonella from an immunoagglutination assay,
254
 
measurement of urine, saliva and sweat pH,
176,255
 quantitation of vitamin D measured 
using a competitive lateral flow IA,
194
 and prostate specific antigen (PSA) quantitation 
from a sandwich microfluidic IA with a lower limit of detection (LLoD) of 3.2 ng/ml 
PSA in serum samples.
103
 Most smartphone detection systems reported so far are based 
on colorimetric detection. 
256
 Although colorimetric detection is usually more cost-
effective, easy-to-use and rapid,
148
 fluorescence detection should present higher 
sensitivity for quantitative POC diagnostics, allowing low analyte cut off values in 
small sample volumes which is vital for many clinical biomarkers. Smartphone 
fluorescence detection has been reported in some bioassays, such as quantification of 
albumin using a dye based assay,
257
 in a lateral flow assay,
258
 and finally to detect 
bacteria using a lateral flow assay with fluorescence nanoparticles.
259
 However, 
smartphone fluorescence detection has not yet been reported in sandwich ELISA 
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systems for accurate quantitation of analytes, and this would bring POC microfluidic 
diagnostics to a new level of portability and sensitivity.  
In this study we present a flexible smartphone based colorimetric and fluorescence 
detection system, termed the MCFphone, capable of detecting PSA from whole blood in 
the relevant clinical range in 13 minutes using colorimetric detection and 22 minutes 
using fluorescence detection. PSA is the mostly widely used prostate cancer biomarker, 
and continuous monitoring of PSA levels in patients with prostate cancer is a vital 
diagnostic tool. PSA blood levels determination in conjugation with digital rectal 
examination was approved by the Food and Drugs Administration to test asymptomatic 
men aged 50 year old with a cut off value of 4 ng/ml of PSA.
181,182
Many studies 
suggested that prostate cancer mortality can be decreased by early detection, and so 
screening programs have been proposed utilising PSA quantitation in blood. We 
propose that a quantitative whole blood PSA sandwich assay in a rapid, sensitive, and 
portable test device would allow POC prostate cancer monitoring and screening even in 
remote areas of developing countries where laboratory facilities are limited. The 
MCFphone detection system could easily be combined with the “Lab-in-a-briefcase” 
assay platform reported recently,
152
 replacing the flatbed scanner readout system and 
increasing portability, flexibility and sensitivity. 
6.3. Materials and Methods 
6.3.1. Materials & Reagents 
Enzymatic chromogenic and fluorescence products 2,3-diaminophenazine (DAP) and 
fluorescein isothiocyanate (FITC), dimethyl sulfoxide (DMSO), streptavidin alkaline 
phosphatase, SIGMAFASTTM OPD (o-Phenylenediamine dihydrochloride) tablets and 
FDP (fluorescein diphosphate) were sourced from Sigma-Aldrich (Dorset, UK). High 
sensitivity streptavidin-HRP was supplied by Thermo Scientific (Lutterworth, UK).  
Human kallikrein 3/ Prostate Specific Antigen (PSA) ELISA kit was purchased from 
R&D Systems (Minneapolis, USA). The kit contained a monoclonal mouse Human 
Kallikrein 3/PSA antibody (capture antibody or CapAb), a Human Kallikrein 3/PSA 
polyclonal biotynilated antibody (detection antibody or DetAb) and recombinant 
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Human Kallikrein 3/PSA (standard). Phosphate buffered solution (PBS) and Bovine 
Serum Albumin (BSA) were sourced from Sigma Aldrich, Dorset, UK. PBS pH 7.4, 
10mM was used as the main IA buffer. Carbonate buffer 50 mM pH 8 and Tris Buffer 
50 mM pH 9.2 were used for fluorescence detection with alkaline phosphatase. The 
blocking solution consisted in 3% w/v protease-free BSA diluted in PBS buffer. For 
washings, PBS with 0.05% v/v of Tween-20 (Sigma-Aldrich, Dorset, UK) was used. 
The whole blood used was obtained from donation system at Loughborough University, 
Sports Department, and collected into 5 ml tubes with citrate phosphate as 
anticoagulant. 
The MicroCapillary Film (MCF) platform is fabricated from fluorinated ethylene 
propylene co-polymer (FEP-Teflon®) by melt-extrusion process by Lamina Dielectrics 
Ltd. (Billinghurst, West Sussex, UK). The number and internal diameter of the 
microcapillaries is easily controlled by the design of the die and the operational 
conditions set during the continuous melt-extrusion process. The two primary light 
sources used include an Auraglow AG166 Blue LED bulb, from Argos UK and an 
Ultraviolet Mini Lantern UV Fluorescent purchased from Mapplin UK. A 60x 
magnification attachment for iPhone® 4/4S purchased from Amazon (Slough, 
Berkshire) and a 50mm square dichroic additive green filter sourced from Edmund 
Optics (York, UK). 
6.3.2. MCFphone – System overview 
The MCFphone detection system is composed by a 10 bore fluoropolymer MCF strips 
pre-coated with immobilised CapAb and blocked with BSA protein (1), smartphone 
(iPhone® 4S, 8 megapixels camera) (2) integrated magnifying lens (3), light source 
(blue LED, with peak wavelength of 450 nm for chromogenic detection) (4), or UV 
black light for fluorescence detection (5), and a dichroic additive green filter (6) for 
fluorescence detection (Figure 6.1A). 
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Figure 6.1 - MCFphone system overview. 
A Main components of MCFphone (1) Microcapillary Film (MCF) (2) Smartphone (3) 
Magnifying lens (4) Blue LED (5) UV black light for fluorescence detection, light 
source for chromogenic detection (6) dichroic filter. B The Microcapillary Film (MCF), 
melt extruded from fluorinated-ethylene-propylene (FEP) copolymer (i) 5 meter MCF 
reel (ii) MCF cross section with 10*200 µm embedded in the FEP polymer. C 
MCFphone detection in operation (i) MCFphone components (ii) MCFphone 
colorimetric image of a sample and a reference strips filled up with 2,3-
diaminophenazine (DAP), the product of HRP conversion of o-Phenylenediamine 
dihydrochloride. 
141 
 
The MCF used consisted of a fluoropolymer melt-extruded plastic film with 10 
embedded parallel microcapillaries and a mean 200 µm internal diameter. Each strip has 
4.5 ±0.1 mm in width and 0.6 ± 0.05 mm depth (Figure 6.1B). This platform was first 
presented as a cost-effective microfluidic IA platform by Edwards et al. (2011); the 
hydrophobicity of FEP material allows simple yet effective immobilisation of 
antibodies by passive adsorption on the plastic surface of the microcapillaries, and the 
transparency of the MCF material results in high signal-to-noise ratios (Edwards et al., 
2011) which is fundamental for sensitive signal quantitation. 
The MCFphone working principle consists in illuminating the MCF test strip sample 
with a light source (blue LED for chromogenic detection and UV black light for 
fluorescence detection) and capturing the signal (digital image) with a smartphone 
camera attached with a magnifying lens (Figure 6.1C). The digital images were then 
analysed with Image J software (NIH, Maryland, USA) for colourimetric or 
fluorescence signal quantitation. 
6.3.3. PSA sandwich ELISA (Enzyme Linked ImmunoSorbent Assay) 
6.3.3.1. Fabrication of MCF test s trips  
A solution of 40 µg/ml of Human Kallikrein 3/PSA CapAb in PBS buffer was aspirated 
into a 100 cm lengh MCF and incubated for two hours at room temperature in a petri 
dish covered with a wet tissue to avoid evaporation of solution in the microcapillaries. 
A 3% BSA solution in PBS buffer was then aspirated and incubated in the MCF for an 
additional two hours at room temperature to block any additional binding sites in the 
microcapillaries. The MCF strip was then washed with 0.05% Tween in PBS, and 
stored in the fridge at 4 
o
C or used immediatetly. The MFC was then trimmed into 3 cm 
long test strips and interfaced with a single 1ml syringe using  a short 3 mm i.d. silicon 
tubing and a plastic clamp or integrated in a 8-channel multi-syringe aspirator; this 
semi-automatic device allows 8 test strips and a total of 80 capillaries to be filled 
simultaneously using a set of 1 ml plastic syringes with minimum training as described 
elsewhere.
152
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6.3.3.2. PSA sandwich assay 
The PSA sandwich assay consisted in pre-loading 150 µl of sample and IA reagents into 
each well in microplate especially designed to interface the MCF strips. The test strips 
were then immersed in microplate wells and solutions aspirated sequentialy by 
manually moving the piston plunger of the disposable syringe as illustrated in Figure 
6.2A. In all experiments shown in this paper 8 MCF strips were operated 
simultaneously based on the multi-syringe aspirator, which is capable of runing a 7 
point full response curve plus a control or analysing multiple samples simultaneously. 
From the perspective of end use, it only requires rotating the knob that controls the 
position of the piston plungers in the array of 1ml disposable syringes and moving the 
device along a multiplexed microplate containing all pre-loaded reagents. On each 
incubation step, about 78 µl of solution are aspirated corresponding to 6 full rotations of 
the knob. With this design, the total number of steps required to complete the PSA 
sandwich IA was reduced to 5, and all waste solutions were kept inside the 1ml 
disposable syringes throughout the assay. The incubation times used for PSA IA were 2, 
5, 5 and 1 minute for the sample, DetAb, enzyme and enzymatic substrate, respectively. 
The concentration of biotinylated DetAb was 1 µg/ml and PSA recombinant protein 
standards were diluted in PBS or whole blood where appropriate.  
For colorimetric detection, 1 µg/ml solution of high sensitivity streptavidin-HRP was 
used for enzymatic amplification, and the chromogenic substrate consisted of 4 mg/ml 
OPD and 1 mg/ml H2O2. Smartphone microphotographies of the MCF strips were taken 
with a iPhone® 4S at 20 seconds interval for a total of 2 minute after addition of the 
enzymatic substrate. For fluorescence detection, 2 µg/ml of alkaline phosphatase was 
diluted in carbonate buffer 50 mM pH 8, and the fluorescence enzymatic substrate 
consisted in 0.25 mM solution of fluorescent substrate FDP; the MCF strips were 
photographed at 60 seconds interval for a total of 10 minutes. On both colourimetric and 
fluorescence assays, the MCF strips were extensively washed with PBS-Tween before 
aspirating the enzymatic substrate. 
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Figure 6.2 - PSA sandwich assay with MCFphone signal quantitation. 
A PSA sandwich assay steps. B Colorimetric signal quantitation (i) RGB and green 
channel image (1 mg/ml) with reference strip (0.5 mg/ml) of 2,3-diaminophenazine 
(DAP) (ii) Correspondent grey scale analysis. C Fluorescence signal quantitation (i) 
RGB and green channel image (0.5 mM of fluorescein isothiocyanate, FITC, with 
reference strip of 0.125 mM) (ii) Correspondent grey scale analysis. 
6.3.4. Colorimetric and Fluorescence detection 
Accurate quantitation with smartphone cameras demands control of environment 
light,
256
, since the exposure time of the camera is automatically adjusted in response to 
the amount of light passing through the detection region.
194
 In order to control 
environmental light during colorimetric detection a small polyethylene box and a blue 
LED, with peak 450 nm emission (absorption peak for DAP) were set together. The 
blue LED was placed so that the light penetrated along the length of the channels rather 
than across them. However, even with the external environment light control, the light 
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passing through the detection region was not always consistent due to different 
absorbance of the samples. To eliminate the effect of different exposure times of the 
camera, all smartphone images were taken with a reference MCF strip (Figure 6.1B (i)) 
loaded with the final product of enzymatic conversion; the signal from this strip was 
then further used for data normalisation as detailed in section 6.3.5. 
To test for sensitivity of smartphone detection, MCF strips were filled with the 
chromogenic substance 2, 3-diaminophenazine (DAP, resulting from OPD enzymatic 
substrate conversion) in 1:2 serial dilution in distilled water, from 0.074 to 9.5 mM and 
imaged with the MCFphone. Sensitivity of the detection system was calculated by 
analysing the grey scale in the microphotographs of the MCF strips and adding 3 times 
the blank standard deviation to the blank value. This gives the minimum absorbance 
value detectable with the colorimetric setup, therefore setting the sensitivity of the 
system. 
Fluorescence quantitation was carried out in the dark using an Ultraviolet Mini Lantern 
UV to excite the fluorescence product in the microcapillaries. The UV light was placed 
under a mask with an aperture sufficient to place both the MCF strip sample and 
reference. The MCF strips were then overlap with a green dichroic additive filter 
allowing only the green colour (530 nm) to pass through and be capture by the 
smartphone placed on the top of the filter. 
Sensitivity of fluorescence detection mode was tested by filling up 8 MCF strips with 
1:2 serial dilution of Fluorescein Isothiocyanate (FITC) in distilled water in the 7.8 to 
500 µM concentration range. The strips were placed in the dark metal support according 
to fluorescence MCFphone detection setup and smartphone photographs recorded. In 
the same way to colorimetric system sensitivity, fluorescence sensitivity was calculated 
by adding 3 times the blank standard deviation to the blank after image analysis. 
6.3.5. Image Analysis 
The iPhone® 4S images were analysed with ImageJ software, and consisted in splitting 
the acquired RGB images into Red, Green and Blue (RGB) channels for both 
colorimetric and fluorescence detection modes. For colorimetric quantitation, the 
absorbance (Abs) was calculated from the mean pixel intensity in grey scale in the green 
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channel as shown in Figure 6.2B (i) based in equation  (6:1), where I0 is the mean grey 
scale intensity of the baseline and I is determined based on the difference between the 
baseline and the maximum grey scale peak height, h as seen in equation (6:2) (Figure 
6.2C (ii)). The microcapillaries in the MCF have a circular to elliptical geometry, 
therefore the transmittance images have a minimum grey scale intensity at the centre of 
the capillaries where the light path distance is maximum. The Abs value presented for 
each MCF sample studied is a mean Abs value calculated by averaging the whole array 
of 10 individual microcapillaries in each MCF strip. The Abs value for each strip was 
further normalised based on the Abs value of the reference strip in order to compensate 
for the automatic settings of the smartphone camera, yielding the Absorbance ratio, 
Absratio shown in equation (6:3). 
 
Abs = −log10 (
I
I0
) 
 (6:1) 
 
 I = I0 − h  (6:2) 
 
 
Abs Ratio =
Abssample,i
Absref
 
 (6:3) 
 
For fluorescence quantitation in the MCFphone, the split green channel image (Figure 
6.2C (i)) was used to produce a grey scale plot from where the fluorescence intensity, 
Iint was measured for each individual microcapillary in the MCF strips (Figure 6.2C 
(ii)). The intensity of the peaks for each capillary was then normalised by the mean 
intensity peak of the reference strip, Iint,ref thus eliminating variability of camera 
exposure settings. Consequently, fluorescence signal is presented as an average of 
fluorescence intensity ratio (fluorescence ratio) of the 10 capillaries in each MCF strip 
equation (6:4). 
 
Fluorescence ratio =
Iint,sample
Iint,ref
 
 (6:4) 
 
The LLoD was determined as the minimum concentration yielding a signal higher than 
the blank value plus 3 times the standard deviation of the blank. When appropriate this 
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value was calculate using a 4PL (4 parameter logistic model) best-fitted to the 
experimental response curve. 
6.3.6. Recovery PSA experiments from whole blood samples 
%Recovery was calculated for three different anticoagulated fresh whole blood samples 
(samples S1, S2 and S3) spiked with 0.74, 6.7 and 60 ng/ml of PSA recombinant 
protein. Fluorescence intensity was then determined in the MCFphone for the different 
blood samples using procedure described in section 6.3.5. The %Recovery was 
calculated based on the ratio of the Abs or fluorescence signal in assay buffer to the 
signal in the blood sample in percentage basis. A iPhone® 5s was used to 
microphotograph the MCF test strips. 
6.4. Results and Discussion 
6.4.1. Sensitivity of MCFphone for detection of chromogenic and 
chemifluorescence substrates 
Optical detection based on simple and cost-effective technologies like a smartphone 
demands specific optical properties from the assay platform to be able to use small 
changes in transmitted light intensity for analyte quantitation. The MCF fluoropolymer 
has special optical properties, such as high degree of transparency obtained by a 
matched refractive index of FEP material with an aqueous sample, combined with the 
film flat geometry that minimises light diffraction, reflection or scattering.
127
 This 
favours sensitive IAs that combined with short diffusion distances yields a powerful 
miniaturised and portable POC IA concept. 
Colorimetric detection is inherently less sensitive than fluorescence, due to fundamental 
limitations of colorimetry itself. From one hand, in order to measure low concentrations 
of a chromogen, small differences in intensity must be measured at high light intensity, 
which limits the LLoD. On the other hand, relationship between optical Abs and 
intensity of transmitted light is logarithmic. Therefore, at high chromogen 
concentrations relatively large differences in optical absorbance correspond to small 
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differences in the intensity of unabsorbed light, which usually corresponds to narrow 
dynamic range for IAs.
108
 However, colorimetric detection is still widely used in IAs, 
offering speed, simplicity, well established assay chemistry and high quality reagents, 
and widespread availability of cost-effective readers. For this reason researchers still 
focused in finding new ways to increase the performance of colorimetric detection, for 
example through enzymatic amplification systems.
109,110
 Besides being inherently less 
sensitive, colorimetric detection sensitivity can also be limited by the working range of 
the instrument.  
In our recent study, we have measured PSA in biological samples in less than 15 
minutes using a flatbed scanner (Barbosa et al, 2014).
152
 In this study we aimed turning 
the “Lab-in-a briefcase” power-free, by using a portable detection system. 
Understanding the sensitivity and dynamic range of colorimetric measurement using the 
MCFphone setup is therefore fundamentally important, since performance for 
absorbance measurement will limit the working range and sensitivity of MCF IAs. As a 
benchmark, a spectrophotometer was used to measure a range of concentrations of 
DAP, the chromogenic product of enzymatic conversion of the substrate OPD 
commonly used in enzyme-linked immunosorbent assays (ELISA). At the peak 
absorption of 425 nm (Figure 6.3A), the spectrophotometer has a LLoD of < 2.3 µM of 
DAP (Figure 6.3B). In contrast, the MCFphone sensitivity for DAP measurement was 
148 µM (Figure 6.3C), i.e. 2 orders of magnitude less sensitive than a sophisticated 
spectrophotometer with a 1 cm thick cuvette. This drop in sensitivity can be accounted 
for by the broad wavelengths measured of RGB system, compared to the specific 
narrow wavelength selection in a spectrophotometer. Also, the MCFphone presents a 
50-fold reduction in the light path when compared to the spectrophotometer cuvette, 
which reduces the absolute absorbance for any concentration of a chromogen.  
Sophisticated benchtop instruments allow higher sensitivity measurement for 
colorimetric substrates, however they are not suitable for POC. Clinical relevant 
sensitivities from colorimetric portable detection system must therefore be achieved by 
assay optimisation, for example using enzymatic amplification, as previously observed 
in ELISA systems, and as demonstrated in the PSA assay results presented in this paper. 
Fluorescence detection systems are characteristically more sensitive since they are 
measured relatively to an absence of light.
108
 The MCF phone fluorescence calibration 
curve, presented a dynamic range of 7.8-500 µM for FITC and a LLoD below 7.8 µM 
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(Figure 6.3D). The fluorescence detection system selected for further study with PSA 
IAs uses UV light which emits radiation between 340 and 400 nm to excite fluorescein 
to emit green light at 530 nm. Although this reduces the absorbance efficiency 
compared to excitation at the peak absorbance of around 480 nm, this system exploits a 
large stokes shift resulting in a large increase from excitation to emission wavelength, 
thus eliminating the interference of the incident light with the image acquired by the 
smartphone which is very insensitive to UV light. This system does not require the use 
of an expensive bandpass filter, further increasing the simplicity of the optics. 
Combined with a good quantum efficiency fluorescein is an attractive substrate.
39
  
The MCFphone achieved similar sensitivity with fluorescence detection to absorbance 
measurement in the bench-top spectrophotometer, allowing sensitive and portable 
measurement and justifying the use of fluorescence detection in microfluidic IAs.
148,260
 
The MCFphone is a flexible detection system, with a choice of rapid colour detection or 
sensitive fluorescence detection that can be selected to suit different applications. 
 
Figure 6.3 - Sensitivity of MCFphone for colorimetric and fluorescence detection.  
A Absorption spectrum of 2,3-diaminophenazine (DAP). B Sensitivity of 
spectrophotometer DAP relative. C MCFphone chromogenic sensitity determination 
(DAP serial dilution). D MCFphone fluorescence sensitivity determination (fluorescein 
isothiocyanate, FITC serial dilution). 
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Sophisticated benchtop instruments allow higher sensitivity measurement for 
colorimetric substrates, however they are not suitable for POC. Clinical relevant 
sensitivities from colorimetric portable detection system must therefore be achieved by 
assay optimisation, for example using enzymatic amplification, as previously observed 
in ELISA systems, and as demonstrated in the PSA assay results presented in this paper. 
Fluorescence detection systems are characteristically more sensitive since they are 
measured relatively to an absence of light.
108
 The MCF phone fluorescence calibration 
curve, presented a dynamic range of 7.8-500 µM for FITC and a LLoD below 7.8 µM 
(Figure 6.3D). The fluorescence detection system selected for further study with PSA 
IAs uses UV light which emits radiation between 340 and 400 nm to excite fluorescein 
to emit green light at 530 nm. Although this reduces the absorbance efficiency 
compared to excitation at the peak absorbance of around 480 nm, this system exploits a 
large stokes shift resulting in a large increase from excitation to emission wavelength, 
thus eliminating the interference of the incident light with the image acquired by the 
smartphone which is very insensitive to UV light. This system does not require the use 
of an expensive bandpass filter, further increasing the simplicity of the optics. 
Combined with a good quantum efficiency fluorescein is an attractive substrate.
39
  
The MCFphone achieved similar sensitivity with fluorescence detection to absorbance 
measurement in the bench-top spectrophotometer, allowing sensitive and portable 
measurement and justifying the use of fluorescence detection in microfluidic IAs.
148,260
 
The MCFphone is a flexible detection system, with a choice of rapid colour detection or 
sensitive fluorescence detection that can be selected to suit different applications. 
6.4.2. Effect of Enzyme on sensitivity of PSA sandwich ELISA in the MCFphone 
Enzymes are the most versatile and common group of labelling substances used in 
IAs.
108
 Macromolecules are measurable at very low concentrations typically in the 
picomolar to femtomolar range by utilizing its catalytic properties to generate coloured, 
fluorescent, or luminescent compounds from a neutral substrate. A single enzyme 
molecule may cause the conversion of 10
7
 molecules of substrate per minute, increasing 
the strength of the signal and therefore the sensitivity by a million-fold when compared 
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to a label that produces just a signal event.
39
 When enzymes are associated with 
antibodies in a sandwich IAs, the most specific and sensitive type of heterogeneous 
IAs,
29
 a powerful analytical tool is produced.  
Although the colorimetric substrate measurement in the MCFphone was about 2 orders 
of magnitude less sensitive than the benchtop spectrophotometer, this system was still 
able to quantify PSA in its clinical relevant range (i.e. a clinical threshold of >4 ng/ml 
requiring further examination) with LLoD of 0.9 ng/ml PSA (Figure 6.4A) in 13 
minutes total assay time reaction time is important for POC applications, where quick 
tests are required.  
 
Figure 6.4 - PSA full response curves in buffer, with MCFphone colorimetric and 
fluorescence systems. 
A PSA MCFphone colorimetric quantitation: (i) RGB and green channel digital images, 
and (ii) full response curve, showing a lower limit of detection, LLoD < 0.9 ng/ml PSA. 
B PSA MCFphone fluorescence quantitation: (i) RGB and green channel digital images, 
and (ii) full response curve with LLoD clearly below 0.9 ng/ml of PSA. 
 
In conventional microtiter plate based ELISA high sensitivity is achieved using long 
incubation times and long assay times, however kinetic studies in MCF platform 
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showed that is possible to achieve high sensitivity with short incubation times and that 
long incubation times will actually increase the background decreasing sensitivity. 
Therefore, short incubation times favoured higher signal-to-noise-ratios in the PSA IA. 
Despite previous optimization of PSA assay, the best sensitivity was achieved by 
combining a sandwich heterogeneous assay format with a horseradish peroxidase (HRP) 
label. HRP has a high turnover number and due to short diffusion distance of capillaries 
it was possible to increase the OPD substrate concentration and optimize the molar ratio 
of OPD to H2O2 contributing to faster and higher signal amplification and compensating 
for the lower sensitivity of colorimetric MCFphone readout. 
Fluorescence measurement using the MCFphone gave greater sensitivity than 
colorimetric, achieving similar LLoD to the benchtop spectophometer. This increased 
sensitivity resulted in even greater assay sensitivity when a full PSA response curve was 
tested (Figure 6.4B) and a LLoD of 0.08 ng/ml PSA was achieved. The increased 
sensitivity of the assay can be attributed to fluorescence detection combined with other 
factors including the alkaline phosphatase label that like HRP has high enzymatic 
turnover and the ability of the fluorogenic product (fluorescein) to absorb UV radiation 
around 380 nm and emit green radiation around 530 nm, which was enhanced with the 
use of the dichroic additive green filter. 
Although fluorescence detection increased sensitivity, the fluorogenic substrate 
incubation time was longer than that for the chromogenic substrate (i.e. 10 versus 1 
minute), due to differences in reaction rates of the two enzymes. Further optimisation 
may be required to reduce the overall assay time, and previous work with HRP has 
demonstrated the improvements to assay time and sensitivity that are possible with 
systematic assay optimisation in MCF IAs.
152
  
Similar studies measured PSA with a microfluidic device incorporating colorimetric 
smartphone detection, and reported 3.2 ng/ml PSA as the LLoD in 30 minutes total 
assay time using magnetic microbeads,
103
 thus a 3.5 lower sensitivity for double of the 
assay time compared to the MCFphone. 
Fluorescent measurements performed with the immuno-pillar microfluidic platform 
reported a LLoD of 0.1 ng/ml in 12 minutes total assay time, which means similar 
sensitivity, but double of time for fluorescence detection on MCFphone. However, it is 
important to emphasise that the detection equipment used to quantify PSA in the 
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immuno-pillar platform was an inverted fluorescence microscope, which is not portable, 
cost-effective or power-free, therefore not suitable for POC applications.
58
 An 
immunochromatographic test integrated with a Laser Fluorescence Scanner was able to 
detect PSA in biological samples with a lower limit of detection of 0.02 ng/ml PSA in 
15 minutes total assay time.
228
 This assay was able to obtain better sensitivity than the 
MCFphone in less time. Nevertheless, lateral flow tests have certain limitation 
compared with microfluidic devices, for example they lack the possibility to perform 
calibration curves in simultaneous with the samples,
229
 which can be an important 
feature for biomarker quantitation at POC. Besides the drawbacks of lateral flow 
technology, the Laser Fluorescence Scanner is not as flexible as a smartphone, since it 
can be used for colorimetric detection, for data analysis and for results communication 
all in one single power-free and portable device, which is quickly becoming a cost-
effective equipment. In addition, this is the first time to our knowledge that a 
smartphone is used to quantify fluorescence in a sandwich ELISA assay. 
6.4.3. PSA measurement in whole blood samples 
In POC testing, sample processing needs to be minimised or eliminated to speed up the 
diagnostic process,
234
 so whole blood samples are preferred. However, whole blood has 
one of the most complex matrices, with interference possible due to serum proteins that 
can bind non-specifically to analytes, antibodies or surfaces.
237
 This biological fluid also 
presents a high viscosity that can alter the binding efficiency 
235
 and the diffusion time 
of the analyte to the immobilised antibody. Significant work has been published 
describing methods to overcome the effect of biological matrices in order to achieve 
robust assay sensitivity and reproducibility in other laboratory and POC assay 
platforms.
237
 Matrix effects are system specific, depending on matrix type, detection 
method, antibody system and platform. The matrix effect has already been reported by 
our research group for sandwich ELISA detection of PSA in whole blood in the MCF 
platform using a flatbed scanner readout system.
152
 From these studies we concluded 
that PSA could be accurately quantified in whole blood samples in the MCF platform. 
However, non-diluted whole blood matrices did show lower signals for the same 
incubation times as buffer matrices. This signal reduction could be overcome either by 
dilution or by extended sample incubation times. As the aim of this work is to create a 
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rapid POC diagnostic system, sample dilution was chosen here instead of extended 
sample incubation times to maintain the sensitivity and reproducibility of PSA assay in 
biological samples and restrict total assay time. Sample dilution is often used in 
serology and does not represent an additional step in the assays, as the sample wells can 
be provided with diluent buffer. 
In this study, the MCFphone fluorescence detection system was used to quantify PSA 
from diluted whole blood (Figure 6.5). The sensitivity calculated and assay signal were 
in the same order of magnitude (Figure 6.5A and Table 6:1) when compared to the 
assay performed in buffer across all the PSA assay range.  
Table 6:1 - Sensitivity comparison between MCFphone colorimetric and fluorescence 
PSA assay. 
 
Further experiment using whole blood from 3 additional patients showed a %Recovery 
very consistent when spiked with PSA concentration in the low linear range (0.74 
ng/ml), middle range (6.7 ng/ml) and higher linear range (60.0 ng/ml). In all cases, 
%Recovery values calculated for the different whole blood samples remained within 80-
120%, which is regarded as the desirable range, with the exception of S2 spiked with 
60.0 ng/ml of PSA which returned 74.2%. This ultimately demonstrates the MCFphone 
as an efficient PSA measurement system from fresh anticoagulated whole blood 
samples, simplifying sample preparation required for clinical testing. Future studies will 
aim understanding blood matrix effect on variability between samples, and test the 
MCFphone with patients diagnosed with prostate cancer.  
 Lowest PSA conc. 
tested (ng/ml) 
Data correlation 
with 4PL model (R
2
) 
LLoD (ng/ml) Precision 
PSA colour assay  0.9 0.9979 0.40 7% at 15ng/ml 
PSA 
PSA fluorescent 
assay 
0.9 0.9933 0.08 8% at 15 ng/ml 
PSA 
PSA fluorescent 
assay in whole blood 
0.08 0.9978 0.04 11% at 2.2 ng/ml 
PSA 
154 
 
 
Figure 6.5 - Smartphone fluorescence detection of PSA in the MCF in whole blood. 
A Full response curve using 1:3 dilution series. B Comparison between PSA sandwich 
assay in buffer and 50% whole blood. C %Recovery for 3 different blood samples from 
female donors spiked with 3 different concentrations of recombinant protein (PSA), 
0.74, 6.7 and 60 ng/ml. Average coefficient of variation different samples % of recovery 
is 12% for 0.74 ng/ml PSA, is 15% for 6.7 ng/ml PSA and 16% for  60 ng/ml PSA. 
6.5. Conclusions 
The MCFphone is a flexible, power-free and portable IA detection system capable of 
rapid colorimetric detection and sensitive fluorescence detection from whole blood 
samples. In this present study, the MCFphone was able to detect and quantify PSA 
within the dynamic range of 0.9 to 60 ng/ml PSA in 13 minutes, using colorimetric 
detection and within 0.08 ng/ml to 60 ng/ml of PSA, using fluorescence detection from 
whole blood samples. Considering the PSA clinical range of 4 ng/ml for prostate 
biopsy, this device can provide reliable measurements for prostate cancer screening and 
155 
 
detection in remote areas outside laboratory facilities. Further improvements in 
fluorescence sensitivity could be obtained with optimization of enzymatic reaction, a 
more robust and intense UV light source and filters, as well as higher resolution 
smartphone cameras. Automation of multistep ELISA and further integration and 
miniaturisation of all fluidic and optoelectronics components will addressed in future 
publications with the MCFphone concept. 
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7. Managing biological matrix interference in 
microfluidic microcapillaries 
7.1.  Abstract  
In this study it was shown that was possible to eliminate the sample matrix effect in the 
Microcapillary Film (MCF), a novel FEP-Teflon platform for rapid immunoassays (IA). 
This was achieved without any sample preparation in three different sandwich assays 
systems: mouse IgG-anti-IgG, PSA (prostate specific antigen) and IL-1β cytokine. The 
choice of appropriated capture antibody (CapAb) coverage and sample incubation time 
enabled the biological matrix interference elimination in the MCF sandwich assays. 
Other variables were studied in order to understand biological sample interference in 
microcapillaries, such as viscosity and diffusion distance. It was found that viscosity 
interferes with antibody-antigen binding kinetics, but not with the reaction equilibrium. 
While diffusion distance, in this system, was intrinsically related with CapAb surface 
coverage, therefore reducing the diffusion distance altered the antibody-antigen 
equilibrium.  
Comparison between IL-1β sandwich assay in whole blood and human serum shows 
similar absorbance values, which suggests blood cells do not interfere with IA in FEP-
Teflon microcapillaries.  
The possibility of performing quantitative sandwich assays without any type of sample 
preparation has not been previously reported in literature and it can bring microfluidic 
diagnostic research for Point-of-Care (POC) closer to commercialisation. 
Immunoassays (IA) are analytical tools that use the unique capacity of antibodies to 
specifically recognize and bind an antigen.
21
 In diagnostics the antigen/analyte (the 
target specimen to be quantitated) is diluted in a biological matrix which can be saliva, 
urine, plasma, serum or blood. The influence of  biological sample properties on the 
measurement is named matrix effect of an assay.
261
 These effects are responsible for 
erroneous diagnostics of certain diseases, with false positive and negative results, 
leading to unnecessary treatment or mistreatment of certain conditions. Understanding 
the biological matrix interference and finding strategies to overcome it is therefore a 
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paramount in diagnostic industry, especially for Point-of-Care (POC) diagnostic tests 
where minimal sample treatment is required.
262,263
  
The main protein biomarkers currently used in diagnostics, are prostate specific antigen 
(PSA) for prostate cancer diagnostics, cardiac markers (troponin I and T, BMP, C 
reactive protein) for cardiovascular accident risk assessment, and cytokine biomarkers 
for sepsis and other inflammatory diseases, all measured from blood samples. Blood is a 
highly complex matrix with cellular components ranging in size between 2 µm 
(platelets) to 20 µm (leukocytes) and a very heterogeneous liquid fraction, plasma, 
constituted by water (92%), proteins (8%) and other substances in traceable amounts.
237
 
Important plasma proteins include serum albumin, immunoglobulins (antibodies), blood 
clothing factors (e.g. fibrinogen) and lipoproteins.  
Blood components can interfere in IA, as they change the physical properties of the 
medium where the analyte is dissolved, such as viscosity, pH or salt concentration. 
Small changes in blood properties can change the binding efficiency of the 
antigen/analyte to the bioanalytical antibodies when compared to the same reaction in a 
different medium.
235,237
 Also some proteins, such as hormones and antibodies, and 
anticoagulants can bind the analyte decreasing its available concentration in solution. 
For example steroids can bind to sex hormone binding globulin
264
 and prevalent 
autoantibodies to tyroid hormones in non-tyroid autoimmune conditions have been 
reported.
265
 Some other blood compounds, such as heterophilic antibodies (antibodies 
produced against poorly defined antigens presenting low affinity and weak binding)
266
 
interfer with the assay by binding to the immobilised bioanalytical antibody or the label 
antibody in two site sandwich IAs. When the heterophilic antibody, bond to the CapAb, 
binds to the label antibody, the assay yields false positives. On the contrary, if the 
heterophilic antibody, bond to the CapAb, does not allow the analyte and the label 
antibody to bind, it will promote false negative results.
262,263
 Interfering antibodies are 
called heterophilic when they are multispecific and the host individual has not been 
treated with animal immunoglobulins.
267
 Human anti-animal antibodies (HAAA) are 
generated when the immune system is in contact with animal antibodies. These 
antibodies show high affinity and compete with the test antigen by cross-reacting with 
the bionalytical antibodies of the same species.
268
 Other plasma proteins such as 
albumin, lysozyme, fibrogen and paraprotein can interfere with bioanalytical reagents in 
IAs. 
269
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Studies of antibody interference (heterophilic and human anti-animal antibodies) in IAs 
indicate low interference prevalence from 0.03 to 6%.
270,271
 However, a study by 
Boscato et al. (1986) showed that analyte antibody binding substances were detected in 
40% of studied samples (688 samples) causing 15% interference in assays.
272
  
Techniques for minimizing antibody interferences in IAs include gel chromatography, 
immunoextraction, precipitation, centrifugation, filtration and heat-treatment. These 
sample pre-treatment techniques aim to remove the assay interfering 
antibody/substances.
237,273,274
 Other simple techniques rely on the addition of blocking 
reagents to the sample or directly to the assay as sample diluents.
272,273,275
 Sample 
dilution is another approach for minimizing interferences and it has been reported to be 
effective even in sensitive systems.
276–278
 However, matrix dilutions also implies analyte 
dilution, therefore compromising assay sensitivity and simplicity.  
Recently, quantitative diagnostics have been translated to POC miniaturized platforms, 
which aim for sensitive, rapid and cost effective diagnostics. Microfluidic IAs platforms 
are the most common attempt for quantitative POC IAs due to their large surface-area-
to-volume ratio (SAV) allowing fast and sensitive IAs.  
In POC diagnostics, sample preparation needs to be minimized to speed up the test and 
eliminate extra cost. Whole blood and urine are the most common sample types,
234
 yet, 
microfluidics research has focused its attention on the improvement of the analytical 
reaction, with sample pre-treatment still being performed off chip. deMello et al. (2003) 
reviewed several microfluidic device structures that could possibly integrate sample 
processing treatment with bioanalytical purposes, like the micro-filter with pillars 3 µm 
wide and 50 µm surrounding reaction chambers allowing 500 pL sample volumes, for 
separation of interfering substances from the analyte;
279
 and a lateral percolation filter, 
where the sample penetrates a filter bed and particulates with dimensions larger than the 
minimum filter features (1.5 mm) were successfully restricted.
280
 Another approach is 
the H-filter where two different laminar flow fluids (carrier stream and diluent stream) 
are brought together in a central channel and filtration occurs due to the different 
diffusion coefficients of molecules.
281
 Other microfluidic adaptations of liquid/liquid 
extraction and solid phase extraction have been fully reviewed.
282
 
Although laboratories have to deal with biological sample interference, the nature of 
this interference is still not currently clear. This lack of knowledge extends to 
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microfluidic IAs, since they are a relatively new approach to diagnostics. Previous 
studies of PSA sandwich assay in the MCF platform have shown it is possible to 
manage human serum and whole blood matrix interference in MCF platform through 
sample dilution or by extending sample incubation times. This relates the matrix 
interference effect with the viscosity increment of the medium where antibody-antigen 
binding reaction occurs.
152,153
 
This study aims at extending the knowledge and understanding of matrix interference 
effect in microfluidic IA, by presenting sample interference effects and strategies to 
overcome it, in three different systems: mouse IgG/anti-IgG direct assay, PSA sandwich 
assay and IL-1β cytokine sandwich assay in FEP-Teflon microcapillaries. In our 
approach by changing the capillary diameter, the antibody immobilised density and the 
sample incubation time is possible to minimize or even overcome the biological 
samples matrix effect in IA. This will eliminate the need of sample preparation for POC 
diagnostics. The experiments in this study were performed in the MCF platform (Figure 
7:1A), which consists in flat fluoropolymer film with 10 parallel microcapillaries 
embedded on it. Since the nature of the matrix effect is not clear, it was assumed the 
biological matrix effect was caused by one factor, named the interfering factor (Figure 
7:1B). 
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Figure 7:1 – Biological matrix effect in microcapillaries. 
A Three different MCFs with mean 378, 223, 128 µm bore diameter were used for solid 
phase IAs. The capillaries are filled with a food dye for clarity. B Components of a solid 
phase immunoassay in a capillary. The interfering factor is substance from the 
biological matrix which interferes in the assay in an unknown way.  
7.2. Materials an Methods 
7.2.1. Materials & Reagents 
Mouse IgG (whole antibody) was purchased from Life Technologies (Paisley 
UK), rabbit anti-IgG (whole molecule) conjugated with peroxidase and SIGMAFAST
TM
 
OPD (o-Phenylenediamine dihydrochloride) tablets were supplied from Sigma-Aldrich 
(Dorset, UK). The BCA Protein Assay Reagent (bicinchoninic acid) was purchase from 
Thermo Scientific (Lutterworth, UK). The IL-1β recombinant protein, Anti-Human IL-
1β biotin and Anti-Human IL-1β purified were supplied from eBiosciences (Hatfield, 
UK). High sensitivity streptavidin-HRP was supplied by Thermo Scientific 
(Lutterworth, UK). Human kallikrein 3/ Prostate Specific Antigen (PSA) ELISA kit was 
purchased from R&D Systems (Minneapolis, USA). The kit contained a monoclonal 
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mouse Human Kallikrein 3/PSA antibody (CapAb), a Human Kallikrein 3/PSA 
polyclonal biotinylated antibody (DetAb) and recombinant Human Kallikrein 3/PSA 
(standard). 
Phosphate buffered solution (PBS) and Bovine Serum Albumin (BSA) were sourced 
from Sigma Aldrich (Dorset, UK). PBS pH 7.4, 10mM was used as the main 
experimental buffer. The blocking solutions consisted in 3% w/v protease-free BSA 
diluted in PBS buffer and a Super Blocking solution purchased by Thermo scientific 
(Lutterworth, UK). For washings, PBS with 0.05% v/v of Tween-20 (Sigma-Aldrich, 
Dorset, UK) was used. A female human serum was supplied from BBI solutions 
(Cardiff, UK), aliquot and storage at -20ºC. The human blood was collected into a 5 ml 
vial with citrate phosphate dextrose (CPD) as anti-coagulant, supplied by healthy 
volunteers at Loughborough University.  
The MCFs were fabricated from fluorinated ethylene propylene co-polymer (FEP-
Teflon) by melt-extrusion process by Lamina Dielectrics Ltd. (Billinghurst, West 
Sussex, UK), presenting 10 parallel microcapillaries. Different MCFs were used in this 
study with mean hidraulic diameter of 128±11 µm, 223±23 µm, 378± 40 µm.  
7.2.2. Sample matrix viscosity effect on kinetics of antibody-antigen binding  
Eight MCF strips with 223±23 µm bore diameter were loaded with 40 µg/ml of IL-1β 
CapAb and incubated for 2h at room temperature. This solution was replaced by the 
super blocking solution, incubated for an additional 2h at room temperature. The MCF 
strips were washed with 1 ml of PBS-Tween, the washing buffer and trimmed into 3 cm 
length test strips. The test strips were introduced into the Multiple Syringe Aspirator 
(MSA), a fluid handling device that allows simultaneous aspiration of solutions into 
eight different MCF strips, presented elsewhere.
152
  
Three different solutions of BSA with concentrations of 5, 10 and 25 w/v % were used 
as sample diluents for viscosity increment. Four solutions of 1 ng/ml and 0.1 ng/ml of 
IL-1β recombinant protein were prepared using as sample diluent PBS buffer, 5, 10 and 
25 % of BSA in PBS. These solutions were aspirated into the coated and blocked MCF 
strips connected to the MSA and left to incubate for variable incubation times of 0, 2, 5, 
10, 15 and 30 minutes. For each sample incubation time negative controls, 0 ng/ml of 
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IL-1β, with the different diluents used were performed simultaneously with the positive 
controls. After a washing step, a monoclonal anti-IL-1β biotinylated DetAb was added 
to the MCF test strips and incubated for 10 min followed by another washing step. A 
solution of 4 µg/ml of high sensitivity streptavidin horseradish peroxidase (HRP) was 
aspirated into the capillaries and incubated for 10 min followed by an intensive washing 
step. A 4 mg/ml solution of OPD enzymatic substrate replaced the washing buffer and 
was incubated for 5 min.  
7.2.3. Viscosity measurements 
A U-tube viscometer, size B (nominal constant = 0.01cSt/s), supplied from Technico, 
was used to measure kinematic viscosity (cSt or 1 mm
2
.s
−1
) of PBS, BSA (5, 10 and 
25%) and serum dilution solutions. The solutions were filled into a tube in a water bath 
with temperature control set at 20ºC. The time (seconds) for the liquid to move from 
distance X to Y in the U-tube was measured 3 times for each sample. 
The density of each sample was determined by weighing the sample liquid into a vial 
and determining the volume of the vial by weighing distilled water. Since the density of 
the water is 1g/cm
3
, it was assumed its weight was proportional to its volume. Each 
measurement was performed 3 times in a temperature controlled room. The dynamic 
viscosity (µ) in mPa.s (=0.001Kg.m-1.s-1) or c.p. (centipoise) was obtained by 
multiplying the kinematic viscosity (v) of the sample in cSt (=1E
-6
.m
2
/s) by the sample 
density in kg/dm
3
. 
7.2.4. Capillary diameter effect on kinetics of antibody-antigen binding in biological 
matrices  
Several transversal sections of three FEP-Teflon MCFs with different bore diameter 
were trimmed and a long focal distant point microscope was used for imaging. ImageJ 
software was used to measure the diameter of the 10 capillaries from the 
microphotographs.  
A solution of 200 µg/ml of mouse IgG was filled into three different diameter (128, 223 
and 378 µm) MCF strips with 35 cm each. A negative control strip was filled with PBS 
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buffer. The solutions were incubated for 30 minutes at room temperature and washed 
with 1 ml of PBS-Tween. A solution of 0.6 µg/ml of mouse anti-IgG peroxidase 
conjugated, prepared in PBS buffer, was added to the MCF strip and 4 cm strips were 
trimmed and washed with PBS-Tween after 1, 2, 4,6,8 and 10 minutes of incubation 
anti-IgG. A 1 mg/ml solution of OPD substrate was added to the strips and digital 
images taken with a flatbed scanner after 5, 10, 15 and 20 minutes of enzymatic 
substrate incubation. The procedure was repeated for 0.6 µg/ml mouse anti-IgG 
peroxidase conjugated solutions prepared in non diluted human serum.  
7.2.5. Mass determination of mouse IgG adsorbed by solution depletion technique 
in variable size MCF 
Three MCF strips with 20 cm length and 223 ± 23 µm were filled with 200 µg/ml of 
mouse IgG solution and incubated for 2 hours at room temperature. The solution was 
then collected inside the capillaries for protein quantitation.  
A 1:2 serial dilution solutions of mouse IgG from 0 to 400 µg/ml were prepared for 
protein quantitation in a calibration curve. Triplicates of 25 µl of each collected solution 
were placed in a microwell plate and 200 µl of BCA working reagent (1 reagent B: 50 
reagent A) was added to each sample well and mixed for 5 sec with a multiple 
micropipette. Simultaneously 25 µl of IgG solution was placed in a microwell and 
mixed with 200 µl of BCA working reagent (1:50). The microwell plate was covered 
with parafilm and placed at 37 ºC for 3 hours. IgG standards were prepared in 
triplicates.  
After 3 h incubation of IgG standards and samples with BCA working reagent, the 
microtriter plate was left for a few minutes at room temperature to cool down. The end 
point absorbance measurements were made at 562 nm in each well with the microplate 
reader (Epoch, BIOTEK).  
The concentration of IgG adsorbed (µg/ml) was obtained by equation (7:1) and the 
conversation for adsorbed concentration to adsorbed density (ng/cm2) was made 
through equation (7:2). 
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 [Ads IgG] = [Inicial IgG solution] − [Remain IgG solution] (7:1) 
 
 SA
V
=
2πrl
πr2l
=
4
D
 
(7:2) 
 
Where SA is the surface area, V is the volume and D is the diameter of the capillary. 
The quantitation of IgG adsorbed with 200 µg/ml IgG solution was performed, using the 
same method for 80 cm long strips of 128± 11 µm diameter and for 8 cm length strips 
of 378± 40µm MCF diameter.  
7.2.6. Overcoming biological sample matrix in MCF platform – three antibody-
antigen systems 
In order to understand the effect of antibody surface coverage and sample incubation 
time (related to diffusion distance) in overcoming the biological matrix effect in MCF 
IA, three different assays (mouse IgG/anti-mouse IgG, PSA and IL-1β assay) were 
studied in 223 µm diameter bore MCF. In the three systems two sets of experiments 
were performed, one that relates the immobilise antibody surface coverage for shorter 
and long sample incubation times with the biological matrix effect and another set of 
experiments, directed for sandwich assays full response curves.  
Surface coverage studies and sample incubation time 
For the mouse IgG/anti-mouse IgG system study of the effect of surface coverage in the 
biological matrix interference, eleven MCF strips, with 223 µm diameter and 8 cm 
length, were filled with eleven different solutions of mouse IgG: 0, 0.1, 1, 4, 8, 12, 16, 
25, 50, 100, 200 µg/ml. These solutions were incubated for 30 minutes at room 
temperature, followed by a wash step. The MCF strips were trimmed into 3 cm strips 
and were placed in the Multiple Syringe Aspirator (MSA). A solution of 0.6 µg/ml of 
anti-IgG peroxidase conjugated, prepared in PBS buffer, replaced the wash buffer and 
was incubated for 10 minutes, followed by another washing step. A solution of 1 mg/ml 
of OPD enzymatic substrate was aspirated into the MCF strips and the MSA was placed 
on the flatbed scanner. Digital images were taken for 5, 10, 15, 20, 25 and 30 minutes of 
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enzymatic substrate incubation time. The same procedure was repeated for anti-IgG 
solutions prepared in 100% human serum.  
For the PSA sandwich assay system study of the effect of surface coverage in the 
biological matrix interference, eight MCF strips, with 223 µm diameter and 8 cm length, 
were filled with eight different solutions of PSA CapAb and incubated for 2 hours at 
room temperature. The strips were then filled with 3% BSA solution which was also 
incubated inside the capillaries for 2 hours at room temperature, followed by a washing 
step. The MCF strips were trimmed into 3 cm test strips and placed in the MSA, for 
simultaneous fill of eight MCF test strips. A solution of 3.75 ng/ml of PSA standard was 
prepared in PBS buffer, aspirated into the MCF strips and incubated for 30 minutes, 
followed by a wash step. A solution of 1 µg/ml of biotinylated detection antibody 
(DetAb) replaced the wash buffer and was incubated for 5 minutes, replaced by a 
solution of 1 µg/ml of enzyme incubated for 5 minutes. An intensive washing step was 
performed and a solution of 4 mg/ml of OPD filled the MCF test strips. The MSA was 
placed on the flatbed scanner and digital images were taken in 1, 3, 5, 10, 15, 20, 25, 30 
minutes of enzymatic substrate incubation. The procedure was repeated for PSA 
standards prepared in 100% human serum.  
For the IL-1β sandwich assay system study of the effect of surface coverage in the 
biological matrix interference, eight MCF strips, with 223 µm diameter and 16 cm 
length, were filled with eight different solutions of IL-1β CapAb: 0, 5, 10, 20, 40, 80, 
100 and 200 µg/ml. Solutions were incubated for 2 hours at room temperature. The 
strips were then filled with super block solution also incubated for 2 hours at room 
temperature. The MCF strips were trimmed into 3 cm test strips and eight of them, with 
eight different concentration of CapAb, were placed in the MSA. A solution of 0.125 
ng/ml of IL-1β recombinant protein was prepared in buffer and incubated for 5 minutes, 
followed by a washing step. A solution of 10 µg/ml of biotinylated DetAb was 
incubated for 10 minutes followed by a washing step. A 4 µg/ml solution of enzyme 
was added to the test strips and incubated for 10 minutes followed by an intensive 
washing step. A solution of 4 mg/ml of OPD enzymatic substrate was added to the 
strips and the MSA was placed on the flatbed scanner. Digital images were taken at 2, 5, 
10, 15, 20, 25 and 30 minutes of OPD incubation. The procedure was repeated for 0.125 
ng/ml of IL-1β in 100% human serum and for 0.125 ng/ml of IL-1β incubated for 30 
minutes (instead of 5minutes) in buffer and 100% human serum.  
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Full response curves 
For the PSA (prostate specific antigen) sandwich assay two MCF strips with 223 ± 23 
µm diameter and 30 cm length were filled with 10 µg/ml of PSA CapAb and incubated 
for 2 hours at room temperature. This solution was replaced by 3%BSA solution which 
was incubated for 2 hours at room temperature followed by a washing step with PBS-
Tween. The MCF was trimmed into 3 cm test strips which were incorporated into the 
MSA for simultaneous aspiration of eight MCF test strips. PSA 1:2 serial dilutions in 
the range of 0 to 60 ng/ml were prepared in buffer and 100% human serum. Eight PSA 
serial dilutions in buffer were aspirated into eight MCF test strips with the MSA and 
incubated for 15 minutes. This solution was replaced by 2 µg/ml of PSA biotinylated 
DetAb (detection antibody) which was incubated for 10 minutes, followed by 4 µg/ml 
of high sensitivity HRP incubated for 10 minutes. The eight strips were washed with 
approximately 300 µl of PBS-Tween and a solution of 4mg/ml of OPD was added and 
incubated for 3 minutes while a digital image was taken by a flatbed scanner. 
For the IL-1β full response curve assays five MCF strips with 223 ± 23 µm diameter 
and 30 cm length were filled with 40 µg/ml of IL-1β CapAb and incubated for 2 hours 
at room temperature. The strips were then filled with super blocking solution and 
incubated for 2 hours at room temperature. After a washing step the strips were trimmed 
into 3cm MCF test strips. Each eight MCF strips were incorporated into the multiple 
syringe aspirator (MSA) for simultaneous aspiration. Eight 1:2 serial dilutions of IL-1β 
in the range of 0 to 1 ng/ml were prepared in buffer, 50 and 100% of human serum. The 
serial dilutions in buffer were simultaneous aspirated into 8 previously coated and 
blocked MCF strips and incubated for 5 minutes. After a washing step 10 µg/ml of 
biotinylated anti-IL-1β DetAb was added to the MCF strips and incubated for 10 
minutes followed by a washing step. A 4 µg/ml solution of high sensitivity streptavidin 
HRP enzyme replaced the washing buffer and was incubated for 10 minutes. An 
intensive washing step was performed in the MCF strips and 4 mg/ml of OPD solution 
was added and incubated for 2 minutes, while a digital image was taken by a flatbed 
scanner.  
The same procedure was followed for IL-1β recombinant protein serial dilutions made 
in 50 and 100 % human serum. Two other IL-1β sandwich assays were performed with 
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30 minutes sample incubation with IL-1β serial dilutions made in buffer and 100% 
human serum.  
In order to compared serum and whole blood sample interference 0, 0.03, 0.125 and 0.5 
ng/ml solutions of IL-1β were prepared and assayed in buffer, 50 and 100% whole 
blood. The sandwich assays were performed with 5 and 30 minutes of sample 
incubation. 
7.2.7. Image analysis of MCF IA strips 
RGB digital images were split into 3 separated channels images by Image J software 
(NIH, Maryland, USA). The blue channel images were used to calculate absorbance 
values, based on the grey scale peak height of each individual capillary of FEP-Teflon 
MCF as described previously.
127,152
 Therefore, absorbance signal is calculated for each 
capillary, according to equation (7:3). 
 Abs =  −𝐿𝑜𝑔10(
I
𝐼0
) (7:3) 
Where I is the transmitted light and corresponds to I0 minus peak height, and I0 is the 
maximum grey scale value, corresponding to the initial emitted light. The absorbance 
values presented averages of absorbance from 10 capillaries one MCF stip. 
7.2.8. Kinetic model antibody-antigen kinetic  
The antibody-antigen kinetic results presented in this study were fitted to a theoretical 
IA mathematical model that aims describing the role of transport of analyte in a 
microchannel (convection and diffusion), the kinetics of binding between the analyte 
and the capture antibodies, and the surface density of the CapAb on the assay. Equation 
(7:4) can be solved analytically for a constant analyte concentration and was used to 
estimate the rates of association and dissociation of antibody binding in the MCF 
system.
204
 
 
𝛷 =
𝐾𝑜𝑛 𝛷𝑚𝑎𝑥𝐶
𝐾𝑜𝑛 𝐶 + 𝐾𝑜𝑓𝑓
(1 −  𝑒−(𝐾𝑜𝑛 𝐶+𝐾𝑜𝑓𝑓)𝑡) 
(7:4) 
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Where Φ is the surface density at the time t, C is the analyte concentration Kon the 
association rate and Koff the dissociation rate. And Φmax is the maximum surface 
coverage, which in this study was taken as the maximum absorbance signal obtained.  
7.3. Results and Discussion 
7.3.1. Sample matrix viscosity effect on kinetics of antibody-antigen binding 
Biological samples present complex matrices that interfere with bioanalytical reagents 
in IAs in multiple ways depending on the matrix, on the bioanalytical reagents and solid 
phase platform for the immunoassay. 
Previous MCF assays
152,153
 and real time antibody-antigen binding studies with optical 
sensors, e.g. the IAsys system,
235
 related biological matrix interferences with viscosity 
increment of medium. On a previous study, PSA sandwich assays overcame sample 
matrix effect by sample dilution and by extending sample incubation times, and both 
strategies can be explained if viscosity is the biological matrix interfering factor. 
Solution viscosity can interfere in the diffusion coefficient of a molecule according to 
Einstein and Stokes equation of spherical particles diffusion through a liquid with low 
Reynolds number (equation (7:5)):  
 
𝐷 =  
𝐾𝐵𝑇
6𝜋𝑟𝜂
 
(7:5) 
 
Where D is the diffusion coefficient, KB is the Boltzmann’s constant; T is the absolute 
temperature, r the radius of a spherical particle and η the dynamic viscosity. Therefore, 
the higher the viscosity of the medium, the lower the diffusion coefficient of a molecule 
and consequently the longer the diffusion time, accordingly to the Einstein relation 
(equation (7:6)): 
 𝑡 =  √2𝐷𝑥 (7:6) 
Where t is the diffusion time, D the diffusion coefficient of a molecule and x the 
average distance of diffusion. Considering only the effect of viscosity in a solid phase 
IA capillary, assays with higher viscosity biological solutions would need longer 
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incubation times to reach the same equilibrium than an assay performed in buffer (lower 
viscosity solution). This theoretical consideration is confirmed by the results shown in 
Figure 7:2.  
 
Figure 7:2 – Effect of sample matrix viscosity in antibody-antigen kinetics in an IL-1β 
sandwich assay, using 223 µm diameter bore MCF. 
A Antigen (IL-1β 0.1 and 1 ng/ml ) kinetics with sample matrix with different 
viscosities: PBS, 50, 100 and 250 mg/ml BSA. B Viscosity of BSA solutions with 
different concentrations and viscosity of human serum different dilutions. 
 
Different concentrations of BSA present increasing dynamic viscosity, being PBS 
solution correspondent to 1.027 c.p., 50 mg/ml of BSA to 1.33 c.p., 100 mg/ml to 1.64 
c.p. and 250 mg/ml correspondent to 3.51 c.p., as seen in Figure 7:2B. Figure 7:2A, 
indicates that kinetics of IL-1β recombinant binding is significantly affected by 250 
mg/ml solution of BSA as antigen diluent for antigen concentration of 1 ng/ml. With 
this diluent the reaction takes longer to reach equilibrium than with other diluents 
tested. However the equilibrium is not different from the equilibrium of the antigen 
involved with the other diluents solution. Therefore, it appears that the kinetic delay is 
due to viscosity increase in the matrix (kinetic constants obtained from fitting equation 
(7:4), Figure 7:2A are in Table 7:1).  
Table 7:1 - Kinetic constants of IL-1β binding for 1 ng/ml of IL-1β shown if Figure 
7:2A. 
 PBS 50 mg/ml BSA 100 mg/ml BSA 250 mg/ml BSA 
Kon (M.s
-1) 2.36 x 1015 3.07 x 1011 2.70 x 1011 9.56 x 1010 
Koff (s
-1) 1.11 x 10-1 1.75 x 10-3 1.09 x 10-3 8.88 x 10-4 
KA (M) 2.13 x 10
14 1.76 x 1014 2.48 x 1014 1.08 x 1014 
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This delay in equilibrium was not observed for lower antigen concentrations (Table 
7:2), IL-1β 0.1 ng/ml, probably because with small amounts of antigens only the 
antigens on the boundary layer are bond to the immobilised antibodies, so their 
association constant (Ka) is not dependent on diffusion from the bulk, being the same 
independently of the viscosity of the medium.  
Table 7:2 - Kinetic constants of IL-1β binding for 0.1 ng/ml of IL-1β shown in Figure 
7:2A. 
 PBS 50 mg/ml BSA 100 mg/ml BSA 250 mg/ml BSA 
Kon (M.s
-1) 1.79 x 1011 2.86 x 1011 2.30 x 1011 1.08 x 1011 
Koff (s
-1) 3.81 x 10-4 1.91 x 10-3 3.37 x 10-3 5.57 x 10-4 
KA (M) 4.70 x 10
14 1.49 x 1014 6.83 x 1013 1.93 x 1014 
 
Results showed viscosity only interferes in antigen binding kinetics above a certain 
threshold, which is 3.5 c.p. correspondent to 250 mg/ml of BSA solution. Human serum 
viscosity is equivalent to 100 mg/ml of BSA viscosity, and this BSA concentration did 
not cause kinetics delay, as seen in Figure 7:2A, therefore the interference noticed with 
human serum biological sample matrix does not seem to be related to viscosity, but to 
other factors. 
Whole blood viscosity varies from 3.36 to 5.46 cp
241
, however whole blood IL-1β 
sandwich assay in the MCF platform presents similar matrix interference as human 
serum, being slightly different from buffer for 5 min sample incubation time, but similar 
to buffer for 30 min sample incubation time (Figure 7:3A and B). 
 
Figure 7:3 – Effect of human serum and whole blood matrices interference in IL-1β 
assay in the MCF platform in 223 ± 23 µm capillaries.  
A IL-1β assay with buffer and 100% human serum and whole blood for 5 minutes 
sample incubation. B IL-1β assay with buffer and 100% human serum and whole blood 
for 30 minutes sample incubation.  
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IL-1β sandwich assay showed similar interference in buffer and whole blood samples, 
which means at least with two different blood samples tested, blood viscosity did not 
interfere with the assay. The same was found in PSA sandwich assays performed 
previously.
152
 This means that red blood cells appear not to interfere with the IL-1β 
sandwich assay, which makes this MCF platform assay ideal for POC diagnostics, since 
there is no need for solid phase separation in whole blood samples.  
Data in Figure 7:3 and Figure 7:4 also suggested longer sample incubation times seem 
to minimise biological matrix interference of human serum, whole blood and higher 
BSA concentration solutions in IL-1β sandwich assay. This suggests two possible 
explanations about how the interfering factor affects MCF IA: it can play by changing 
the rate of diffusion of the antigen towards the immobilised antibody layer or it can bind 
to the immobilised antibody with lower affinity compared to the antigen. The last 
explanation means with time the interfering factor (e.g protein, auto-antibody, 
heterophilic antibody, etc) is displaced giving place to the antigen, explaining why 
longer incubation times solve biological matrix effect problems in MCF IA. 
7.3.2. Capillary diameter effect on kinetics of antibody-antigen binding in biological 
matrices 
As diffusion appeared to affect matrix interference in MCF assays and the extended 
incubation times are not ideal for POC testing, the following set of experiments aimed 
at understanding the effect of diffusion distance in MCF assays in matrix interference 
and incubation time simultaneously. The study of antibody kinetics in MCF with 
different capillary diameters in buffer and in human serum was performed using mouse 
IgG and conjugated anti-IgG peroxidase and results shown in Figure 7:4.  
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Figure 7:4 – Relationship between human serum matrix effect and capillary diameter in 
MCF assays.  
A (i) Photograph of 3 different MCFs with of 128±11 µm, 223±23 µm, 378± 40 µm 
mean diameter bore. (ii) Microscope photograph of a cross section from the MCFs with 
128, 223, 378 µm diameter bore. B The effect of diameter size on total surface area 
(SA) and on surface-area-to-volume ratio (SAV). C IgG-anti-IgG binding kinetics on 
different diameter MCFs in buffer matrix. D IgG-anti-IgG binding kinetics in different 
diameter MCFs in non diluted human serum matrix. E Antibody adsorbed density onto 
different MCFs bore diameter. F Diagram relating capillary size with antibody surface 
coverage for a MCF test strip of 4 cm length.  
Changing the capillary diameter of MCF platform affects the total surface area (SA) 
available for antibody adsorption, in the sample volume (V), related to the amount of 
antibody or antigen loaded into the system and, consequently the surface-area-to-
173 
 
volume ratio (SAV), which is related to the overall reaction throughput and speed. Total 
SA increases linearly with diameter, whilst SAV decreases linearly with the reciprocal 
of the diameter (Figure 7:4B). Microfluidic IA systems often only consider SAV as the 
main geometrical parameter. However, to the best of our knowledge no studies have 
explored a balance between the SA and V, and therefore an optimum SAV for 
microfluidic IA performance.  
A decrease in capillary diameter from 223 to 128 µm resulted in 2 min faster antibody-
antigen equilibrium, while an increase in capillary diameter from 223 to 378 µm 
postponed the equilibrium 2 min. MCF assays are therefore diffusion limited (Figure 
7:4C and Table 7:3). Changing the diameter of the capillary in MCF assays seems to 
have a similar effect on antibody binding kinetics as changing the viscosity of the 
matrix in which the antibody/antigen is involved. This can be explained by equations 
(7:5) and (7:6), where diffusion coefficient is inversely related to viscosity and affects 
the diffusion time the same way as the mean displacement of the molecule. 
Consequently, if the interfering factor in biologic human serum matrix was only related 
to diffusion, performing the assay in smaller capillaries should minimise the interfering 
factor effect in MCF assays.  
Table 7:3 - Kinetic constants of anti-IgG binding in buffer in different capillary 
diameter MCF. 
 100 µm MCF 200 µm MCF 400 µm MCF 
Kon (M.s
-1) 6.39 x 106 4.24 x 106 2.65 x 106 
Koff (s
-1) 1.42 x 10-3 1.71 x 10-3 1.55 x 10-3 
KA(M) 4.49 x 10
9 2.48 x 109 1.7E x 109 
 
When a mouse IgG-Anti-IgGAnti-IgG assay was performed in human serum and 
smaller diameter capillaries (128 µm) the assay was made quicker, compared to the 
assays in larger capillary diameters, but the equilibrium reached was different (Figure 
7:4D and Table 7:4) which did not occur when the assay was performed in buffer 
(Figure 7:4C). The assay performed in human serum in the MCF platform with capillary 
diameters 223 and 378 µm reached the same equilibrium, although the assay performed 
in 378 µm took approximately 4 minutes more to reach the equilibrium, which seems to 
indicate a cumulative effect of diffusion and the interfering factor from the biological 
sample matrix. Although in MCF human serum assay interference is not related to 
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diffusion, this process seems to emphasise the biological matrix interference in MCF 
assays, which indicates an optimum capillary diameter, where both the role of diffusion 
and interference are minimised. With smallest capillary diameter tested the effect of the 
interfering factor is irreversible, presenting lower equilibrium constants, when 
compared with assays performed in larger capillaries (Table 7:4).  
Table 7:4 - Kinetic constants of anti-IgG binding in human serum in different capillary 
diameter MCF. 
 100 µm MCF 200 µm MCF 400 µm MCF 
Kon (M.s
-1) 5.38 x 106 3.35 x 106 9.62 x 107 
Koff (s
-1) 8.52 x 10-3 1.91 x 10-3 4.13 x 10-2 
KA (M) 6.31 x 10
8 1.75 x 109 2.33 x 109 
 
One of the causes for the lower equilibrium constant in assays performed in smaller 
capillaries with human serum matrix, could be related to the adsorption equilibrium of 
the immobilised antibody onto FEP-Teflon surfaces which will depend on the geometry 
of the surface. Due to a smaller sample volume loaded, smaller diameter capillaries will 
present a lower amount of antibody to be adsorbed, compared to larger diameter 
capillaries (Figure 7:4F). This is shown in Figure 7:4E where the amount of antibody 
adsorbed determined by solution depletion technique was approximately half on the 128 
µm diameter MCF compared to the amount adsorbed on the 223 µm MCF. The 378 µm 
diameter MCF also presented a significantly higher adsorbed amount when compared to 
the 223 µm MCF (867.8 ng/cm2 and 609.5 ng/cm2, respectively). This amount is less 
than the double, which can indicate that there is an antibody adsorption saturation 
threshold for to FEP-Teflon surfaces, related to the overall SAV of FEP-Teflon surfaces 
(Figure 7:4E). 
7.3.3. Overcoming biological sample matrix in MCF platform – three antibody-
antigen systems 
The fact, that smaller capillaries present lower immobilised antibody density could be 
the cause of different equilibrium constants for the same assay performed in different 
capillary diameter MCF with human serum as biological matrix. This hypothesis is 
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confirmed with studies of different surface coverage assay effect in equilibrium, using 
only 223 µm diameter MCF, in buffer and in undiluted human serum (Figure 7:5).  
 
Figure 7:5 - Surface coverage effect on human serum matrix interference on mouse IgG 
and Anti-IgG binding in 223 µm capillary assays. 
A Relation between surface coverage and absorbance signal of anti-IgG in buffer and 
100% human serum. B Relation between the ratio of Absorbance in buffer and serum 
and the surface coverage.  
 
The surface coverage effect on matrix interference in IgG-anti-IgG binding studies, 
made in equilibrium, have shown that the higher the surface coverage the lower the 
matrix interference of human serum for IgG and anti-IgG system. This relation is very 
clear in Figure 7:5B where the ratio of absorbance in buffer and serum tends to 1 at 
higher concentration of mouse IgG (immobilised antibody) used. A concentration of 50 
µg/ml of mouse IgG seems to be the minimum concentration of immobilised antibody 
solution for minimum matrix interfere effect on the assay. Increasing the density of 
immobilised antibody layer increased the probability of the antigen binding to the 
immobilised layer. The avidity constant, proportional to the ratio between bond and free 
antigen (Scatchard model, equation (7:7)) is closer to the affinity constant of individual 
antibody antigen binding in solution, especially because in mouse IgG and anti-IgG 
systems immobilised antibody orientation is not an issue, since anti-IgG binds to every 
part of mouse IgG.  
 B
F
= 𝑘𝑎 . (Abt − B) 
(7:7) 
Where B is bond antigen, F is the free antigen in solution, ka is the association 
equilibrium constant and Abt is the total concentration of antibody-binding sites.  
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Since there is an excess of total antibody binding sites the effect of the interfering factor 
from the sample matrix is not evident. If we consider the interfering factor binds to the 
immobilised antibody with lower affinity than the antigen, higher surface coverages 
minimise sample matrix interference, even for non equilibrium conditions. Therefore, in 
addition to long incubation times, immobilised antibody density is a key parameter to 
minimise sample matrix interference in MCF assays. 
Although, mouse IgG-anti-IgG system is commonly used to simulate sandwich assays, 
they are not sandwich assays since they lack the antigen. For this reason, the study was 
repeated for PSA sandwich assay in the MCF platform (Figure 7:6). The PSA assay 
uses a monoclonal CapAb and a polyclonal DetAb and these studies were performed in 
223 µm diameter MCF.  
 
Figure 7:6 - Surface coverage effect on human serum matrix interference of PSA 
sandwich assay in 223 µm capillary assays. 
A Relation between surface coverage and absorbance signal of PSA in buffer and 100% 
human serum (3.75 ng/ml PSA). B Relation between the ratio of absorbance in buffer 
and serum and the surface coverage (3.75 ng/ml PSA). C PSA full response curve in 
buffer and 100% serum, with 10 µg/ml of CaptAb, 2 µg/ml of DetAb, 4 µg/ml of 
enzyme and 4 mg/ml of OPD enzymatic substrate.  
The relation between sample matrix interference and surface coverage presents an 
opposite behaviour in the PSA sandwich assay when compared to the IgG-anti-IgG 
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system. In the PSA sandwich assay higher surface coverages emphasise human serum 
matrix interference (Figure 7:6A and B), being favourable to the minimum of sample 
matrix interference the CapAb concentrations between 10 to 20 µg/ml of CapAb. Two 
full PSA response curves performed with 10 µg/ml of CapAb and 15 minutes sample 
incubation time in PBS buffer and human serum overlap along the all PSA range of 0.9 
to 60 ng/ml presenting similar LLoD (Figure 7:6C and Table 7:5), which validates the 
previous conclusions. Previous PSA optimization studies demonstrated that the 
polyclonal DetAb binds directly to the monoclonal CapAb in the absence of antigen and 
that an increment in CapAb would increase the assay background noise. This might be 
the cause for different matrix interfering behaviour. As well as the  different binding 
affinity of PSA antibodies. and the importance of immobilised antibody orientation and 
stability for monoclonal antibodies binding capacity. 
Table 7:5 – PSA sandwich assay sensitivity considerations in buffer and in human 
serum with 15 minutes sample incubation. 
 
Lower limit of 
Detection (LLoD) 
ng/ml 
Precision with 60 
ng/ml PSA 
R2 (with 4PL model) 
Assay in buffer 0.978 16% 0.9966 
Assay in 100% human serum 0.532 13% 0.9984 
 
Since the nature of bioanalytical antibodies seem to affect the matrix effect MCF assays, 
surface coverage studies in buffer and in human serum were performed in IL-1β 
sandwich assays, where the CapAb and the DetAb are monoclonals. Results are shown 
in Figure 7:7.  
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Figure 7:7 - Surface coverage effect on human serum matrix interference of IL-1β 
sandwich assay in 200 µm capillary assays. 
A Relation between surface coverage and absorbance signal of IL-1β in buffer and 
100% human serum (0.125 ng/ml IL-1β  and 30 minutes sample incubation time). B 
Relation between the ratio of absorbance in buffer and serum and the surface coverage 
(0.125 ng/ml IL-1β and 30 minutes sample incubation time). C Relation between 
surface coverage and absorbance signal of IL-1β in buffer and 100% human serum 
(0.125 ng/ml IL-1β and 5 minutes sample incubation time). D Relation between the 
ratio of absorbance in buffer and serum and the surface coverage (0.125 ng/ml IL-1β  
and 5 minutes sample incubation time). E IL-1β full response curve in buffer, 50% 
serum and 100% serum, with 40 µg/ml of CaptAb and 5 minutes sample incubation. F 
IL-1β full response curve in buffer, 50% serum and 100% serum, with 40 µg/ml of 
CaptAb and 30 minutes sample incubation. 
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The matrix effect interference on IL-1β sandwich assays in MCF platform was also 
minimised by the increment of immobilised CapAb density, as the monoclonal DetAb 
does not seem to bind to the CapAb, therefore an increment in CapAb concentration 
does not correspond to a background increment. In equilibrium conditions (30 minutes 
sample incubation) a concentration range of 40 to 80 µg/ml of CapAb was sufficient to 
eliminate the human serum matrix interference (Figure 7:7A and B). For non-
equilibrium (5 minutes sample incubation) a concentration range of 80 to 200 µg/ml of 
CapAb can eliminate the matrix interference effect. Two full IL-1β response curves, in 
buffer and in serum, performed with 40 µg/ml of CapAb and 5 minutes sample 
incubation time, show an interference effect of undiluted human serum, translated in 
absorbance signal differences in MCF assays (Figure 7:7E). However, absorbance 
values were similar when the sample incubation time was 30 min (Figure 7:7F), which 
is coherent with results shown in Figure 7:7A, B, C and D. 
A routine strategy for reducing sample matrix interference with shorter incubation times 
is diluting the sample. This is the most common approach for dealing with biological 
matrix interference in diagnostics and it often works, depending on the sample dilution 
factor.
236,239
 Figure 7:7E shows an overlap of full IL-1β response curves in buffer and in 
50% human serum. Similar conclusions have been reported for PSA sandwich assays in 
MCF platform in human serum and whole blood samples with colorimetric and 
fluorescent detection.
152,153
 However, diluting the sample matrix also means diluting the 
antigen concentration which compromised sensitivity. Since MCF assays are being 
developed for quantitative POC diagnostic applications, managing the sample matrix 
interference without any sample treatment is preferred over the dilution procedure. 
However, Table 7:6shows that the lower limit of detection (LLoD) for IL-1β sandwich 
assay is 3 times lower in 50% human serum matrix than in 100% human serum, which 
implies that sensitivity would not be affected by sample dilution in MCF sandwich 
assays.  
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Table 7:6 – IL-1β sandwich assay sensitivity considerations in buffer and in human 
serum, Figure 7:7. 
 
Lower limit of 
Detection 
(LLoD) ng/ml 
Precision with 
0.125 ng/ml 
IL-1β 
R2 
(with 
4PL 
model) 
5 min sample incubation, in buffer 0.021 9% 0.9992 
5 min sample incubation, in 100% human serum 0.014 6% 0.9989 
30 min sample incubation, in buffer 0.084 20% 0.9929 
30 min sample incubation, in 100% human serum 0.051 10% 0.9965 
5 min sample incubation, in 50% human serum 0.006 19% 0.9991 
 
The data presented above showed no need for sample preparation in the MCF platform 
since in certain reactions conditions the antibody-antigen binding can overcome the 
biological matrix interference. 
Although initial studies suggested viscosity as the main interfering factor, the studies 
presented in this chapter showed equilibrium conditions defined by immobilised 
antibody surface coverage were actually the main factor in managing matrix effect. 
Some studies have already suggest this, also mentioning the importance of 
immobilisation technique, saying that covalently bond antibodies or streptavidin 
orientated outperform compared to passive adsorbed antibodies.
283
 In those studies 
antibody passive adsorption was also feasible for biological matrix effect interference as 
long as surface coverage conditions are the appropriate ones. In addition, extended 
incubation times seem to favour the minimum sample matrix interference for the 
optimal surface coverage conditions. These observations led to matrix components 
interference as the main matrix interfering factor. This has been reported by Sauer et al. 
(2012) where Dy-547 anti-fibrogen, anti-lysosyme and anti-IgGa were added to a IL-6 
and PCFT sandwich assay and were detected in specific monoclonal CapAb spots, 
which means that fibrogen, lysozyme and IgG bond non-specifically to monoclonal 
antibodies.
236
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7.3.4. General methodology for overcoming biological sample matrix in MCF 
platform 
All in all the biological matrix interference can be managed in MCF assays with an 
appropriate capillary diameter (which is around 200 µm), surface coverage (which 
depends on bioanalytical antibody system that is being used) and sample incubation 
time (which also depends on the kinetic equilibrium between bioanalytical antibodies) 
and sample antigen (Figure 7:8A).  
 
Figure 7:8 – Methodology diagrams for minimizing biological matrix interference in 
MCF sandwich assays. 
A Diagram showing the main variables (CapAb concentration and Antigen incubation 
time) for minimizing matrix interference in MCF assays. B Diagram indicating the 
methodology for assay development and optimization for fast, sensitive and minimum 
matrix interference IAs in the MCF platform. 
 
Finding the minimum biological matrix interference in MCF assays is important, 
however for POC diagnostics procedures, besides the minimum sample matrix 
interference, the assays also need to be rapid and sensitive. Developing fast, sensitive 
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and with no sample preparation assays in the MCF platform is possible through an 
appropriate methodology (Figure 7:8B). Rapid assays are important in POC diagnostics; 
therefore the incubation time of reagents should be the first limitation, also because 
limiting time first, allows the choice of fast and sensitive assays simultaneously. 5 
minutes of reagent incubation time is therefore suggested to start the optimisation 
procedure in MCF IA platform. The first phase of MCF assay development is the choice 
of appropriate antibody-antigen equilibrium. In this phase a lower or middle range 
antigen concentration should be tested with different combinations of CapAb and 
DetAb, both in buffer and in serum. After choosing the combination for the best 
sensitivity and the minimum sample matrix, the next phase of assay development is 
sensitivity improvement. In this phase, the CapAb choice is set and combinations of 
DetAb concentration and its incubation time should be performed, in order to choose 
the conditions with best signal-to-noise ratio, therefore being important to perform 
blanks for every condition. Since the DetAb and its incubation time are established, the 
enzyme concentration and its incubation time combinations should be tested in order to 
find the best signal-to-noise ratio. The last phase for MCF development of quantitative 
assays for POC diagnostic is the validation phase. In this phase several antigen 
concentrations should be tested in serum and buffer with different sample incubation 
times. This allows confirmation of assay conditions for several antigen concentrations 
and adjustment of the sample incubation time for the minimum assay interference, 
maximum sensitivity and speed, as long sample incubation times seem to decrease 
sensitivity in the MCF platform, due to background increment (Table 7:5 and Table 
7:6). 
7.4. Conclusion 
Human samples matrix interference was eliminated in three different IA systems (IgG-
anti-IgG, PSA and IL-1β assays) in the novel MCF IA platform. This was achieved 
through the appropriated choice of CapAb surface coverage and sample incubation time, 
without any impact on assay sensitivity. 
The studies show that higher antibody coverages (above 40 µg/ml of CapAb solution) 
minimises matrix interference in two of the assays studied, however this conclusion 
does not apply to the PSA assay, as this antibody system uses a polyclonal DetAb that 
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binds to the CapAb. Long sample incubation times seem to minimise matrix effect in 
the three assay system studied.  
Sample viscosity changes the antibody-antigen kinetics, as reported in previous studies, 
however, only above a certain threshold equivalent to whole blood samples. This shows 
that viscosity is not the only interfering factor in IA, since human serum, which presents 
lower viscosity than whole blood, also interferes with MCF sandwich assays.  
IL-1β assays showed similar values in whole blood and serum samples, which indicates 
that red blood cells do not interfere with assays performed in FEP-Teflon 
microcapillaries.  
The MCF platform is able to perform sensitive assays without any sample preparation, 
which brings the platform closer to POC diagnostic applications and also to 
commercialisation.  
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8. Particle label detection in FEP-Teflon microfluidic 
capillaries 
8.1. Abstract  
In this chapter the use of carbon and gold nanoparticles as immunoassay (IA) labels in a 
novel microfluidic platform, the Microcapillary Film (MCF), is presented. Biotinylated 
anti-IL-1β antibody was quantitated in the dynamic range of 10 to 40 µg/ml using 
carbon nanoparticles conjugated with neutravidin. However, due to low sensitivity of 
the system using a flatbed scanner imaging no sandwich assay was performed. Prostate 
specific antigen (PSA) was quantitated using silver enhanced gold nanoparticles in the 
dynamic range of 10 to 100 µg/ml also using a flatbed scanner for optical detection. 
Particle detection is important for cost effective one step point of care (POC) 
diagnostics and extensively used in nitrocellulose lateral flow tests. Due to their low 
surface area compared to lateral flow membranes, particles are not often used as labels 
for microfluidic systems, however their use combined with low cost readout systems 
could bring microfluidic diagnostics closer to the ideal of POC diagnostics.  
 
Keywords: Carbon nanoparticles, gold nanoparticles, silver enhancement, point-of-
care, microfluidic, capillary geometry. 
8.2. Introduction 
Point-of-Care (POC) diagnostics demand simple and rapid test, preferably using a drop 
of blood, collected from a finger prick, or other type of biological samples (e.g. urine) 
ideally in one step IAs.
2,234
 Nevertheless, some clinical conditions demand sensitive 
quantitation of certain biomarkers, such as cardiovascular diseases, with a troponin 
(TnI) clinical threshold of 40 pg/ml,
17
or sepsis, with cytokines TNF-α, IL-6 and IL-10 
clinical thresholds below 70 pg/ml, 
16
 therefore ideally POC diagnostics should not only 
be simple and rapid tests, but also sensitive tests, capable of detecting a broader number 
of conditions. Heterogeneous IAs, where the free analyte is separated from the bond 
forming the antibody-antigen complex, are the most sensitive bioanalytical tool used in 
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clinical diagnostics. However when translated to POC diagnostics their sensitivity can 
be compromised by the need to perform rapidly, using small sample volumes of 
complex biological matrices with low cost signal detectors.
2
  
In most heterogeneous sandwich assays the antibody-antigen complex is quantified 
through label detection. The label conjugated to a DetAb generates a signal proportional 
to the antigen. The nature of signal depends on the label and will determine the readout 
system. These two aspects work together setting upthe sensitivity of the assay. 
The first labels used in IAs were radioactive isotopes, such as iodine 125,
28
 however 
due to concerns about radioactivity exposure, disposal of radioactive waste and 
instability of radiolabels reagents other labels were developed.
39
 Enzymes,
284
 
fluorophores,
50
 chemiluminophores,
285
 microparticles,
286
 quantum dots,
287
 have been 
extensively applied to signal generation in IA techniques. Enzymes are the most widely 
used label due to their flexibility, since different enzymes can generate color, 
fluorescent or luminescent products from a transparent substrate, and their amplification 
feature, since a single enzyme can convert up to 10
7
 molecules of substrate per minute.
28
 
However, enzymes are not suitable for one step IAs, which can have a big impact in 
POC tests simplicity.  
Lateral flow (LF) IAs is a well established technology for one step IAs. The pregnancy 
hormone (hCG), malaria and HIV LF tests are widely commercialized. Nevertheless, 
this technology lacks the sensitivity necessary to diagnose certain conditions, such as 
sepsis or cardiovascular diseases, as previously mentioned. Microfluidic tests are trying 
to fill up this gap creating simple tests with the necessary sensitivity for a broader 
diagnosis at POC settings, therefore using rapid and simple tests with low cost detection 
modes.  
LF uses a label directly conjugated to the DetAb and so no amplification is performed. 
The sample is placed in a sample pad, moving through capillary action, mixes with the 
label antibody in the conjugated pad, and continue to flow through the test zone.
193
 The 
density of label particles in the test zone generates a signal proportional to the analyte 
concentration. LF technology uses porous membranes, such as nitrocellulose, which 
present a very high surface area even in a very small test zone (1mm width). Translating 
one step IAs into microfluidic platforms which do not present such a high surface area, 
in the detection zone, can be challenging in order to keep the necessary test sensitivity. 
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Therefore, in order to use particles as labels in microfluidic systems, the readout system 
used has to be sophisticated or amplification methods have to be applied. In order to 
achieve higher sensitivities and multiplex capability, microfluidic systems often use 
fluorophores as labels, which cannot be considered particles, however to detect signal 
from these fluorescent labels it is necessary to use complex and expensive equipment, 
such as fluorescent microscopes, flow cytometers and fluorescent scanners. 
50,58
 
There are few examples of microfluidic IAs systems which used particles as labels and 
low cost readout systems. Yet C. et al (2009) reported a protein A sandwich assay where 
the capture antibody (CapAb) was immobilised onto glass slides, surrounded by a 
PDMS structure, the DetAb was conjugated with platinum nanoparticles which suffer 
silver enhancement. The signal was detected by a flatbed scanner and the detection limit 
of the assay was 1 ng/ml.
288
 Lu Y. et al (2009) reported a human IgG/anti-IgG assay, 
with IgG immobilised onto polystyrene surface inside PDMS channels, with the DetAb 
label with gold nanoparticles and also silver enhanced. The signal detection was made 
through a cell phone camera and the detection limit was approximately 1 ng/ml.
289
 PSA 
was  of 5x10
-4
pM with a Bio-Barcode using Verigene ID Scanning system.
51
 
Understanding how particle labels can be detected with low cost readout systems can be 
transformative to microfluidic IAs bringing them closer to an ideal POC diagnostic test.  
This chapter aimed exploring two different particle labels, the carbon nanoparticles and 
gold nanoparticles, in the Microcapillary Film (MCF) platform (Figure 8:1A), in order 
to move MCF closer to one step IA. The MCF is constituted by melt-extruded FEP-
Teflon with 10 parallel microcapillaries with 200 µm diameter average each. This 
geometry offers a similar surface area of the microwell, considering a 1 cm long MCF 
strip, but surface-area-to-volume 370 times larger when compared to a 96 microwell 
plate.  
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Figure 8:1 – Microcapillary Film (MCF) IA platform. 
MCF photograph, showing the transparency of the FEP-Teflon polymer and the 10 
parallel capillaries with 200 µm diameter average.  
8.3. Materials and Methods 
8.3.1. Materials & Reagents 
Purified anti-Human IL-1β biotin and anti-Human IL-1β was supplied by e-Biosciences 
(Hatfield, UK). anti-PSA CapAb and anti-PSA detection antibody (DetAb) conjugated 
with gold nanoparticles was supplied by Wama Diagnóstica (São Carlos, Brazil). The 
silver enhancement kit was supplied by Sigma Aldrich (Dorset, UK). The PSA native 
protein was purchased from Abcam (Cambridge, UK). The Carbon nanoparticles were 
supplied from Food and Biobased Research, Wageningen University and Research 
Centre Wageninger. According to the suppliers the particles present irregular shape and 
an average size of 600 nm. 
Phosphate buffered solution (PBS) and Bovine Serum Albumin (BSA) were sourced 
from Sigma Aldrich (Dorset, UK). PBS pH 7.4, 10mM was used as the main 
experimental buffer. The blocking solutions consisted in 3% w/v protease-free BSA 
diluted in PBS buffer. For washings, PBS with 0.05% v/v of Tween-20 (Sigma-Aldrich, 
Dorset, UK) was used. The FEP-Teflon MicroCapillary Film (MCF) is fabricated from 
fluorinated ethylene propylene co-polymer by melt-extrusion process by Lamina 
Dielectrics Ltd. (Billinghurst, West Sussex, UK). FEP-Teflon MCF presents 10 bore 
parallel capillaries with 223±23 µm diameter.  
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8.3.2. Neutravidin coated carbon nanoparticles detection 
Four solutions of IL-1β biotinylated with 0, 10, 20, 40 and 80 µg/ml and one with 3% of 
BSA were injected in different capillaries using a 1 ml syringe attached with a needle 
(i.d. 200 µm) of a 24 cm MCF strip and incubated for 2 hours at room temperature. The 
biotinylated antibody solution was replaced by 3% BSA solution incubated for 2 hours 
at room temperature in all the capillaries. The long MCF strip was trimmed in 4 cm 
lenght strips and several dilutions of neutravidin conjugated carbon nanoparticles 
solutions (1:1, 1:2, 1:5; 1:7; 1:10 and 1:50) were added to the different 4 cm MCF strips 
being incubated for 2 hours in an orbital shaker, followed by a washing step with PBS 
tween. The strips were then imaged with a flated scanner (HP Scanjet G4050) in 
transmittance mode. 
The MCF was cut exposing the surface area coated with the carbon nanoparticles, gold 
coated for 5 minutes with a Gold Sputter Cater/Carbon evaporator. And placed in a 
SEM high resolution field emission gun (FEGSEM) for imaging at several 
magnifications, being the highest 15 000 KW.  
8.3.3. Gold nanoparticles detection with silver enhancement. 
An MCF strip was filled with 40 µg/ml of anti-PSA CapAb and incubated for 2 hours at 
room temperature. The solution was replaced by 3% BSA incubated for 2 hours at room 
temperature. After a washing step the strip was trimmed in 4 cm MCF test strips. Four 
MCF test strips were filled with 0, 10, 50 and 100 ng/ml of PSA native protein solutions 
and incubated for 10 min. A solution of 1:50 dilution of anti-PSA DetAb conjugated 
with gold nanoparticles was incubated for 1 hour in the orbital shaker followed by a 
washing step. The silver enhancement solution was applied for 10 min at room 
temperature and the fixing solution for 3 min followed by a distilled water washing step. 
The strips imaged with the flatbed scanner in transmittance mode.  
189 
 
8.3.4. MCF image analysis 
RGB digital images were split into 3 separated channels images by Image J software . 
The green channel images were used to calculate absorbance values, based on the grey 
scale peak height of each individual capillary of FEP-Teflon MCF as described in 
previous studies.
127,152
 Therefore, absorbance signal was calculated for each capillary, 
according to equation (8:1). 
 𝐀𝐛𝐬 =  −𝐋𝐨𝐠(
𝐈
𝐈𝟎
)        (8:1) 
Where I is the transmitted light and corresponds to I0 minus peak height and I0 is the 
maximum grey scale value. The absorbance values presented averages of absorbance 
from 10 capillaries one MCF stip. 
8.4. Results and Discussion 
8.4.1. Carbon nanoparticles 
The use of particles as labels instead of enzymes can bring microfluidic systems closer 
to simple one step POC diagnostics, eliminating the time and complexity of multiple 
steps IAs. However, few studies have been performed in order to detect particles in 
microfluidic systems with low cost detection modes, essential for POC diagnostic 
settings.  
The use of carbon nanoparticles in LF assays was used in albumin detection from 0.25 
µg/ml and kunitz-type for trypsin inhibitor was detected from 2.5 ng/ml in competitive 
assay format.
290
 A study that aimed to enhance the detection limit of lateral flow test 
through the evaluation and comparison of bioconjugates reported a 10 fold 
improvement in sensitivity for biotin-streptavidin systems and for dengue detection 
when compared with silver coated gold nanoparticles.
291
 Carbon nanoparticles coated 
with neutravidin were the first carbon particle system to be detected in the MCF 
platform. The particles were bond directly to immobilised biotinylated antibodies and a 
dynamic range between 10 and 40 µg/ml of biotin-antibody was observed with flatbed 
scanner digital images in transmittance mode, followed by grey scale analysis (Figure 
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8:2A and Figure 8:2B). In the grey scale image (Figure 8:2B) is possible to observe the 
difference on the refractive index of MCF capillary walls due to particles attachment. 
 
Figure 8:2 – Biotinylated antibody MCF adsorbed detection with carbon nanoparticles 
neutravidin coated (1:10 dilution). 
A MCF flatbed scanner green channel digital image in transmittance mode, showing 
microcapillaries coated with 80, 40, 20, 10 and 0 µg/ml of biotinylated antibody, 1 to 5 
respectively. B Correspondenting grey scale showing the concentrations of 80, 40, 20, 
10 and 0 µg/ml of biotinylated antibody, 1 to 5 respectively. C Scanning Electon 
Microscope (SEM) pictures with 10, 20, 40 and 80 µg/ml of biotinylated antibody. 
 
The SEM images are coherent with the flatbed scanner images showing an increment in 
the density of carbon nanoparticles from 10 µg/ml and saturation after from 40 to 80 
µg/ml. This showed that it is possible to detect carbon nanoparticles using a flatbed 
scanner as a readout system. However, optimization should be performed in order to 
achieve better sensitivity and apply this label to sandwich IAs. Optimization started 
with screening the concentration of carbon nanoparticle. The results are shown in Figure 
8:3.  
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Figure 8:3– Carbon nanoparticles neutravidin coated detection of 40 µg/ml of biotin-
antibody in the MCF. 
A Flatbed scanner digital image of microcapillaries with 40 µg/ml of biotin-antibody 
and several dilutions of carbon nanoparticles 1, 2, 3, 4, 5, 6 which corresponds to 1:1, 
1:2, 1:5, 1:7, 1:10,1:50 respectively. B Correspondent grey scale image with previously 
mentioned dilutions of carbon nanoparticles and 40 µg/ml of biotin-antibody. C 
Correspondent Scanning Electron Microscope (SEM) pictures with several dilutions of 
carbon nanoparticles. 
 
Figure 8:3 shows that higher concentrations of carbon nanoparticles are not beneficial 
for molecular detection in the MCF since flatbed scanner images with 40 µg/ml of 
biotinylated antibody did not show any signal with non diluted or even 1:2 diluted 
carbon nanoparticles. In the SEM images of these capillaries (Figure 8:3C) is possible 
to see crystals with an average perimeter size of 3 µm, considering the carbon particles 
are irregular in shape and present an average size of 600 nm (according to the 
manufacturer), therefore in certain conditions the carbon nanoparticles agglomerate, 
becoming larger and easier to remove during the washing steps. Carbon nanoparticles 
dilutions above 1:50 are not recommended as well, since there is not enough surface 
density of particles to be detected with the flatbed scanner, although they are visible in 
the SEM images (Figure 8:3C).  
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Optimizing the carbon particles concentration would not be enough to perform sensitive 
IA in the MCF, since the higher surface density achieved is far from full surface 
coverage and the total surface area available is not large enough to promote a good 
naked eye signal. Thus, no attempt of performing a full sandwich assay in MCF with 
carbon nanoparticles was made. Probably changing the direction of the light towards the 
capillaries using an LED system and a portable camera could improve the signal 
intensity.  
8.4.2. Gold nanoparticules label with silver enhancement 
The other particle system used in the MCF platform was the silver enhanced gold 
nanoparticles. With this system the prostate specific antigen (PSA) sandwich assay was 
performed and results shown in Figure 8:4. PSA is a prostate cancer biomarker with a 
clinical threshold of 4 ng/ml. 
 
Figure 8:4 – Gold nanoparticles MCF IAs with silver enhancement. 
A Sandwich assay diagram with gold nanoparticles silver enhancement step. B PSA 
response curve with gold nanoparticles silver enhanced. 
 
The results show a significant difference between 0 ng/ml of PSA and the lowest 
concentration of PSA tested 10 ng/ml. This indicates possible improvement in the 
sensitivity of the assay with optimization. A 4PL (4 parameter logistic) model fitted the 
data with a cross correlation of 0.999. However, the variability between capillaries of 
the same MCF test strip is 34% in the highest PSA concentration, which shows that the 
concentration of gold nanoparticles might not be optimized yielding poor uniformity for 
higher PSA concentrations.  
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To the best of our knowledge is the first time a cancer biomarker is quantified using 
gold nanoparticles silver enhanced in a microfluidic platform. Although, the silver 
enhancement involves a multistep assay, particle labels are flexible, cost effective and 
will, therefore, contribute to increase the flexibility of microfluidic POC systems.  
8.5. Conclusion 
Although the smaller surface area of capillaries when compared to LF test membranes, 
the PSA was quantified in the MCF with gold nanoparticles silver enhanced, presenting 
a dynamic range of 10 to 100 ng/ml of PSA. Carbon nanoparticles enable the 
quantitation of biotinylated antibody in the range of 10 to 40 µg/ml. The assays used a 
low cost flatbed scanner for signal detection. 
Particle detection is possible in the MCF, which opens possibility for development of 
rapid one step microfluidic IA with low cost detection modes, however from this study 
concludes that one step particle detection in MCF requires major improvements to yield 
similar sensitivity to multistep IA.  
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9. Conclusions and Future Perspectives 
 
Sensitive quantitation of protein biomarkers can provide early detection of many non-
communicable diseases, such as cancer and cardiovascular conditions. These are the 
main causes of deaths worldwide. Therefore, their early detection can increase the life 
expectancy and quality of general population. 
Microfluidic diagnostics aim sensitive protein quantitation due to the high throughput 
owed to IA miniaturization and precise fluid control. However, these technological 
advancements are still not enough for POC applications due to high cost of microfluidic 
devices manufacturing process. 
This PhD project aimed developing and optimising novel microfluidic IA platform, the 
Microcapillary Film (MCF) for POC settings, whose manufacture process is cost-
effective and can easily be mass produced. This platform could fill the gap of sensitive 
protein quantitation at POC currently existing in diagnostic market.  
The MCF is produced by melt-extrusion of a fluoropolymer, FEP-Teflon. It consists in a 
transparent flat film with 10 parallel embedded capillaries with an average internal 
diameter of 200 µm. 
Sensitive quantitation of protein biomarkers is usually performed with sandwich IA. 
This assay format implies a certain amount of antibody immobilised to a solid surface. 
The immobilised antibody amount and activity is extremely important for IA 
performance. Therefore, the first specific objective of this thesis was to study antibody 
adsorption onto FEP-Teflon capillaries. From this study it was concluded that is 
possible to irreversibly adsorb antibodies to FEP-Teflon. It was also found that 
antibodies form a monolayer with maximum coverage of approximately 400 ng/cm
2
, 
which can be related to a theoretical monolayer with antibodies in vertical orientation. 
However, surface coverages between 200 and 300 ng/cm
2
 provide the highest signal in 
sandwich assays, probably due to antibody steric hindrance in higher density surfaces. 
The monolayer was formed after 10 minutes due to small capillary diameter. FEP-
Teflon presents the best antibody adsorption properties when compared to LLPED 
which adsorbs 50% less and glass which adsorbs 90% more suggesting multilayer 
formation, not desirable for IA.  
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Signal amplification is other important variable for IA sensitivity, especially if the 
detection method is made off a cost effective, portable and power-free readout system, 
fundamental features for POC diagnostics.  Enzymes are powerful signal amplifiers, 
however to work at their full potential they need the optimal substrate concentrations 
and absence of inhibitors. By studying the OPD conversion by HRP enzyme it was 
found that increasing the OPD concentration from 1.0 to 4.0 mg/ml and OPD/H2O2 
molar ratio from 1:3 to 1:1 the value rate of enzymatic conversion was increased by 4-
fold, which is very beneficial for microfluidic devices that contain short diffusion 
distances. PSA and IL-1β assay increased sensitivity and/or speed by one or two orders 
of magnitude when applying the new conditions for OPD conversion by HRP.  
Understanding the effect of flow in assay speed and sensitivity is important for device 
automation, which is extremely important for POC diagnostics. The effect of flow on 
antibody-antigen bonding showed that a flow rate below 10 µl/min is required for high 
sensitivity assays. For high analyte systems a flow rate of 10 µl/min can be used, yet 
extended incubation times are required to avoid any impact on assay sensitivity.  
POC diagnostics require minimal sample preparation; however is well know the effect 
of biological matrices in IA. Therefore, a systematic study of viscosity effect, 
immobilised antibody coverage and sample incubation time was performed in the MCF 
platform. It was found that although viscosity delays the antibody-antigen equilibrium 
above a certain threshold, human serum presents a viscosity value inferior to that 
threshold, and still affects the assay. Consequently, viscosity is not the fundamental 
parameter affecting assay performance in biological samples. Other important founding 
was the evidence that human serum and human whole blood cause the same degree of 
interference in MCF IA. The main conclusion from matrix effects studies on MCF relies 
on the fact that manipulating the immobilised antibody surface coverage and sample 
incubation time the biological matrix interference can be minimised or even eliminated. 
However, the conditions vary according to the antibody system that is being used. For 
example, while IL-1β assay requires high antibody surface coverage (above 200 
ng/cm
2
), the PSA assay requires lower surface coverage (between 50 and 100 ng/cm
2
) 
due to its polyclonal detection antibody that binds to the immobilised antibody in higher 
extent whenever the last is in higher concentrations. Long sample incubation times 
minimise sample matrix effects in any of the systems. The MCF platform offers a wide 
range of conditions that allow minimising or eliminating the biological matrix effect.  
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These conclusions allowed the fully optimisation of a PSA sandwich assay in whole 
blood using the Lab-in-a-briefcase. PSA ELISA detection using the lab-in-a-briefcase 
components was performed in 15 minutes in biological samples with a LLoD of <0.9 
ng/ml PSA and 3 to 10% intra-assay variability. This means PSA MCF ELISA was 20x 
faster than the standard MTP ELISA (laboratory standard method), whilst maintaining 
similar assay performance in respect to precision and LLoD.  The Lab-in-a-briefcase 
presented a simple and efficient MSA used to simultaneously fill 8 pre-coated MCF test 
strips or 80 capillaries using an array of 1 ml disposable plastic syringes and a flatbed 
scanner as readout system. The components of this portable lab allowed the use of 
conventional ELISA and commercialized assay chemistry on the field, outside the 
laboratory setting. 
Readout systems are a paramount in the conversion of  microfluidic devices in POC 
diagnostic, since it has to be sensitive enough to quantify low analytes concentrations, 
as well as power-free, low-cost and portable. In order to increase the portability and 
energy autonomy of the Lab-in-a-briefcase, the flatbed scanner was replaced by a 
smartphone on an assembled set up named MCFphone. The MCFphone was able to 
detect and quantify PSA within the dynamic range of 0.9 to 60 ng/ml PSA in 13 minutes 
using colorimetric detection, and within 0.08 ng/ml to 60 ng/ml of PSA, using 
fluorescence detection from whole blood samples. Considering the PSA clinical range 
of 4 ng/ml, for prostate biopsy, the MCFphone can provide reliable measurements for 
prostate cancer screening and detection in remote areas outside laboratory facilities. 
An attempt to speed up the assay by using particle labels instead of enzymes was made, 
however it was clear that the particle density achieved was not high enough for 
macroscopic detection desired at POC settings. Therefore, the PSA assay presented a 
higher LLoD with a dynamic range between 10 to 100 ng/ml of PSA, using gold 
nanoparticles silver enhanced and flatbed scanner. Carbon nanoparticles enabled the 
quantitation of biotinylated antibody in the range of 10 to 40 µg/ml with a flatbed 
scanner, and SEM microphotographs confirmed the increasing of particles density in the 
capillary surface within this range.   
Although, the initial aims were achieved during this PhD project many other 
suggestions can be presented and discussed, especially concerning the 
commercialisation of MCF diagnostic tests.   
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In order to commercialise MCF tests is necessary to perform an up-scale process of the 
MCF coating method, which implies coating up to 30 meters of MCF film at once. For 
this purpose, a connector between the MCF and a pump must be built. This connector 
must be able to completely seal, allowing the uniform filling of the microcapillaries. 
The coating chemistry should also be general to a series of assay tests, which is possible 
by replacing passive antibody adsorption by streptavidin coatings, which then can be 
used with any type of biotinylated CapAb. 
For the MCF to become a commercial product, stability studies of immobilised 
antibodies for minimum 6 months must be performed, which implies conservatives 
addition and drying procedures with minimal loss of antibody activity.  
Fluid automation is another major step towards commercialisation of MCF test strips. 
Two different approaches can be developed towards automation: passive flow or 
autonomous pressure driven. To apply the passive flow approach, the inner surface of 
the capillaries needs to be changed so that capillaries become hydrophilic. The 
autonomous pressure driven can be achieved using micro pumps systems.  
MCF assays still present a number of steps that make it difficult to automate. Reducing 
the number of steps without compromising sensitivity would be important for successful 
commercialisation. This could be achieved through elimination of the enzymes as signal 
amplifiers and introduction of higher amount of active immobilised antibody.   
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